



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Board Meeting

August 13, 2020

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; info@pharmacy.la.gov. (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; h&q@legis.la.gov. (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; s&q@legis.la.gov.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*



Table of Contents – Public Meeting Binder

0 – A.	Table of Contents	002
0 – C.	Acronyms	004
0 – D.	Agenda	010
1.	Call to Order	
2.	Quorum Call	
3.	Call for Additional Agenda Items & Adoption of Agenda	
4.	Consideration of Draft Minutes from Previous Meetings ~ July 28, 2020	015
5.	Report on Action Items	022
6.	Confirmation of Acts	
7.	Opportunity for Public Comment	
8.	Special Orders of the Day	
9.	Committee Reports	
A.	Finance	
	(1) Review of <i>Final Report for Fiscal Year 2019-2020</i>	040
	(2) Consideration of <i>Proposed Budget Amendment No. 1 for FY 20-21</i>	056
B.	Application Review	
C.	Reciprocity	
	(1) List of Pharmacists Licensed by Reciprocity	066
D.	Violations	
	(1) Consideration of Proposed Voluntary Consent Agreements	
	(2) Consideration of Proposed Revision of <i>PPM-I.C.7.a ~ Publication of Final Adverse Actions</i>	068
E.	Impairment	
F.	Reinstatement	
	(1) List of Credential Reinstatements	
G.	Tripartite	
H.	Regulation Revision	
	(1) Consideration of Renewal of Pilot Projects	074
	(2) Consideration of Regulatory Proposals and Projects	
	(a) Regulatory Proposal 454-2019-03 ~ Medication Administration (Draft 3) and Proposed Emergency Rule re Medication Administration	075 079
	(b) Regulatory Proposal 454-2019-13 ~ Staffing Ratios for Pharmacy Technicians (Draft #2)	082
	(c) Regulatory Proposal 454-2019-34 ~ Telepharmacy Dispensing Sites (Draft #3)	083
	(d) Regulatory Proposal 2020-G ~ Delivery of Dispensed Marijuana Products (Draft #1)	085
	(e) Regulatory Proposal 2020-H ~ Marijuana Product Labeling (Draft #2)	086
	(f) Regulatory Proposal 2020-J ~ Emergency Dispensing (Draft #2)	088
	(g) Regulatory Proposal 2020-K ~ Veterinary Drug Reference (Draft #1)	089
	(h) Regulatory Proposal 2020-M ~ Occupational Licensing for Military Families (Draft #1)	090
	(i) Regulatory Project 2020-2 ~ Automated Medication Systems (Draft #8)	097
I.	Executive	
	(1) Consideration of Compliance Questionnaire for 2020 Financial Audit	111
	(2) Consideration of Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products Between the <i>[insert state board of pharmacy or other appropriate state agency]</i> and the U.S. Food and Drug Administration	118

	(3) Consideration of Regulatory Proposal 2020-D ~ CDS License for Hemp Facility (Draft #3)	130
	(4) Consideration of Renewal of Agreement with Metrc for Board Access to Louisiana Medical Marijuana Tracking System (LMMTS)	132
10.	Staff Reports	
	J. Assistant Executive Director – Mr. Fontenot	
	(1) Quarterly Report from Prescription Monitoring Program (PMP)	137
	(2) Consideration of Requests for Waivers from PMP Reporting Rule	147
	K. General Counsel – Mr. Finalet	
	(1) Consideration of Proposed Voluntary Consent Agreements and Voluntary Surrenders	
	L. Executive Director – Mr. Broussard	
	(1) Narrative Report	152
	(2) Internal Reports	
	➤ Credentials Div. – Census Report	158
	➤ Credentials Div. – Licensure Activity Report	170
	➤ Credentials Div. – Pending Application Report	171
	➤ Credentials Div. – Exceptions Report	172
	➤ Compliance Div. – Census Report	174
	➤ Compliance Div. – Complaint Investigation Policy Monitor	175
	➤ Compliance Div. – Annual Statistical Report	176
	External Reports	
	➤ Annual Report for Fiscal Year 2019-2020	182
	➤ Roster & Inventory of Agency Publications	199
	(3) Examination Reports	
	➤ Pharmacists – MPJE	203
	➤ Pharmacists – NAPLEX	209
	➤ Technicians – ExCPT	215
	➤ Technicians – PTCB	218
11.	Request for Opinion	
	A. Delivery of Dispensed Prescriptions to Lockers for Employees	227
12.	New Agenda Items Added During Meeting	
13.	Announcements	231
14.	Adjourn	232

Acronyms

AACP	American Association of Colleges of Pharmacy
AAPS	American Association of Pharmaceutical Scientists
AAPT	American Association of Pharmacy Technicians
ACA	American College of Apothecaries
ACCME	Accreditation Council for Continuing Medical Education
ACCP	American College of Clinical Pharmacy
ACE	Advisory Committee on Examinations (NABP)
ACHC	Accreditation Commission for Health Care
ACPE	Accreditation Council for Pharmacy Education
ADA	American Dental Association
ADC	automated dispensing cabinet
ADS	automated dispensing system
AFDO	Association of Food & Drug Officials
AFPE	American Foundation for Pharmaceutical Education
AIHP	American Institute of the History of Pharmacy
AMA	American Medical Association
AMCP	Academy of Managed Care Pharmacy
AMS	automated medication system
APEC	Australian Pharmacy Examining Council
APhA	American Pharmacists Association
APPE	advanced pharmacy practice experience
ASAE	American Society of Association Executives
ASAP	American Society for Automation in Pharmacy
ASCP	American Society of Consultant Pharmacists
ASHP	American Society of Health-System Pharmacists
ASPEN	American Society of Parenteral & Enteral Nutrition
ASPL	American Society for Pharmacy Law
ATT	authorization to test
AVMA	American Veterinary Medical Association
AWARxE	NABP consumer protection program
BNDD	Bureau of Narcotics and Dangerous Drugs
BPS	Board of Pharmacy Specialties
CAC	Citizen Advocacy Center
CCAPP	Canadian Council for Accreditation of Pharmacy Programs
CCGP	Commission for Certification in Geriatric Pharmacy
CDC	U.S. Centers for Disease Control and Prevention
CDER	U.S. Center for Drug Evaluation and Research (FDA)
CDTM	collaborative drug therapy management
CDS	controlled dangerous substances
CE	continuing education
CFR	Code of Federal Regulations
CHPA	Consumer Healthcare Products Association
CLEAR	Council on Licensure, Enforcement and Regulation
CMI	consumer medication information
CMS	U.S. Centers for Medicare and Medicaid Services
CPD	continuing professional development
CPhA	Canadian Pharmacists Association
CPPA	Center for Pharmacy Practice Accreditation
CPSC	U.S. Consumer Product Safety Commission

DEA	U.S. Drug Enforcement Administration
DEQ	La. Department of Environmental Quality
DME	durable medical equipment
DMEPOS	durable medical equipment, prosthetics, orthotics, and supplies
DNV	Det Norske Veritas (Norwegian accreditation organization)
DOA	La. Div. of Administration
DOA – FPC	La. Div. of Administration – Facility Planning & Control
DOA – ORM	La. Div. of Administration – Office of Risk Management
DOA – OSR	La. Div. of Administration – Office of State Register
DOA – OSRAP	La. Div. of Administration – Office of Statewide Reporting & Accounting Policy
DOE	La. Dept. of Education
DPSC	La. Dept. of Public Safety & Corrections
DSCS	La. Dept. of State Civil Service
DSM	disease state management
EDK	emergency drug kit
ELTP	Electronic Licensure Transfer Program (NABP)
EPA	U.S. Environmental Protection Agency
EPCS	Electronic Prescribing of Controlled Substances (DEA)
ETS	Educational Testing Service
EU	European Union
ExCPT	Examination for the Certification of Pharmacy Technicians
FARB	Federation of Associations of Regulatory Boards
FBI	Federal Bureau of Investigation
FD&C	Federal Food, Drug & Cosmetic Act
FDA	U.S. Food & Drug Administration
FEIS	Fiscal & Economic Impact Statement
FIP	Federation Internationale Pharmaceutique
FMI	Food Marketing Institute
FPGEC	Foreign Pharmacy Graduate Examination Committee (NABP)
FPGEE	Foreign Pharmacy Graduate Equivalency Examination (NABP)
FSBPT	Federation of State Boards of Physical Therapy
FSMB	Federation of State Medical Boards
FRC	Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP)
FTC	U.S. Federal Trade Commission
GOHSEP	Governor’s Office of Homeland Security & Emergency Preparedness
GPhA	Generic Pharmaceutical Association
GPO	U.S. Government Publishing Office
gTLD	generic top level domain (Internet addresses)
HCFA	Health Care Financing Administration
HDMA	Healthcare Distribution Management Association
HIPAA	Health Insurance Portability and Accountability Act (of 1996)
HIPDB	Healthcare Integrity and Protection Data Bank
HMO	health maintenance organization
IACP	International Academy of Compounding Pharmacists
ICANN	Internet Corporation for Assigned Numbers and Names
ICPT	Institute for the Certification of Pharmacy Technicians
IDOI	Internet Drug Outlet Identification (NABP)
INEOA	International Narcotic Enforcement Officers Association
IOM	Institute of Medicine
IPPE	introductory pharmacy practice experience
IRS	U.S. Internal Revenue Service

ISMP	Institute for Safe Medication Practices
JCPP	Joint Commission of Pharmacy Practitioners
JLCB	Joint Legislative Committee on the Budget
LAC	Louisiana Administrative Code
LAMP	Louisiana Academy of Medical Psychologists
LANP	Louisiana Association of Nurse Practitioners
LAPA	Louisiana Academy of Physician Assistants
LASERS	La. State Employees Retirement System
LASIE	Louisiana Association of Self-Insured Employers
LBDDD	La. Board of Drug & Device Distributors
LBP	La. Board of Pharmacy
LDA	Louisiana Dental Association
LDAF	La. Dept. of Agriculture & Forestry
LDH	La. Dept. of Health
LDI	La. Dept. of Insurance
LDR	La. Dept. of Revenue
LFO	Legislative Fiscal Office
LHA	Louisiana Hospital Association
LIPA	Louisiana Independent Pharmacies Association
LLA	La. Legislative Auditor
LPA	Louisiana Pharmacists Association
LPC	Louisiana Pharmacy Congress
LPTA	Louisiana Physical Therapy Association
LPTB	Louisiana Physical Therapy Board
LSA	Louisiana Sheriffs' Association
LSBD	La. State Board of Dentistry
LSBME	La. State Board of Medical Examiners
LSBN	La. State Board of Nursing
LSBOE	La. State Board of Optometry Examiners
LSBPNE	La. State Board of Practical Nurse Examiners
LSBVM	La. State Board of Veterinary Medicine
LSHP	Louisiana Society of Health-System Pharmacists
LSMS	Louisiana State Medical Society
LSNA	Louisiana State Nurses Association
LTC	long term care
LTCF	long term care facility
LVMA	Louisiana Veterinary Medical Association
MPJE	Multistate Pharmacy Jurisprudence Examination (NABP)
MRC	MPJE Review Committee (NABP)
NABP	National Association of Boards of Pharmacy
NABP-F	National Association of Boards of Pharmacy Foundation
NABPLAW	National Association of Boards of Pharmacy – Law Database
NACDS	National Association of Chain Drug Stores
NADDI	National Association of Drug Diversion Investigators
NAMSDL	National Alliance for Model State Drug Laws
NAPLEX	North American Pharmacist Licensure Examination (NABP)
NAPRA	National Association of Pharmacy Regulatory Authorities (Canada)
NASCSA	National Association of State Controlled Substance Authorities
NASPA	National Alliance of State Pharmacy Associations
NASPER	National All Schedules Prescription Electronic Reporting Act
NCC MERP	National Coordinating Council for Medication Error Reporting and Prevention

NCPA	National Community Pharmacists Association
NCPDP	National Council for Prescription Drug Programs
NCPIE	National Council on Patient Information and Education
NCPO	National Conference of Pharmaceutical Organizations
NCSBN	National Council of State Boards of Nursing
NCVHS	National Committee on Vital and Health Statistics
NDC	National Drug Code
NDMA	Nonprescription Drug Manufacturing Association
NIPCO	National Institute for Pharmacist Care Outcomes
NISPC	National Institute for Standards in Pharmacist Credentialing
NOCA	National Organization for Competency Assurance
NPA	National Pharmacy Association
NPC	National Pharmaceutical Council
NPDB	National Practitioner Data Bank
NPTA	National Pharmacy Technician Association
NRC	NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission
OAL	Optometry Association of Louisiana
OBRA	Omnibus Budget Reconciliation Act
OIG	Office of Inspector General
ONDCP	Office of National Drug Control Policy
ONDD	Office of Narcotics and Dangerous Drugs
OPEB	other post employment benefits
OSHA	Occupational Safety and Health Administration
PBM	pharmacy benefit management
PCAB	Pharmacy Compounding Accreditation Board
PCCA	Professional Compounding Centers of America
PCMA	Pharmaceutical Care Management Association
PCOA	Pharmacy Curriculum Outcomes Assessment (NABP)
PDMA	Prescription Drug Marketing Act
PEBC	Pharmacy Examining Board of Canada
PhRMA	Pharmaceutical Research and Manufacturers of America
PMP	Prescription Monitoring Program
PMP-i	Prescription Monitoring Program Interconnect (NABP)
PTAC	Pharmacy Technician Accreditation Commission
PTCB	Pharmacy Technician Certification Board
PTCE	Pharmacy Technician Certification Examination
PTEC	Pharmacy Technician Educators Council
PTTP	pharmacy technician training program
RFID/EPC	Radio Frequency Identification / Electronic Product Code
RS	Louisiana Revised Statutes
SAMSHA	U.S. Substance Abuse & Mental Health Services Administration
SEGBP	State Employees Group Benefit Program
TJC	The Joint Commission
TOEFL	Test of English as a Foreign Language
TOEFL iBT	Test of English as a Foreign Language Internet-based Test
TSE	Test of Spoken English
URAC	Utilization Review Accreditation Commission
USP	United States Pharmacopeia / United States Pharmacopeial Convention
USP DI	U.S. Pharmacopeia Dispensing Information
USP-NF	U.S. Pharmacopeia – National Formulary

VAWD	Verified-Accredited Wholesale Distributors (NABP)
Vet-VIPPS	Veterinary-Verified Internet Pharmacy Practice Sites (NABP)
VIPPS	Verified Internet Pharmacy Practice Sites (NABP)
VPP	Verified Pharmacy Practice (NABP)
WHO	World Health Organization
WHPA	World Health Professions Alliance



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Meeting Notice & Certification

WHEREAS, the Governor renewed the current public health emergency in *Proclamation No. 96 JBE 2020 ~ COVID-19 Public Health Emergency / Renewal of Phase 2 of Resilient Louisiana*; and

WHEREAS, the restrictions in the above referenced proclamation include a limitation on the number of people that may occupy the Board office building at the same time – 50% of the total occupancy as determined by the State Fire Marshal; and

WHEREAS, but for the use of videoconference technology the Board would not be able to operate due to quorum requirements; and

WHEREAS, the Board's presiding officer has determined it necessary to call a meeting of the Board; and

WHEREAS, the Board's presiding officer has certified the agenda for this meeting is limited to one or more of the following:

- (a) Matters that are directly related to the Board's response to the emergency and are critical to the health, safety, or welfare of the public.
- (b) Matters that if they are delayed will cause curtailment of vital public services or severe economic dislocation and hardship.
- (c) Matters that are critical to continuation of the business of the Board and that are not able to be postponed to a meeting held in accordance with the other provisions of the Open Meetings Law due to a legal requirement or other deadline that cannot be postponed or delayed by the Board.

THEREFORE, the Board's presiding officer has determined it appropriate, pursuant to the provisions of R.S. 42:17.1, to utilize videoconferencing technology for its meeting on August 13, 2020; and further,

The agenda for this meeting is attached and includes instructions for accessing the videoconference as well as a mechanism for interested parties to submit comments.

Malcolm J Broussard
Executive Director
August 11, 2020

NOTICE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTICE: In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; info@pharmacy.la.gov. (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; h&ga@legis.la.gov. (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; s&g@legis.la.gov.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and will be conducted by videoconference at 9:00 a.m. on Thursday, August 13, 2020. The meeting website is www.zoom.us; in the upper right corner of the homepage select the link for Join a Meeting. Enter meeting identification number **982 3517 3775** and the meeting password (passcode) **486149**. This meeting has been called for the following purpose:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 08-11-2020

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Consideration of Draft Minutes from Previous Meeting – [July 28, 2020](#)
5. Report on Action Items
6. Confirmation of Acts
7. Opportunity for Public Comment
8. Special Orders of the Day
9. Committee Reports
 - A. Finance – Mr. Pitre
 - (1) Consideration of Final Report for Fiscal Year 2019-2020
 - (2) Consideration of Proposed Budget Amendment No. 1 for FY 2020-2021
 - B. Application Review – Mr. Robichaux
 - C. Reciprocity – Mr. Cassidy
 - D. Violations – Mr. Indovina
 - (1) Consideration of Proposed Voluntary Consent Agreements
 - (a) Case No. 19-0125 ~ PHY.004057 – Walgreen La. Co., Inc. *d/b/a* Walgreen Pharmacy No. 04566 [Lafayette, LA]
 - (b) Case No. 19-0130 ~ PHY.003934 – Walgreen La. Co., Inc. *d/b/a* Walgreen Pharmacy No. 04192 [New Iberia, LA]
 - (c) Case No. 19-0131 ~ PHY.005012 – Walgreen La. Co., Inc. *d/b/a* Walgreen Pharmacy No. 07166 [New Iberia, LA]
 - (d) Case No. 19-0292 ~ PHY.005775 – Louisiana CVS Pharmacy, LLC *d/b/a* CVS Pharmacy No. 5344 [Monroe, LA]
 - (e) Case No. 20-0030 ~ PHY.007919 – Central Rx Services, LLC *d/b/a* IngenioRx Specialty or CVS Specialty [Las Vegas, NV]
 - (f) Case No. 19-0386 ~ PHY.005063 – Wal-Mart Stores East, LP *d/b/a* Wal-Mart Pharmacy No. 10-5315 [Orlando, FL]
 - (g) Case No. 19-0224 ~ PST.015447 – Charles Edward Maier

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; info@pharmacy.la.gov. (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; h&ga@legis.la.gov. (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; s&q@legis.la.gov.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

9. Committee Reports

D. Violations (cont.)

- (1) Consideration of Proposed Voluntary Consent Agreements
 - (h) Case No. 20-0025 ~ PHY.006815 – Neumann’s Pharmacy, LLC *d/b/a* Neumann’s Pharmacy [Tallulah, LA]
 - (i) Case No. 20-0027 ~ SWP.000776 & PTC.021233 – Carla Lawrence Nordquist
 - (j) Case No. 20-0014 ~ PHY.007000 – Charbonnet Health, LLC *d/b/a* Charbonnet Family Pharmacy [New Orleans, LA]
 - (k) Case No. 19-0341 ~ PST.019325 – Lynn Ann Johnson
 - (l) Case No. 20-0023 ~ PHY.004234 – City Drug, Inc. *d/b/a* City Drug Store [Bunkie, LA]
 - (m) Case No. 19-0394 ~ PHY.005007 – The Compounding Center Pharmacy, LLC *d/b/a* The Compounding Center Pharmacy [Lafayette, LA]
 - (n) Case No. 19-0395 ~ PST.012078 – Darrell Glenn Granger
- (2) Consideration of Proposed Revision of *PPM.I.C.7.a ~ Violations Committee – Publication of Final Adverse Actions*

E. Impairment – Ms. Hall

- (1) Consideration of Committee Recommendations re Applications

F. Reinstatement – Mr. Valentine

- (1) Consideration of Committee Recommendations re Applications

G. Tripartite – Mr. Resweber

H. Regulation Revision – Mr. McKay

- (1) Consideration of Renewal of Pilot Projects
 - (a) Remote Dispensing System by Highgate Ventures, LLC: Winn Community Health Center Pharmacy [Winnfield, LA]
 - (b) Automated Medication System at Institutional Pharmacies of Louisiana
- (2) Consideration of Regulatory Proposals and Projects
 - (a) Consideration of [Regulatory Proposal 454-2019-03](#) ~ Medication Administration (Draft #3) and [Proposed Declaration of Emergency](#)
 - (b) Consideration of [Regulatory Proposal 454-2019-13](#) ~ Staffing Ratios for Pharmacy Technicians (Draft #2)
 - (c) Consideration of [Regulatory Proposal 454-2019-34](#) ~ Telepharmacy Dispensing Sites (Draft #3)
 - (d) Consideration of [Regulatory Proposal 2020-G](#) ~ Delivery of Dispensed Marijuana Products (Draft #1)
 - (e) Consideration of [Regulatory Proposal 2020-H](#) ~ Marijuana Product Labeling (Draft #2)

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; info@pharmacy.la.gov. (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; h&ga@legis.la.gov. (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; s&q@legis.la.gov.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

9. Committee Reports
 - H. Regulation Revision (cont.)
 - (2) Consideration of Regulatory Proposals and Projects
 - (f) Consideration of [Regulatory Proposal 2020-J](#) ~ Emergency Dispensing (Draft #2)
 - (g) Consideration of [Regulatory Proposal 2020-K](#) ~ Veterinary Drug Reference (Draft #1)
 - (h) Consideration of [Regulatory Proposal 2020-M](#) ~ Occupational Licensing for Military Families (Draft #1)
 - (i) Consideration of [Regulatory Project 2020-2](#) ~ Automated Medication Systems (Draft #8)
 - I. Executive Committee – Mr. Aron
 - (1) Consideration of Compliance Questionnaire for 2020 Financial Audit
 - (2) Consideration of [Memorandum of Understanding](#) Addressing Certain Distributions of Compounded Human Drug Products Between the [*insert State Board of Pharmacy or Other Appropriate State Agency*] and the U.S. Food and Drug Administration
 - (3) Consideration of [Regulatory Proposal 2020-D](#) ~ CDS License for Hemp Facility (Draft #2)
 - (4) Consideration of Renewal of Agreement with Metrc for Board Access to Louisiana Medical Marijuana Tracking System (LMMTS)
10. Staff Reports
 - J. Assistant Executive Director – Mr. Fontenot
 - (1) Quarterly Report of Prescription Monitoring Program (PMP)
 - (2) Consideration of Requests for Waivers from PMP Reporting Requirement
 - K. General Counsel – Mr. Finalet
 - (1) Consideration of Proposed Voluntary Consent Agreements & Surrenders
 - (a) Case No. 20-0185 ~ PST.022162 – Anh Thi Phuong Tran
 - (b) Case No. 20-0184 ~ CPT.012189 – Tabitha Danielle Hatfield
 - (c) Case No. 20-0183 ~ CDS.038941-PHY – Folsie Pharmacy, Inc. *d/b/a* Folsie Pharmacy [Marrero, LA]
 - (d) Case No. 20-0194 ~ PST.019238 – Patience Marie Viator Bergeron
 - (e) Case No. 20-0187 ~ CPT.001884 – Cindy Stevens Rodrigue
 - (f) Case No. 20-0207 ~ CPT.009162 – Jasmine Noell Foster
 - (g) Case No. 20-0236 ~ PST.016774 – Melissa Williams Richardson
 - (h) Case No. 20-0226 ~ CPT.013373 – Brianna Arianna Brown
 - L. Executive Director – Mr. Broussard
11. Requests for Opinion
 - A. Delivery of Dispensed Prescriptions to Lockers for Employees (Adria Kerr, Director of Retail Pharmacy, Franciscan Missionaries of Our Lady Health System)

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; info@pharmacy.la.gov. (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; h&ga@legis.la.gov. (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; s&q@legis.la.gov.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

12. New Agenda Items Added During Meeting
13. Announcements
14. Adjourn

Notes:

1. The public meeting binder will be posted on the Board's website 24 hours prior to the beginning of the meeting.
2. Interested parties may submit public statements or comments on agenda items via email; communications addressed to mbroussard@pharmacy.la.gov and received prior to 4:00 pm on Wednesday, August 12, 2020 will be provided to the members prior to the meeting.

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; info@pharmacy.la.gov. (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; h&ga@legis.la.gov. (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; s&q@legis.la.gov.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Consideration of Minutes from Previous Meetings



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Minutes

DRAFT

Special Meeting

Tuesday, July 28, 2020 at 9:00 a.m.

Location:

Videoconference

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
1.	Call to Order	03
2.	Amendments to Board Roster	03
3.	Quorum Call	03
4.	Call for Additional Agenda Items & Adoption of Agenda	04
5.	Consideration of Draft Minutes from Previous Meeting	04
6.	Report on Action Items	04
7.	Confirmation of Acts	04
8.	Opportunity for Public Comment	05
*	Statement of Purpose	05
9.	Special Orders of the Day	
A.	Consideration of Regulatory Proposal 2020-N ~ Marijuana Recommendations (Draft #2)	05
B.	Consideration of Declaration of Emergency	05
10.	New Agenda Items Added During Meeting	06
11.	Announcements	06
12.	Adjourn	06

1 A special meeting of the Louisiana Board of Pharmacy was held on Tuesday, July 28,
2 2020 by videoconference. As noted on the meeting agenda, the Board certified it could
3 not achieve an in-person quorum due to the provisions of *Governor's Proclamation No.*
4 *83 JBE 2020 ~ Additional Measures for COVID-19 – Stay at Home.* Therefore, as
5 permitted by *Governor's Proclamation No. 84 JBE 2020 ~ Additional Measures for*
6 *COVID-19 Public Health Emergency,* the Board elected to conduct its meeting by
7 videoconference.
8

9 *1. Call to Order*

10 Mr. Carl Aron, President, called the meeting to order at 9:00 a.m.

11
12 *2. Amendments to Board Roster*

13 Mr. Aron informed the members and guests of two changes in the Board's membership
14 since the previous meeting. Mr. Ronald Moore and Mr. Richard Soileau completed their
15 terms of service on June 30, with each of them serving for 12 years. Mr. Aron then
16 introduced Mr. David Darce and Mr. Anthony Mercante, noting their term of service
17 began on July 1, 2020 and would conclude on June 30, 2026 unless reappointed by the
18 Governor. Mr. Aron noted Mr. Darce represents District 3 and practices pharmacy at
19 Thrifty Way Pharmacy of St. Martinville; and further, Mr. Mercante represents District 6
20 and practices pharmacy at Ponchatoula Family Pharmacy in Ponchatoula.
21

22 *3. Quorum Call*

23 Mr. Aron called upon the Secretary, Mr. Richard Indovina, to call the roll of members to
24 establish a quorum.
25

26 **Members Present:**

27 Mr. Carl W. Aron
28 Mr. Allen W. Cassidy, Jr.
29 Dr. J. Robert Cloud
30 Mr. David A. Darce
31 Ms. Jacqueline L. Hall
32 Mr. Richard M. Indovina, Jr.
33 Mr. Kevin LaGrange
34 Mr. Richard Mannino
35 Mr. Marty R. McKay
36 Mr. Anthony G. Mercante
37 Mr. Don L. Resweber
38 Mr. Douglas E. Robichaux
39 Dr. Raymond J. Strong
40

41 **Members Absent:**

42 Mr. Robert C. LeBas
43 Mr. Blake P. Pitre
44 Mr. Rhonny K. Valentine
45

46 **Staff Present:**

47 Mr. Malcolm J. Broussard, Executive Director

1 Mr. Carlos M. Finalet, III, General Counsel
2 Mr. M. Joseph Fontenot, Assistant Executive Director
3 Mr. Benjamin S. Whaley, Chief Pharmacist Compliance Officer
4 Ms. Nicole L. Gross, Pharmacist Compliance Officer
5 Ms. Becky C. Parker, Pharmacist Compliance Officer
6 Ms. Kelley L. Villeneuve, Office Manager
7

8 **Guests:**

9 Mr. Ben Sims
10 Mr. Jeff Brown
11 Mr. Perry Catchings
12 Ms. Simone Ginn
13 Ms. Kathryn Thomas
14 Mr. Peter Prevot
15 Mr. Jacob Irving
16 Ms. Allison Hall
17 Ms. Brandi Armand
18 Dr. Jessica Clark
19 Mr. John Davis
20

21 Mr. Indovina certified 13 of 16 members were present, constituting a quorum for the
22 conduct of official business. Mr. LeBas, Mr. Pitre, and Mr. Valentine were absent.
23

24 *4. Call for Additional Agenda Items & Adoption of Agenda*

25 Mr. Aron asked if there were any additional agenda items to be added. With no
26 requests to amend the agenda, and without objection, the members adopted the
27 agenda dated July 20, 2020.
28

29 *5. Consideration of Draft Minutes from Previous Meeting*

30 Mr. Aron informed the members the draft minutes from the previous meeting on June 25
31 had been posted for review. With no objections, he waived the reading of the minutes.
32 No corrections were offered. With no objections, Mr. Aron declared the minutes were
33 approved as presented.
34

35 *6. Report on Action Items*

36 Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed the members
37 to the report in their meeting binder. There were no questions from the members or any
38 public comments.
39

40 *7. Confirmation of Acts*

41 Pursuant to Mr. Aron's declaration that the officers, committees, and executive director
42 had attended to the business of the Board since their previous meeting in accordance
43 with policies and procedures previously approved by the Board. Mr. Robichaux moved,
44 **Resolved**, that the actions taken and decisions made by the Board officers,
45 Board committees, and Executive Director in the general conduct and
46 transactions of Board business since June 25, 2020 are approved, adopted, and
47 ratified by the entire Board.

1 There were no member questions or public comments. The motion was adopted after a
2 unanimous roll call vote in the affirmative.

3
4 **8. Opportunity for Public Comment**

5 Mr. Aron reminded the members and guests the Open Meetings Law requires all public
6 bodies to provide an opportunity for public comment at all meetings and for each
7 agenda item upon which a vote is to be taken. He reminded the participants an agenda
8 entry solicited public comments prior to the meeting. Mr. Broussard reported the receipt
9 of one public comment from Peter Van, MD prior to the meeting relative to the pending
10 regulatory proposal on the meeting agenda and that it was distributed to the members
11 prior to the meeting. Mr. Aron then solicited general public comments about non-
12 agenda items; there were none.

13
14 *** Statement of Purpose**

15 Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy
16 by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the
17 members to keep their legislative mandate in mind as they considered all the matters
18 before them.

19
20 **9. Special Orders of the Day**

21 **A. Consideration of Regulatory Proposal 2020-N ~ Marijuana Recommendations**
22 **(Draft #2)**

23 Mr. Aron reminded the members of their assignment to the Regulation
24 Revision Committee to develop a regulatory proposal to address the law
25 changes in Act 286 of the 2020 Legislature which would become effective on
26 August 1. He reported the committee met on July 16 and developed a
27 regulatory proposal for the Board's consideration. To facilitate discussion, Mr.
28 McKay offered the motion on behalf of the committee and moved,

29 **Resolved**, to approve *Regulatory Proposal 2020-N ~ Marijuana*
30 *Recommendations (Draft #2)*, and further, to authorize the
31 Executive Director to promulgate the proposed rule upon the
32 instruction of the President, and further, to authorize the President
33 to approve acceptable amendments as may become necessary
34 during the promulgation process.

35 There were no member questions or public comments. The motion was
36 adopted after a unanimous roll call vote in the affirmative.

37 **B. Consideration of Declaration of Emergency**

38 Mr. Aron informed the members the motion just adopted authorized the
39 routine promulgation process which takes several months to complete. He
40 reported the committee also voted to recommend the Board issue that
41 proposed rule as an Emergency Rule to become effective on August 1 to
42 coincide with the effective date of the new law. To facilitate discussion, Mr.
43 McKay offered the motion on behalf of the committee and moved,

44 **Resolved**, to approve the *Declaration of Emergency for Regulatory*
45 *Proposal 2020-N ~ Marijuana Recommendations (Draft #2)*, and
46 further, to authorize the Executive Director to publish the proposed
47 rule as an Emergency Rule in the Louisiana Register to become

1 effective on August 1, 2020 and to re-publish the Emergency Rule
2 as often as necessary until the Final Rule is promulgated, and
3 further, to authorize the Executive Director to submit the required
4 notices for emergency rules.

5 There were no member questions or public comments. The motion was
6 adopted after a unanimous roll call vote in the affirmative.
7

8 *10. New Agenda Items Added During Meeting*

9 No new agenda items were added during the meeting.
10

11 *11. Announcements*

12 Mr. Aron directed the members to the announcements page in their meeting binder.
13

14 *12. Adjourn*

15 Having completed the tasks itemized on the posted agenda, with no further business
16 pending before the Board, and without objection, Mr. Aron adjourned the meeting at
17 9:25 a.m.
18

19 *Minutes prepared by Malcolm Broussard*
20
21

22 These minutes were approved by the Board during its meeting on _____.
23
24

25 _____
26 Richard M. Indovina, Jr.
27 Secretary
28



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Report on Action Items



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



August 13, 2020

Agenda Item 5: Report on Action Items

During your July 28 meeting, you considered one regulatory proposal and an accompanying declaration of emergency.

With respect to the proposed rule and its accompanying declaration of emergency:

- You approved *Regulatory Proposal 2020-N ~ Marijuana Recommendations*. We submitted the proposed rule package to the Occupational Licensing Review Commission to initiate the promulgation process. The commission is scheduled to meet on August 27, 2020 to review the proposed rule. On their approval of the proposed rule, we will submit a proposed fiscal and economic impact statement with the Legislative Fiscal Office. Once that statement has been approved, we will publish the *Notice of Intent* in the *Louisiana Register* and schedule a public hearing to receive comments and testimony on the proposed rule.
- You approved the *Declaration of Emergency for Regulatory Proposal 2020-N ~ Marijuana Recommendations*. We filed the required notices on July 28 with the Office of the Governor, Office of the Attorney General, President of the Senate, Chair of the Senate Committee on Health & Welfare, Speaker of the House of Representatives, Chair of the House Committee on Health & Welfare, and Director of the *Louisiana Register*. The *Louisiana Register* published the *Emergency Rule* on their website that same day reflecting the August 1, 2020 effective date. We have scheduled the re-publication of the same *Emergency Rule* at the required intervals to maintain the *Emergency Rule* in effect until the *Final Rule* is promulgated.

The following resources are appended to this report:

[Project 454-2019 Summary Report](#);
[Cumulative Project Promulgation Record](#); and
[Legislative Action Plan Implementation Report](#).

Respectfully submitted,
Malcolm J Broussard
Executive Director

Louisiana Board of Pharmacy
Regulatory Project 454-2019

<u>Item No.</u>	<u>Source</u>	<u>Rule</u>	<u>Request</u>	<u>Preliminary Decision</u>	<u>Current Status of Request</u>
1	Nguyen, K.	(none)	Requested mandatory lunch breaks for pharmacists	Assigned to Cmte	Item 1 11/13/2019 Board approved Draft #2
2	NACDS	§511	Remove requirement to notify Board of employment changes	Board declined to change	Item 2 9/3/2019 Board gave notice
3		§521.B	Eliminate separate Authority to Administer document, allowing the prescription for the medication to allow that activity, for the life of the prescription.	Assigned to Cmte	Item 3 11/13/2019 Board approved Draft #2 7/16/2020 Cmte approved Draft #3 8/13/2020 Draft #3 on Board agenda
4		§709.B	Eliminate ratios for pharmacy interns.	Assigned to Cmte	Item 4 2/5/2020 Board rejected Draft #1
5		§901	Amend definition of pharmacy technician training program to allow the Board to approve programs that are not nationally accredited.	Board declined to change	Item 5 9/3/2019 Board gave notice
6		§903.A.2.c.i	Change proof of enrollment requirement for pharmacy technician training program, to allow either nationally accredited or board approved, but not both.	Board declined to change	Item 6 9/3/2019 Board gave notice
7		§903.A.3.f	Remove requirement for pharmacy technicians and pharmacy technician candidates to notify the Board of pharmacy employment changes.	Board declined to change	Item 7 9/3/2019 Board gave notice
8		§903.B.2	Eliminate requirement for pharmacy technician training programs to notify the Board when pharmacy technician candidates separate from the program.	Board declined to change	Item 8 9/3/2019 Board gave notice
9		§903.D.1	Remove board approval of pharmacy technician certification examinations and specify such examinations must be accredited by National Commission for Certifying Agencies.	Board declined to change	Item 9 9/3/2019 Board gave notice
10		§903.D.2	Remove time delay on re-examination for technicians.	Project 2019-9 in process	Item 10 4/20/2020 Final Rule published
11		§905.A.3.a	Amend eligibility for pharmacy technician certificate to allow for completion of either a nationally-accredited or a board-approved training program.	Board declined to change	Item 11 9/3/2019 Board gave notice
12		§905.A.3.b	Reduce the experiential training requirement for pharmacy technician candidates, from 600 hours to 320 hours (8 weeks), or in the alternative, 400 hours as required by PTCB.	Assigned to Cmte	Item 12 2/5/2020 Board rejected Draft #1
13		§907.A.2	Eliminate staffing ratios for pharmacy technician candidates and pharmacy technicians.	Assigned to Cmte	Item 13 7/16/2020 Cmte rejected Draft #2 8/13/2020 Draft #2 on Board agenda

Louisiana Board of Pharmacy
Regulatory Project 454-2019

<u>Item No.</u>	<u>Source</u>	<u>Rule</u>	<u>Request</u>	<u>Preliminary Decision</u>		<u>Status of Request</u>
14	§907.A.3		Re-frame the scope of practice for pharmacy technicians and pharmacy technician candidates from a list of prohibited tasks to a list of permitted tasks, citing a list of activities associated with medication dispensing and assisting with clinical duties.	Board declined to change	Item 14	9/3/2019 Board gave notice
15	§1101.C		Remove the requirement for the signature of the PIC on the application for a new pharmacy permit, and require only the name of the PIC on the form.	Board declined to change	Item 15	9/3/2019 Board gave notice
16	§1101.C.2		Change the pharmacy permit renewal cycle, from annual to biennial.	Assigned to Cmte	Item 16	11/13/2019 Board rejected Draft #1
17	§1103		Remove structural requirements such as square footage, counter space, and aisle space.	Assigned to Cmte	Item 17	11/13/2019 Board approved Draft #1
18	§1103.H.1		Remove the first sentence specifying storage space.	Assigned to Cmte	Item 18	11/13/2019 Board approved Draft #1
19	§1103.K		Remove the requirement for a printed law book.	Project 2019-17 in process	Item 19	2/28/2020 Final Rule published
20	§1105.A.1.b		Reduce the amount of practice experience to qualify for a PIC privilege, from 2 years to either 6 months or one year.	Board declined to change	Item 20	9/3/2019 Board gave notice
21	§1105.A.2		Remove the minimum number of hours a PIC must be physically present and practicing in the pharmacy.	Board declined to change	Item 21	9/3/2019 Board gave notice
22	§1105.I		Change the amount of time a pharmacy has to give notice of a change in the PIC of the pharmacy.	Assigned to Cmte	Item 22	11/13/2019 Board approved Draft #1
23	§1109		Clarify that a pharmacist assisting a patient in a clinical capacity does not create a pharmacist absence from the pharmacy.	Board agreed to clarify	Item 23	9/3/2019 Board issued clarification
24	§1111		Clarify that a pharmacist assisting a patient in a clinical capacity does not create a temporary absence from the pharmacy.	Board agreed to clarify	Item 24	9/3/2019 Board issued clarification
25	§1113		Repeal the prohibition on mechanical dispensing devices, or allow when approved by the Board.	Proposal 2019-C in Cmte	Item 25	5/29/2020 Now Project 2020-2; Public Hearing scheduled
26	§1123.K.2		Remove the requirement to store hardcopy prescription forms for one year, in favor of allowing imaging systems to retain those records for at least two years.	Assigned to Cmte	Item 26	11/13/2019 Board approved Draft #2.
27	§1131.A.1		Remove the requirement for a PIC signature, in favor of the signature of an authorized representative.	Board declined to change	Item 27	9/3/2019 Board gave notice
28	§1131.A.4		For pharmacy opening procedures, remove the language relative to a federal DEA registration.	Assigned to Cmte	Item 28	11/13/2019 Board approved Draft #1

Louisiana Board of Pharmacy
Regulatory Project 454-2019

<u>Item No.</u>	<u>Source</u>	<u>Rule</u>	<u>Request</u>	<u>Preliminary Decision</u>	<u>Item</u>	<u>Date</u>	<u>Status of Request</u>
29	§1201		Amend the definition of 'final check of work' to allow for technology solutions in lieu of mandatory human checks.	Proposal 2019-C in Cmte	Item 29	5/29/2020	Now Project 2020-2; Public Hearing scheduled
30	§1207.A		Amend the rule to designate the PIC or verifying pharmacist as accountable for the accuracy of the automated medication system, with additional clarification that counting machines are not considered as automated medication systems.	Proposal 2019-C in Cmte	Item 30	5/29/2020	Now Project 2020-2; Public Hearing scheduled
31	§2307.A.1.c		Remove the two-year practice requirement for the PIC privilege.	Board declined to change	Item 31	9/3/2019	Board gave notice
32	§2425.A.1		Reduce the mileage distance for telepharmacy dispensing sites, from 20 miles to 10 miles.	Project 2019-4 in process	Item 32	2/28/2020	OLRC hearing
33	§2425.A.6		Remove the requirement for a telepharmacy dispensing site to close if a new community pharmacy opens within 20 miles of the telepharmacy dispensing site.	Project 2019-4 in process	Item 33	2/28/2020	OLRC hearing
34	§2425.E.2.c		Remove references to staffing parameters and staffing ratios.	Assigned to Cmte	Item 34	8/13/2020	Draft #3 on Board agenda
35	§2425.E.3.g		Amend patient counseling rule in telepharmacy dispensing site to require such counseling only on new prescriptions and only require an offer to counsel for prescription refills.	Assigned to Cmte	Item 35	8/13/2020	Draft #3 on Board agenda
36	§2511.C.1		Remove the minimum size of a prescription form.	Board declined to change	Item 36	9/3/2019	Board gave notice
37	§2511.C.5		Allow for electronic capture of facsimile prescriptions.	Assigned to Cmte	Item 37	11/13/2019	Board approved Draft #1
38	§2511.C.5.d		Remove the 2016 expiration date.	Assigned to Cmte	Item 38	11/13/2019	Board approved Draft #1
39	§2511.D.1		Allow a pharmacy intern or pharmacy technician to enter a transcription of a verbal prescription directly into a pharmacy information system, with the pharmacist held accountable.	Assigned to Cmte	Item 39	11/13/2019	Board rejected Draft #1
40	§2513		Repeal the section on receipt and verification of prescriptions as redundant and unnecessary.	Assigned to Cmte	Item 40	11/13/2019	Board approved Draft #2
41	§2519.B.2		Remove C-V prescriptions, in alignment with 21 CFR 1306.22.	Assigned to Cmte	Item 41	11/13/2019	Board approved Draft #1
42	§2521		Extend the 72-hour allowance for emergency refills to a 30-day supply, or in the alternative, an exception for unit-of-use items.	Assigned to Cmte	Item 42	11/13/2019	Board approved Draft #1
43	§2525.B.2		Remove the 6-month expiration for C-V prescriptions	Assigned to Cmte	Item 43	11/13/2019	Board approved Draft #1
44	§2733.C.1.a		Remove the annual inventory requirement for controlled substances in pharmacies as unnecessary.	Board declined to change	Item 44	9/3/2019	Board gave notice
45	§2747.B.5		Allow for the partial dispensing of Schedule II prescriptions when requested by patients.	Project 2019-12 in process	Item 45	4/20/2020	Final Rule published

Louisiana Board of Pharmacy
Regulatory Project 454-2019

<u>Item No.</u>	<u>Source</u>	<u>Rule</u>	<u>Request</u>	<u>Preliminary Decision</u>	<u>Status of Request</u>		
46	CVS Health	§907	Eliminate staffing ratios for pharmacy technician candidates and pharmacy technicians. <i>[Duplicate of Item 13]</i>	Assigned to Cmte	Item 46	8/12/2020	Draft #2 on Board agenda
47		§1109	Clarify that a pharmacist assisting a patient in a clinical capacity does not create a pharmacist absence from the pharmacy.	Board agreed to clarify	Item 47	9/3/2019	Board issued clarification
48		§1111	Clarify that a pharmacist assisting a patient in a clinical capacity does not create a temporary absence from the pharmacy.	Board agreed to clarify	Item 47	9/3/2019	Board issued clarification

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2020-8	Marijuana Recommendations	8/1/2020 8/27/2020	Emergency Rule #1 issued; will expire 11/28/2020. OLRC scheduled to consider initial approval					
2020-7	Suspension of Renewal Fees	6/30/2020	Emergency Rule #1 issued; will expire 10/27/2020					
2020-6	COVID-19 Dispensing Limitations	3/22/2020	Emergency Rule issued; rescinded 3/23/2020					
2020-5	Marijuana Pharmacy	4/20/2020 2/28/2020	5/29/2020	7/23/2020		7/23/2020		OLRC approved completion of project
2020-4	Pharmacy Benefit Managers	2/28/2020 8/27/2020	OLRC deferred consideration On OLRC agenda					
2020-3	Pharmacist Display of License	4/20/2020 2/28/2020	5/29/2020	7/23/2020		7/23/2020		OLRC approved completion of project
2020-2	Automated Medication Systems	4/20/2020 2/28/2020	5/29/2020	<i>Comments prompted substantive revision, requiring a second public hearing</i>				OLRC approved initiation of promulgation
2020-1	Prescription Monitoring Program	4/20/2020 2/28/2020	5/29/2020	<i>Comments prompted substantive revision, requiring a second public hearing</i>				OLRC approved initiation of promulgation 8/26/2020
2019-18	Cannabis MDI	11/20/2019 9/3/2019	12/27/2019	3/6/2020	[none]	4/20/2020	8/1/2020	OLRC issued waiver from 1st review OLRC approved completion of project
2019-17	Pharmacy Records	11/20/2019 8/29/2019	12/27/2019	3/6/2020	[none]	4/20/2020	8/1/2020	OLRC approved initiation of promulgation OLRC approved completion of project

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2019-16	Pharmacy Compounding	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-15	Drug Disposal by Pharmacies	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation	<i>Comments prompted substantive revision, requiring a second public hearing</i> 4/28/2020	4/27/2020 [none]	OLRC approved completion of project 6/20/2020	8/1/2020	
454-2019	Comments on Entirety of Rules	5/20/2019	6/26/2019					
2019-14	Rulemaking Procedures	11/20/2019 4/22/2019	12/27/2019 OLRC issued waiver from 1st review	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-13	CDS License for 3PL Providers	11/20/2019 4/22/2019	12/27/2019 OLRC issued waiver from 1st review	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-12	Partial Fill of C-II Prescriptions	11/20/2019 4/22/2019	12/27/2019 OLRC issued waiver from 1st review	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-11	Continuing Education Records	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-10	License Transfer for Pharmacy Technicians	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-9	Delays of Licensure Examinations	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-8	Dispensing of Prescription Refills	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-7	Veterinary Hospital Pharmacy	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2019-6	Prescription Monitoring Program	With additional PMP-related regulatory proposals, this project was deferred in favor of Project 2020-1 (see above). 4/12/2019 OLRC issued waiver from 1st review						
2019-5	Correctional Center Pharmacies	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-4	Telepharmacy Dispensing Sites	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-3	Investigational Drugs	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	<u>8/1/2020</u>	
2019-2	Pharmacy Immunizations	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-1B	Licensing of Marijuana Pharmacies	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation	3/6/2020	[none] 2/28/2020	4/20/2020 OLRC approved completion of project	8/1/2020	
2019-1A	Marijuana Pharmacies	4/20/2019 3/20/2019	5/29/2019 OLRC issued waiver from 1st review	9/3/2019	[none] 9/3/2019	10/20/2019 OLRC issued waiver from 2nd review	8/1/2020	1/31/2020
2018-3	Drugs of Concern - Naloxone	9/20/2018	10/26/2018	12/3/2018	[none]	1/20/2019	8/1/2019	2/26/2019
2018-2	La. Uniform Prior Authorization	8/20/2018	9/28/2018	10/25/2018	[none]	12/20/2018 <i>Delayed effective date: 1/1/2019</i>	8/1/2019	2/26/2019
2018-1	Pharmacy Benefit Managers	5/20/2018	6/25/2018	9/11/2018	10/8/2018	<i>Sen. H&W Cmte rejected proposed rule.</i>		
2017-2	Equivalent Drug Product Interchange	4/20/2017	5/30/2017	9/27/2017	[none]	11/20/2017	11/20/2017	2/6/2018
2017-1	Internship Requirements	4/20/2017	5/30/2017	9/27/2017	[none]	11/20/2017 <i>Delayed effective date: 1/1/2018</i>	1/1/2018	2/6/2018

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2016-6	Marijuana Pharmacy	1/20/2017	3/2/2017 6/26/2017	<i>Comments prompted substantive revision, requiring a second public hearing</i> 7/5/2017	[none]	8/20/2017	11/1/2017	2/6/2018
2016-5	Reinstatement of CDS License	11/17/2016 3/15/2017	Emergency Rule #1 issued; expired 3/17/2017 Emergency Rule #2 issued; cancelled upon publication of Final Rule on 5/20/2017					
		1/20/2017	3/1/2017	3/27/2017	[none]	5/20/2017	11/1/2017	2/6/2018
2016-4	Standing Orders for Distribution of Naloxone	8/10/2016 12/7/2016 4/5/2017	Emergency Rule #1 issued; expired 12/8/2016 Emergency Rule #2 issued; expired 4/6/2017 Emergency Rule #3 issued; cancelled upon publication of Final Rule on 5/20/2017					
		1/20/2017	3/1/2017	3/27/2017	[none]	5/20/2017	11/1/2017	2/6/2018
2016-3	Medication Synchronization	4/20/2016	5/25/2016	8/1/2016	[none]	9/20/2016	2016	2/1/2017
2016-2	Pharmacist-in-Charge of Nonresident Pharm	4/20/2016	5/25/2016	11/14/2016	[none]	1/20/2017	2017	2/6/2018
2016-1	CDS Prescriptions	4/20/2016	5/25/2016	6/3/2016	[none]	7/20/2016	2016	2/1/2017
2015-9	Accreditation of Technician Training Program	11/30/2015 3/24/2016 7/21/2016 11/17/2016 3/15/2017 7/10/2017 11/6/2017	Emergency Rule #1 issued; it expired 3/28/2016. Emergency Rule #2 issued; it expired 7/22/2016. Emergency Rule #3 issued; it expired 11/18/2016. Revised Emergency Rule issued; it expired 3/17/2017 Revised Emergency Rule #2 issued; it expired 7/13/2017 Revised Emergency Rule #3 issued; it expired 11/7/2017 Revised Emergency Rule #4 issued; cancelled upon effective date of Final Rule on 1/1/2018					
		1/20/2017	3/1/2017 6/26/2017	<i>Comments prompted substantive revision, requiring a second public hearing</i> 11/6/2017	[none]	12/20/2017 <i>Delayed effective date: 1/1/2018</i>	1/1/2018	2/6/2018
2015-8	Remote Access to Medical Orders	7/20/2015	8/26/2015	9/8/2015	[none]	10/20/2015	2016	2/22/2016

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2015-7	Remote Processor Pharmacy Permit	7/20/2015	8/26/2015	9/8/2015	[none]	10/20/2015	2016	2/22/2016
2015-6	Telepharmacy Services Permit	7/20/2015	8/26/2015	9/8/2015	[none]	10/20/2015	2016	2/22/2016
2015-5	Electronic Signature on Fax Prescription	6/1/2015 9/21/2015	Emergency Rule #1 issued; expired 9/30/2015 Emergency Rule #2 issued; cancelled upon publication of Final Rule on 10/20/2015					
		7/20/2015	8/26/2015	9/8/2015	[none]	10/20/2015	2016	2/22/2016
2015-4	Compounding for Office Use for Veterinarians	6/1/2015 9/21/2015 1/15/2016 2/24/2016	Emergency Rule #1 issued; expired 9/28/2015 Emergency Rule #2 issued; expired 1/19/2016 Emergency Rule #3 issued; expired 5/14/2016 Emergency Rule #4 issued; cancelled upon publication of Final Rule on 6/20/2016					
		7/20/2015	8/26/2015 4/19/2016	<i>Comments prompted substantive revision, requiring a second public hearing</i> 5/10/2016	[none]	6/20/2016	2016	2/1/2017
2015-3	Electronic Product Verification	4/20/2015	6/25/2015	6/29/2015	[none]	8/20/2015	2016	2/22/2016
2015-2	Expiration Date of Schedule II Prescriptions	12/20/2014	1/28/2015	3/3/2015	[none]	4/20/2015	2016	2/22/2016
2015-1	Dispenser Reporting to PMP	12/20/2014	1/28/2015	3/3/2015	[none]	4/20/2015	2016	2/22/2016
2014-6	Special Event Pharmacy Permit	9/20/2014	10/30/2014	11/18/2014	[none]	1/20/2015	3/15/2015	2/22/2016
2014-5	Prescriptions	6/20/2014	7/28/2014 10/30/2014	<i>Comments prompted substantive revision, requiring a second public hearing</i> 11/18/2014	[none]	1/20/2015	3/15/2015	2/22/2016
2014-4	Pharmacy Compounding	8/8/2014 12/5/2014	Emergency Rule #1 issued; expired 12/8/2014 Emergency Rule #2 issued; cancelled upon publication of Final Rule on 1/20/2015					
		9/20/2014	10/30/2014	11/18/2014	[none]	1/20/2015	3/15/2015	2/22/2016

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2014-3	Pharmacy Records	3/20/2014	4/29/2014 9/30/2014	<i>Comments prompted substantive revision, requiring a second public hearing</i> 10/3/2014		11/20/2014	3/15/2015	3/13/2015
2014-2	Veterinarian Exclusion from PMP	3/20/2014	4/29/2014	5/8/2014	[none]	6/20/2014	3/15/2015	3/13/2015
2014-1	PMP Delegates	3/20/2014	4/29/2014	5/8/2014	[none]	6/20/2014	3/15/2015	3/13/2015
2013-06	Penal Pharmacy Permit Revision	7/20/2013	8/27/2013	10/3/2013	[none]	11/20/2013	1/15/2014	2/7/2014
2013-05	Collaborative Drug Therapy Management	7/20/2013	8/27/2013	11/8/2013	[none]	12/20/2013	1/15/2014	2/7/2014
2013-04	Preferential Licensing for Military Personnel	7/20/2013	8/27/2013	9/23/2013	[none]	11/20/2013	1/15/2014	2/7/2014
2013-03	Technician Training Programs [Chap. 9]	4/20/2013	5/30/2013	6/4/2013	[none]	7/20/2013	1/15/2014	2/7/2014
2013-02	Hospital Off-Site Satellite Pharmacies [Chap.	1/20/2013	2/27/2013	3/15/2013	[none]	5/20/2013	1/15/2014	2/7/2014
2013-01	Compounding for Prescriber Use ~ ER-1	12/13/2012	Emergency Rule issued		1/18/2013	<i>Sen H&W Cmte rejected Emergency Rule</i>		
	Compounding for Prescriber Use ~ ER-2	1/31/2013 5/29/2013 9/27/2013 2/6/2014 4/4/2014	Replacement Emergency Rule #1 issued; expired 5/31/2013 Replacement Emergency Rule #2 issued; expired 9/29/2013 Replacement Emergency Rule #3 issued; expired 1/24/2014 Replacement Emergency Rule #4 issued; expired 4/4/2014 Replacement Emergency Rule #5 issued; expired 8/4/2014; see Project 2014-4 above for new ER					
	Compounding for Prescriber Use [Chap 25]	1/20/2013 1/20/2014	2/27/2013 5/30/2013	<i>Comments prompted substantive revision, requiring a second public hearing</i> <i>Comments prompted substantive revision; additional hearing required</i>				
			Time has expired for the 2013 Notice of Intent - New Project & Notice of Intent required.					
2012-11	DME Permit [Chapter 24]	11/20/2012	12/27/2012	1/5/2013	[none]	3/20/2013	4/15/2013	2/7/2014
2012-10	PMP [Chapter 29]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-09	CDS in EDK [§1713, 2743]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2012-08	CDS Lic. For Non-Resident Distributor [§2705]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-07	Security of Rx Dept [§1103]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-06	Interstate Remote Processing [§1139, 1143]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-05	Institutional Pharmacy [§1705, 1727]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-04	Chapter 24 - DME Permits ~ Emergency Rule	5/2/2012 8/31/2012 12/28/2012	Emergency Rule - valid for 120 days Emergency Rule re-issued - valid for 120 days Emergency Rule re-issued - valid for 120 days			<i>Permanent rule promulgated with Project 2012-11 (see above)</i>		
2012-03	Remote Processing [§1143, 1525]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2012-02	Hospital Pharmacy [§1501, 1512, 1513]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2012-01	E-Communications [§505, 905, 1203]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2011-07	Penal Pharmacy [Chapter 18]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2011-02	Cognitive Services [§525]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2011-01	PIC Requirements [§1105]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2009-04	Digital Imaging of Prescriptions [§1123]	12/20/2009	1/27/2010	2/26/2010	[none]	4/20/2010	1/31/2011	4/5/2011
2009-03	Prescription Transfers [§2523]	12/20/2009	1/27/2010	2/26/2010	[none]	4/20/2010	1/31/2011	4/5/2011
2009-02	Pharmacy Interns [§709]	12/20/2009	1/27/2010	2/26/2010	[none]	4/20/2010	1/31/2011	4/5/2011
2009-01	Drugs of Concern [§2901]	12/20/2009	1/27/2010	2/26/2010	[none]	4/20/2010	1/31/2011	4/5/2011
2008-03	CDS [Chapter 27]	6/20/2008	7/30/2008	8/21/2008	[none]	10/20/2008	1/31/2011	3/16/2009

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2008-02	Pharmacies [§1107.B + §1727]	4/20/2008	5/28/2008	6/2/2008	[none]	7/20/2008	1/31/2011	3/16/2009
2008-01	Pharmacy Interns [§521.G + §705.C]	4/20/2008	5/28/2008	6/2/2008	[none]	7/20/2008	1/31/2011	3/16/2009
2007-01	Prescription Monitoring Program [Chapter 29]	4/20/2007	5/30/2007	6/5/2007	[none]	7/20/2007	1/31/2011	2/13/2008
2006-03	Pharmacy Practice	11/20/2006 3/30/2007	12/27/2006 4/20/2007	<i>Comments prompted substantive revision, requiring a second public hearing</i>		6/20/2007	1/31/2011	2/13/2008
2006-02	Proposal No. 2006-11 - Certified Preceptors	9/20/2006	10/30/2006	11/1/2006	[none]	12/20/2006	1/31/2011	3/30/2007
2006-01	Proposal No. 2006-11 - Certified Preceptors	9/1/2006	Emergency Rule - valid for 120 days		[none]	N/A	N/A	3/30/2007
2005-03	§705 - Practical Experience for Interns	12/20/2005	1/25/2006	1/30/2006	[none]	4/20/2006	9/1/2006	3/30/2007
2005-02	§705 - Practical Experience for Interns	12/20/2005	Emergency Rule - valid for 120 days		[none]	N/A	N/A	3/30/2007
2005-01	§907 - Scope of Practice for Technicians	6/20/2005	7/27/2005	8/25/2005 1/30/2006	<i>Refiled report due to disruption caused by Hurricanes Katrina & Rita</i>		9/1/2006	3/30/2007
2004-01	Chapter 8 →Chapter 9: Pharmacy Technician	8/20/2004	9/27/2004	10/5/2004	[none]	11/20/2004	1/1/2005	3/18/2005
2003-01	Complete Revision of Board Rules	7/20/2003	8/26/2003	8/28/2003	[none]	10/20/2003	1/1/2004	2/27/2004
2001-01	§1109 - Prescription Forms	9/20/2001	10/25/2001	11/5/2001	[none]	11/20/2001	1/1/2002	N/A
2000-04	Chapter 7 - Pharmacy Interns	6/20/2000	7/27/2000	8/28/2000	[none]	10/20/2000	12/1/2000	N/A
2000-03	Chapter 8 - Pharmacy Technicians	4/20/2000 7/20/2000	5/30/2000 8/24/2000	7/5/2000 8/28/2000	<i>Comments prompted substantive revisions, requiring a 2nd hearing</i>		12/1/2000	N/A
2000-02	§3517 - Drug Donations / Charitable Pharmac	4/20/2000	5/30/2000	6/20/2000	[none]	8/20/2000	10/1/2000	N/A
2000-01	§3517 - Drug Donations / Charitable Pharmac	3/20/2000	Emergency Rule - valid for 120 days		[none]	N/A	N/A	N/A

Louisiana Board of Pharmacy
Regulatory Projects - Promulgation Record

<u>Project No.</u>	<u>Project Name</u>	<u>1st Report Notice of Intent</u>	<u>Public Hearing</u>	<u>2nd Report Hearing Record</u>	<u>Oversight Hearing</u>	<u>Final Rule Published</u>	<u>Law Book Published</u>	<u>3rd Report Completion</u>
1999-01	Chapter 12 - Automated Medication Systems	9/20/1999	11/29/1999	3/13/2000	[none]	6/20/2000	6/1/2000	N/A

Louisiana Board of Pharmacy
Implementation of Legislation from 2020 Regular Session

<u>Bill</u>	<u>Act</u>	<u>Topic</u>	<u>Citation(s)</u>	<u>Law Book</u>	<u>Rules</u>	<u>PPM</u>	<u>Guidance</u>	<u>Forms</u>	<u>Completion</u>
HB 089	2020-010	Update to CDS schedules	40:964	8/1/2020					8/1/2020
HB 418	2020-147	Extended immunity for medical marijuana	40:966(F)(6), (7), (8)	8/1/2020					8/1/2020
HB 613	2020-200	Occupational licenses for military families	37:3651	8/1/2020	Reg. Proposal 2020-M in process				
HB 619	2020-202	Licensure fees for PBMs	37:1184	8/1/2020					8/1/2020
HB 633	2020-155	Cybersecurity training for employees	42:1267				Div. Admin.		
HB 819	2020-286	Recommendations for medical marijuana	40:1046(A)	8/1/2020	Reg. Project 2020-8 in process				
HB 843	2020-344	Hemp-derived cannabidiol products	3:1481 through 1485	8/1/2020					8/1/2020
HCR 071		Temporary suspension of licensing fees			Reg. Project 2020-7 ER in effect				
HCR 081		Task Force - Cannabis Industry Workforce				PPM.I.B.6			
SB 273	2020-117	IT managed service providers to state agencies	51:2111 through 2116				Div. Admin.		

Louisiana Board of Pharmacy
Implementation of Legislation from 2019 Regular Session

<u>Bill</u>	<u>Act</u>	<u>Topic</u>	<u>Citation(s)</u>	<u>Law Book</u>	<u>Rules</u>	<u>PPM</u>	<u>Guidance</u>	<u>Forms</u>	<u>Completion</u>
HB 138	2019-354	Revised definitions; new drugs in Schedule I	40:961 and 964	8/1/2019					8/1/2019
HB 243	2019-423	Reporting of opioid-related overdoses	40:978.2.1	8/1/2019					8/1/2019
HB 284	2019-426	Prescriber overrides of 7-day supply	40:978(G)(2)	8/1/2019					8/1/2019
HB 358	2019-284	Cannabis metered-dose inhalers	40:1046(A)(1)	8/1/2019	LAC 46:LIII.2443.C.1.h				4/20/2020
HB 375	2019-219	CBC for CDS license applicants	40:973.1	8/1/2019				5/1/2020	5/1/2020
HB 423	2019-227	Repeal of student loan disqualifications	37:2951 repealed					8/1/2019	8/1/2019
HB 433	2019-161	Pharmacist may decline to fill prescription	37:1219(D through F)	8/1/2019	Board determined no rule needed				8/14/2019
HB 452	2019-231	Scheduling of mitragynine	40:964 and 40:989.3	8/1/2019					8/1/2019
HB 491	2019-164	Hemp-derived CBD oil products	40:961.1	8/1/2019			8/14/2019		8/14/2019
HB 507	2019-331	7% tax on gross sales of marijuana products	40:1046(H)(8)(a)	8/1/2019					8/1/2019
HB 614	2019-256	Public notice for public records	44:33.1(B)						8/1/2019
SB 41	2019-124	Licensure and regulation of PBMs	37:1252 et seq; 40:2861 et seq	8/1/2019	Reg. Project 2020-4 in process				
SB 53	2019-080	Access to PMP by federal jurisdictions	40:1007(G)	8/1/2019	Reg. Project 2020-1 in process				
SB 99	2019-052	Board member qualifications	37:1174(A)(4)	8/1/2019	Board determined no rule needed				8/14/2019
SB 119	2019-351	Palliative Care Advisory Council	40:2018.6			PPM.I.B.6			8/14/2019
SB 241	2019-204	Revision of APA re small business impact	49:953 et seq				OSR		10/7/2019



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Finance Committee



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 E-mail: info@pharmacy.la.gov



Finance Committee

Final Report for Fiscal Year 2019-2020

August 13, 2020

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
Finance Committee

Final Report for Fiscal Year 2019-2020

Table of Contents

Statement of Net Position	03
Statement of Equity	05
Statement of Cash Flow	06
Statement of Revenue, Expenses, & Budget Performance	07
Statement of Fund Balance Changes	09
Budget Variance Report	10
Summary of Board Actions	12
Iberia Bank – General Reserve Fund Statement	13
Iberia Bank – OPEB Reserve Fund Statement	13
Iberia Bank – Pension Reserve Fund Statement	14
Cumulative Fund Balance Report	15

Louisiana Board of Pharmacy
FY 2019-2020
Statement of Net Position

FY 18-19	FY 19-20
Q4 06/30/2019 (A)	Q4 06/30/2020

ASSETS & DEFERRED OUTFLOWS

Assets

> **Current Assets**

* Cash

General Operations

HancockWhitney Bank

228,043.77

228,272.24

Iberia Bank

1,692,446.15

708,278.15

Investment Accounts - Iberia Bank

Money Market Funds

268,913.41

638,356.84

Funds Maturing Within One Year

297,229.20

3,011,851.06

* Total Cash & Cash Equivalents

2,486,632.53

4,586,758.29

* Accounts Receivable

Grants

210,667.00

0.00

End of Year Deposits

20,100.00

22,235.00

CPSC Inspections

3,000.00

0.00

Returned Checks & Consent Orders

1,195.00

0.00

* Total Accounts Receivable

234,962.00

22,235.00

* Accrued Interest Receivable

11,671.80

11,361.22

* Prepaid Expenses

Critical Point Staff Education

1,995.00

0.00

Metric Product ID Module

15,000.00

0.00

Appriss Additional Deliverables

33,850.00

882.30

Essential Solutions

2,989.10

2,500.00

PMP Gateway Integration Project

390,643.04

647,199.11

Drug Price Transparency Website

16,907.72

0.00

Rx Check Maintenance Fee

0.00

12,898.63

Information Systems

1,906.85

7,385.19

* Total Prepaid Expenses

463,291.71

670,865.23

Total Current Assets

3,196,558.04

5,291,219.74

> **Noncurrent Assets**

* Investment Accounts

Iberia Bank - General Reserve Fund

1,071,526.95

0.00

Iberia Bank - OPEB Reserve Fund

960,691.67

0.00

Iberia Bank - Pension Reserve Fund

1,711,007.96

789,970.63

3,743,226.58

789,970.63

* Fixed Assets

Land: Lot 5-A, Towne Center Business Park

709,079.90

709,079.90

Land: Lot 1-A-2, Leonard Place Subdivision

295,860.00

295,860.00

Office Building - 3388 Brentwood Drive

1,354,876.72

1,354,876.72

Office Equipment

230,345.19

170,019.03

Furniture

177,074.08

155,620.46

Software: Licensure & Website

408,560.00

408,560.00

Accumulated Depreciation

(995,793.19)

(910,246.88)

2,180,002.70

2,183,769.23

Louisiana Board of Pharmacy
FY 2019-2020
Statement of Net Position

	FY 18-19 <u>Q4 06/30/2019 (A)</u>	FY 19-20 <u>Q4 06/30/2020</u>
<i>Total Noncurrent Assets</i>	5,923,229.28	2,973,739.86
Total Assets	9,119,787.32	8,264,959.60
Deferred Outflows of Resources		
OPEB Reserve Fund	71,452.00	126,364.00
Pension Reserve Fund	<u>972,930.00</u>	<u>1,331,670.00</u>
<i>Total Deferred Outflows of Resources</i>	<i>1,044,382.00</i>	<i>1,458,034.00</i>
 <u>TOTAL ASSETS & DEFERRED OUTFLOWS</u>	 <u>10,164,169.32</u>	 <u>9,722,993.60</u>
LIABILITIES, DEFERRED INFLOWS, & EQUITY		
Liabilities		
> Current Liabilities		
Unearned grant revenue	1,443,299.76	647,199.12
Accrued salaries and benefits	45,716.43	66,228.42
Unemployment taxes payable	184.03	87.08
Payroll taxes payable	0.00	17.48
State taxes withheld	4,820.00	0.00
Accounts payable	12,483.43	13,577.38
Compensated absences (ST)	44,648.86	47,623.39
PES fee payable	200.00	0.00
Other Post Employment Benefits (OPEB) Payable	<u>47,351.00</u>	<u>0.00</u>
Total Current Liabilities	1,598,703.51	774,732.87
> Long Term Liabilities		
Compensated absences (LT)	90,377.73	111,479.26
Other Post Employment Benefits (OPEB) Payable	1,881,586.00	1,790,462.00
Net Pension Liability	<u>5,297,583.00</u>	<u>6,298,728.00</u>
Total Long Term Liabilities	7,269,546.73	8,200,669.26
<i>Total Liabilities</i>	<i>8,868,250.24</i>	<i>8,975,402.13</i>
Deferred Inflows of Resources		
OPEB Reserve Fund	154,202.00	321,265.00
Pension Reserve Fund	<u>80,208.00</u>	<u>38,794.00</u>
<i>Total Deferred Inflows of Resources</i>	<i>234,410.00</i>	<i>360,059.00</i>
Equity		
Fund Balance at End of Prior Year	(1,600,918.63)	(1,372,910.15)
Fund Balance - Designated	241,038.00	250,650.00
Invested in Capital Assets	2,180,002.70	2,183,769.23
Net Income	<u>241,387.01</u>	<u>(673,976.61)</u>
<i>Total Equity</i>	<i>1,061,509.08</i>	<i>387,532.47</i>
 <u>TOTAL LIABILITIES, DEFERRED INFLOWS, & EQUITY</u>	 <u>10,164,169.32</u>	 <u>9,722,993.60</u>

Louisiana Board of Pharmacy
 FY 2019-2020
 Statement of Equity

	FY 18-19 <u>Q4 06/30/2019 (A)</u>	FY 19-20 <u>Q4 06/30/2020</u>
Balance of Equity at Beginning of Year	820,122.07	1,061,509.08
Net Income	<u>241,387.01</u>	<u>(673,976.61)</u>
Balance of Equity at End of Year	1,061,509.08	387,532.47
Components of Equity:		
Fund Balance at End of Prior Year	(1,600,918.63)	(1,372,910.15)
Fund Balance - designated	241,038.00	250,650.00
Invested in Fixed Assets	<u>2,180,002.70</u>	<u>2,183,769.23</u>
	820,122.07	1,061,509.08

Louisiana Board of Pharmacy
FY 2019-2020
Statement of Cash Flow

Cash flows from operating activities	
Receipts from licenses, permits, and fees	3,430,895.83
Receipts from grants and contributions	1,006,767.64
Payments to suppliers for goods and services	(2,560,230.06)
Payments to employees for services	(2,788,726.05)
Net cash provided by operating activities	(911,292.64)
Cash flows from capital and related financing activities	
Purchase of capital assets	(65,429.09)
Net cash used by capital and related financing activities	(65,429.09)
Cash flows from investing activities	
Purchase of investment	(100,026.70)
Proceeds from redemption of investment	398,000.00
Interest income	72,153.46
Net cash provided (used) by investing activities	370,126.76
Net decrease in cash and cash equivalents	(606,594.97)
Cash and cash equivalents, beginning of period	2,181,502.20
Cash and cash equivalents, end of period	1,574,907.23
Reconciliation of operating income to net cash provided by operating activities	
Cash flows from operating activities	
Operating income	(801,847.13)
Adjustments to reconcile operating income to net cash provided by operating activities	
Depreciation	58,351.04
Changes in current assets and liabilities	
Decrease in accounts receivable	2,060.00
Decrease in grant receivable	210,667.00
Increase in prepaid expenses	(207,573.23)
Increase in deferred outflows related to pensions	(358,740.00)
Increase in deferred outflows related to OPEB	(54,912.00)
Increase in accounts payable and PES fee payable	8,795.03
Decrease in unearned grant revenue	(796,100.93)
Increase in salaries and benefits payable	20,511.99
Decrease in payroll tax liability	(4,899.47)
Increase in compensated absences	24,076.06
Increase in net pension liability	1,001,145.00
Decrease in OPEB payable	(138,475.00)
Decrease in deferred inflows related to pensions	(41,414.00)
Increase in deferred inflows related to OPEB	167,063.00
Total adjustments	(109,445.51)
Net cash provided by operating activities	(911,292.64)

Louisiana Board of Pharmacy
 FY 2019-2020
 Statement of Revenue, Expenses, and Budget Performance

Revenue

	FY 18-19 Q4 06/30/2019 (A)	FY 19-20 Q4 06/30/2020	FY 19-20 Budget (A#2)	<u>Notes</u>
Licensing Fees				
PST License Application Fee	170,400.00	169,500.00	170,000.00	1
PST License Reciprocity Application Fee	48,750.00	42,450.00	40,000.00	2
PST License Renewal Fee	872,200.00	885,450.00	883,000.00	3
PNT Registration Application Fee	3,520.00	3,360.00	3,000.00	4
PTC Registration Application Fee	27,125.00	25,525.00	25,000.00	5
CPT Certificate Application Fee	55,400.00	41,100.00	40,000.00	6
CPT Certificate Renewal Fee	340,500.00	305,075.00	340,000.00	7
PHY Permit Application & Renewal Fee	280,925.00	275,425.00	271,000.00	8
AMS Registration Application & Renewal Fee	21,750.00	25,350.00	23,000.00	9
DME Permit Application & Renewal Fee	85,350.00	85,975.00	85,000.00	10
EDK Permit Application & Renewal Fee	11,725.00	10,625.00	13,000.00	11
CDS License Application & Renewal Fee	531,170.00	542,345.00	500,000.00	12
Credential Reinstatement Fee	25,340.00	28,450.00	26,000.00	13
Delinquent Renewal Fee for PST & CPT	14,500.00	13,637.50	12,000.00	14
Delinquent Renewal Fee for PHY & CDS	11,647.50	12,745.00	12,000.00	15
Sales of Goods & Services				
Product Charge for Duplicate Credentials	4,350.00	3,445.00	3,000.00	16
Product Charge for PST Original Certificate	5,475.00	5,550.00	6,000.00	17
Product Charge for PST Silver Certificate	500.00	600.00	500.00	18
Product Charge for Law Book & Supplement	375.00	510.00	500.00	19
Product Charge for Official List of Licensees	25,650.00	25,050.00	26,000.00	20
Product Charge for Document Copies	272.00	27.50	50.00	21
Service Charge for Document Certification	4,240.00	3,540.00	3,000.00	22
Service Charge for Inspection Services	6,000.00	0.00	0.00	23
Service Charge for PNT Practical Experience	350.00	340.00	250.00	24
Disposal of Assets	0.00	0.00	0.00	
Administrative Fees				
Recovery of Bank Charges for NSF Fees	200.00	300.00	500.00	25
Handling & Mailing Fees	377.00	160.00	200.00	26
Enforcement Activities				
Administrative Hearing Fee	22,750.00	18,750.00	19,000.00	27
Fines	268,250.00	271,000.00	271,000.00	28
Cost Recoveries	25,653.33	24,652.82	25,000.00	29
Prescription Monitoring Program (PMP)				
PMP Assessments	591,220.00	607,875.00	560,000.00	30
Grants				
Private Grants	81,200.00	0.00	42,000.00	31
Government Grants	367,367.24	796,100.64	600,000.00	32
Miscellaneous	283.06	23.01	0.00	33
TOTAL REVENUE	3,904,815.13	4,224,936.47	4,000,000.00	34

Louisiana Board of Pharmacy
FY 2019-2020
Statement of Revenue, Expenses, and Budget Performance
Expenses

	FY 18-19 Q4 06/30/2019 (A)	FY 19-20 Q4 06/30/2020	FY 19-20 Budget (A#2)	<u>Notes</u>
Operations				
Equipment Rentals	14,974.91	14,651.45	15,000.00	35
Equipment Maintenance	2,201.88	2,239.92	2,200.00	36
Telephone	18,034.76	17,946.06	20,000.00	37
Printing	18,099.33	36,871.37	36,000.00	38
Postage	60,055.00	56,075.33	60,000.00	39
Dues & Subscriptions	10,671.61	13,246.87	14,000.00	40
Financial Service Charges	52,713.75	61,038.45	53,000.00	41
Office Meeting Expenses	5,067.38	2,896.19	5,000.00	42
Office Supply Expenses	21,956.05	20,663.33	22,000.00	43
Utilities	10,422.52	9,302.46	11,000.00	44
Civil Service Assessments (DSCS)	7,966.00	8,321.00	8,400.00	45
Office Insurance (ORM)	16,980.00	21,269.00	22,000.00	46
Depreciation of Fixed Assets	55,621.06	58,351.04	55,000.00	47
Acquisitions	5,676.36	10,546.34	25,000.00	48
Miscellaneous Expenses	0.00	38.86	0.00	
Personal Services				
Salaries for Employees	1,669,429.89	1,772,765.00	1,710,000.00	49
Wages for Temporary Labor	12,420.31	9,416.35	15,000.00	50
Payroll Taxes (FICA & FUTA)	28,503.45	28,752.14	34,000.00	51
Health Insurance Premiums (SEGBP)	170,746.80	142,267.16	189,000.00	52
Pension Plan Premiums (LASERS)	655,213.95	1,312,323.15	696,000.00	53
Other Post-Employment Benefits (OPEB)	13,687.00	19,288.00	15,000.00	54
Board Member Per Diem	30,000.00	17,475.00	25,000.00	55
Professional Services				
Accounting & Expense Reimbursement	28,129.50	32,528.00	30,000.00	56
Legal & Expense Reimbursement	47,564.60	1,260.00	5,000.00	57
Information Systems	117,018.15	130,404.35	154,000.00	58
Prescription Monitoring Program	137,915.04	258,894.11	250,000.00	59
PMP Statewide Integration Project	384,274.96	779,192.92	586,000.00	60
Drug Price Transparency Website	64,292.28	60,167.72	42,000.00	61
Property Management	22,091.28	22,132.08	25,000.00	62
Staff Expenses				
Executive Director	4,822.99	2,719.90	3,000.00	63
General Counsel	9,868.05	5,997.02	7,000.00	64
Assistant Executive Director	4,853.17	2,184.96	3,000.00	65
Compliance Officer - Travel	6,995.39	3,005.21	7,000.00	66
Compliance Officer - Rental Cars	8,991.96	3,733.92	6,000.00	67
Compliance Officer - Fuel for Rental Cars	3,328.07	1,931.20	3,000.00	68
Compliance Officer - Conference Travel Expenses	2,710.29	13,782.28	14,000.00	69
House Staff Travel & Education	25.00	386.80	400.00	70
Mileage	28,049.76	36,525.06	30,000.00	71
Board Expenses				
Board Meetings	17,492.94	11,653.61	13,000.00	72
Committee Meetings	9,520.15	4,019.11	5,000.00	73
Conference Travel Expenses	19,782.78	3,139.40	4,000.00	74
President's Expenses	7,233.21	4,263.65	5,000.00	75
Mileage - Members & President	19,831.98	13,117.83	15,000.00	76
TOTAL EXPENSES	3,825,233.56	5,026,783.60	4,240,000.00	77

Louisiana Board of Pharmacy
 FY 2019-2020
 Summary of Income and Fund Balance Changes

Summary

	FY 18-19 Q4 06/30/2019 (A)	FY 19-20 Q4 06/30/2020	FY 19-20 Budget (A#2)	Notes
Income Statement				
Total Revenue	3,904,815.13	4,224,936.47	4,000,000.00	78
Total Expenses	3,825,233.56	5,026,783.60	4,240,000.00	79
Net Ordinary Income	79,581.57	(801,847.13)	(240,000.00)	80
Other Income & Expenses				
Investments	161,805.44	131,182.04	0.00	81
Disposal of Assets	0.00	(3,311.52)	0.00	
Net Income	241,387.01	(673,976.61)	(240,000.00)	82
Fund Balance				
Beginning Fund Balance	820,122.07	1,061,509.08	1,061,509.08	
Total Income	4,066,620.57	4,356,118.51	4,000,000.00	
Total Expenses	3,825,233.56	5,030,095.12	4,240,000.00	
GASB Restatements	0.00	0.00	0.00	
Ending Fund Balance	1,061,509.08	387,532.47	821,509.08	
Reservations of Fund Balance	1,750,000.00	1,750,000.00	1,750,000.00	
Unreserved Fund Balance	(688,490.92)	(1,362,467.53)	(928,490.92)	
<i>Notes on Reservation of Fund Balance</i>				
Unfunded Pension Liability	1,000,000.00	1,000,000.00	1,000,000.00	
Unfunded OPEB Liability	600,000.00	600,000.00	600,000.00	
Compensated Absences	150,000.00	150,000.00	150,000.00	
<i>Total</i>	<i>1,750,000.00</i>	<i>1,750,000.00</i>	<i>1,750,000.00</i>	

Louisiana Board of Pharmacy
 FY 2019-2020
 Budget Variance Notes

<u>Notes</u>	<u>Account Name</u>	<u>% Variance</u>	<u>Comment</u>
		Revenue	
1	PST License Application Fee	(0.29)	Overestimated by 2 applicants
2	PST Reciprocity Application Fee	6.13	Underestimated by 16 applicants
3	PST License Renewal Fee	0.28	Underestimated by 24 applicants
4	PNT Registration Fee	12.00	Underestimated by 36 applicants
5	PTC Registration Fee	2.10	Underestimated by 21 applicants
6	CPT Certificate Application Fee	2.75	Underestimated by 11 applicants
7	CPT Certificate Renewal Fee	(10.27)	Overestimated by 698 applicants
8	PHY Application & Renewal Fees	1.63	Underestimated growth and renewals
9	AMS Application & Renewal Fees	10.22	Underestimated by 15 applicants
10	DME Application & Renewal Fees	1.15	Underestimated growth and renewals
11	EDK Application & Renewal Fees	(18.27)	Overestimated by 95 permits
12	CDS Application & Renewal Fees	8.47	Underestimated growth and renewals
13	Credential Reinstatement Fee	9.42	Underestimated by 12 applicants
14	Delinquent Renewal - PST & CPT	13.65	Underestimated number of delinquent renewals
15	Delinquent Renewal - PHY & CDS	6.21	Underestimated number of delinquent renewals
16	Duplicate credentials	14.83	Underestimated demand
17	PST Original Certificate	(7.50)	Overestimated demand by 6 requests
18	PST Silver Certificate	20.00	Underestimated demand by 1 request
19	Law Books & Supplements	2.00	Underestimated demand by 1 request
20	Official Lists of Licensees	(3.65)	Overestimated demand by 6 requests
21	Document Copies	(45.00)	Overestimated demand
22	Document Certification	18.00	Underestimated demand by 27 requests
23	Inspection Services	0.00	US CPSC has paused state inspection contracts
24	PNT Experience Certifications	36.00	Underestimated demand by 9 requests
25	NSF Fee Recoveries	(40.00)	Overestimated incidence of NSF checks
26	Handling & Mailing Fees	(20.00)	Overestimated demand
27	Administrative Hearing Fees	(1.32)	Overestimated caseload by 1 case
28	Fines	0.00	Lucky guess
29	Cost Recoveries	(1.39)	Overestimated cost recoveries
30	PMP Assessments	8.55	Underestimated growth and renewals of CDS licenses
31	Private Grants	(100.00)	Grantor is delinquent on payment for FY 20
32	Government Grants	(32.68)	Timing issue for LDH; balance rec'd July 2019
33	Miscellaneous		Underestimated minor revenue
34	Total Revenue	5.62	Underestimated total revenue

Louisiana Board of Pharmacy
FY 2019-2020
Budget Variance Notes

<u>Notes</u>	<u>Account Name</u>	<u>% Variance</u> Expenses	<u>Comment</u>
35	Equipment Rentals	(2.32)	Reduction in use of color printing
36	Equipment Maintenance	1.82	Close estimate
37	Telephone	(10.27)	Overestimated utilization
38	Printing	19.09	Rule printing charges doubled total printing from FY19
39	Postage	(6.54)	Overestimated utilization
40	Dues & Subscriptions	(5.38)	New virtual meeting tools with subscriptions
41	Financial Service Charges	15.17	Increased use of online renewals
42	Office Meeting Expenses	(42.08)	Overestimated need for security for physical meetings
43	Office Supply Expenses	(6.08)	Close estimate
44	Utilities	(15.43)	Overestimated use
45	Civil Service Assessments (DSCS)	(0.94)	Premium set by state
46	Office Insurance (ORM)	(3.32)	Premium set by state
47	Depreciation of Fixed Assets	6.09	Underestimated amount of depreciation
48	Acquisitions	(57.81)	Deliberate deferrals
49	Salaries for Employees	8.84	Includes about \$24,000 for compensated absences
50	Wages for Temporary Labor	(37.22)	Planned use of student labor stalled by PHE
51	Payroll Taxes (FICA & FUTA)	(15.43)	Overestimate related to reduced use of student labor
52	Health Insurance (SEGBP)	(24.73)	Premiums are approximately 10% of salary load
53	Pension Plan (LASERS)	88.55	Includes about \$601,000 for GASB-68 adjustment
54	OPEB	28.59	Premium set by state
55	Board Member Per Diem	(30.10)	Overestimated meeting activity
56	Accounting Services	8.43	Underestimated cost of audit-related services
57	Legal Services	(74.80)	Overestimated cost of services
58	Information Systems	(15.32)	Overestimated need for special support services
59	Prescription Monitoring Program	3.56	New features on phased implementation
60	PMP Statewide Integration Project	32.97	Timing issue with LDH; balance paid in July
61	Drug Price Transparency Website	43.26	Contract converting to fiscal year timeline
62	Property Management	(11.47)	Overestimated property maintenance costs
63	Staff - Executive Director	(9.34)	Overestimated cost of meeting travel
64	Staff - General Counsel	(14.32)	Overestimated cost of meeting travel
65	Staff - Asst. Exec. Director	(27.17)	Overestimated cost of meeting travel
66	C.O. - Travel	(57.07)	Reduced need for travel during PHE
67	C.O. - Rental Cars	(37.77)	Reduced need for travel during PHE
68	C.O. - Fuel for Rental Cars	(35.63)	Reduced need for travel during PHE
69	C.O. - Conference Travel	(1.56)	Limited to USP 795/797/800 training
70	House Staff - Travel & Education	(3.30)	Limited to CBC-related travel
71	Mileage - entire staff	21.75	Underestimated mileage for staff
72	Board - Meeting Expenses	(10.36)	Overestimated meeting travel needs
73	Board - Committee Expenses	(19.62)	Overestimated committee meeting activity
74	Board - Conference Travel	(21.52)	Overestimated conference meeting activity
75	Board - President's Expenses	(14.73)	Overestimated meeting travel
76	Mileage - Board & President	(12.55)	Overestimated mileage for members
77	Total Expenses	18.56	Underestimated total expenses

Summary

78	Total Revenue	8.2% increase over FY19; 5.6% over FY20 budget
79	Total Expenses	31.4% increase over FY19; 18.6% increase over FY20 budget
80	Net Ordinary Income	1107% decrease from FY19; 234% decrease from FY20 budget
81	Investments	18.9% decrease from FY19
82	Net Income	379% decrease from FY19; 180% decrease from FY20 budget

Louisiana Board of Pharmacy
FY 2019-2020
Summary of Board Actions

Date	Action
11/13/2018	Original Budget - Finance Committee Approval
11/14/2018	Original Budget - Board Approval
8/13/2019	Budget Amendment #1 - Finance Committee Approval
8/14/2019	Budget Amendment #1 - Board Approval
	Budget Amendment #2 - Finance Committee Approval
5/27/2020	Budget Amendment #2 - Board Approval
	Acceptance of Final Report

Investment Account ~ Portfolio Snapshots

Reserve Account



Holdings by Investor
H5E-049797

Prepared for: LA Board of Pharmacy

As of: 6/30/20

LA Board of Pharmacy

Account Name: Louisiana Board of Pharmacy

Account Number: H5E049797

Account Type: Non-Profit Organization

ASSET	TICKER	INVESTMENT OBJECTIVE	MGT. NAME	QUANTITY	PRICE (\$)	VALUE (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	68,129.44	1.00	68,129.44
CASH		CASH		146,178.13	1.00	146,178.13
US TREAS INFLAT PROT	912828NM8	LONG-TERM BOND		25,000.00	1.18	29,544.11
US TREASU NT 1.375% UST NOTE DUE 08/31/20	912828L32	NON-CLASSIFIED		593,000.00	1.00	596,877.29
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44942	NON-CLASSIFIED		457,000.00	1.01	462,099.17
Louisiana Board of Pharmacy Total:						\$1,302,828.13
LA Board of Pharmacy Total:						\$1,302,828.13

OPEB Account



Holdings by Investor
H5E-077160

Prepared for: LA Board of Pharmacy

As of: 6/30/20

LA Board of Pharmacy

Account Name: OPEB Reserve account

Account Number: H5E077160

Account Type: Non-Profit Organization

ASSET	TICKER	INVESTMENT OBJECTIVE	MGT. NAME	QUANTITY	PRICE (\$)	VALUE (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	124,850.12	1.00	124,850.12
CASH		CASH		162,433.13	1.00	162,433.13
US TREASU NT 1.375% UST NOTE DUE 08/31/20	912828L32	NON-CLASSIFIED		241,000.00	1.00	242,575.76
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44942	NON-CLASSIFIED		728,000.00	1.01	736,122.97
OPEB Reserve account Total:						\$1,265,981.98
LA Board of Pharmacy Total:						\$1,265,981.98

Pension Account



Holdings by Investor
H5E-102679

Prepared for: LA Board of Pharmacy

As of: 6/30/20

LA Board of Pharmacy

Account Name: Pension Reserve account

Account Number: H5E102679

Account Type: Non-Profit Organization

ASSET	TICKER	INVESTMENT OBJECTIVE	MGT. NAME	QUANTITY	PRICE (\$)	VALUE (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	99,840.39	1.00	99,840.39
CASH		CASH		36,925.63	1.00	36,925.63
US TREASU NT 1.375% UST NOTE DUE 01/31/21	TSRYS44942	NON-CLASSIFIED		297,000.00	1.01	300,737.44
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44942	NON-CLASSIFIED		648,000.00	1.01	655,230.33
US TREASURY N/B 2% 31 DEC 2021	912828U81	NON-CLASSIFIED		769,000.00	1.03	789,970.63
Pension Reserve account Total:						\$1,882,704.43
LA Board of Pharmacy Total:						\$1,882,704.43

Louisiana Board of Pharmacy

Cumulative Fund Balance Reports

	<u>FY 98-99 Actual</u>	<u>FY 99-00 Actual</u>	<u>FY 00-01 Actual</u>	<u>FY 01-02 Actual</u>	<u>FY 02-03 Actual</u>	<u>FY 03-04 Actual</u>	<u>FY 04-05 Actual</u>	<u>FY 05-06 Actual</u>	<u>FY 06-07 Actual</u>	<u>FY 07-08 Actual</u>
Beginning Fund Balance	910,394	1,127,239	1,267,076	1,351,191	1,521,807	1,588,141	1,478,412	1,587,349	1,677,669	2,077,236
Total Income	984,414	1,030,423	1,168,798	1,200,575	1,223,872	1,274,804	1,524,411	1,627,306	2,228,918	2,657,168
Total Expenses	767,569	890,586	1,084,683	1,029,959	1,157,538	1,384,533	1,415,474	1,536,986	1,829,351	2,184,076
Ending Fund Balance	1,127,239	1,267,076	1,351,191	1,521,807	1,588,141	1,478,412	1,587,349	1,677,669	2,077,236	2,550,328
Reservations of Fund Balance	48,884	102,368	476,000	524,000	1,210,000	1,245,000	1,300,000	1,300,000	1,400,000	2,050,000
Unreserved Fund Balance	1,078,355	1,164,708	875,191	997,807	378,141	233,412	287,349	377,669	677,236	500,328

	<u>FY 08-09 Actual</u>	<u>FY 09-10 Actual</u>	<u>FY 10-11 Actual</u>	<u>FY 11-12 Actual</u>	<u>FY 12-13 Actual</u>	<u>FY 13-14 Actual</u>	<u>FY 14-15 Actual</u>	<u>FY 15-16 Actual</u>	<u>FY 16-17 Actual</u>	<u>FY 17-18 Actual</u>
Beginning Fund Balance	2,550,328	2,607,575	2,715,185	2,810,463	2,936,874	3,225,350	(620,086)	363,796	1,293,857.73	1,493,402.25
Total Income	2,570,282	2,706,829	2,808,468	2,775,418	2,849,249	3,059,394	3,615,033	3,512,690	3,191,751.77	3,348,540.33
Total Expenses	2,513,035	2,599,219	2,713,190	2,649,007	2,560,773	2,764,020	2,631,151	2,582,629	2,992,207.25	3,270,134.51
GASB Restatements						(4,140,810) (GASB-68)				(751,686.00) (GASB-75)
Ending Fund Balance	2,607,575	2,715,185	2,810,463	2,936,874	3,225,350	(620,086)	363,796	1,293,857	1,493,402.25	820,122.07
Reservations of Fund Balance	1,900,000	1,650,000	1,650,000	500,000	750,000	2,162,000	1,272,000	772,000	1,750,000.00	1,750,000.00
Unreserved Fund Balance	707,575	1,065,185	1,160,463	2,436,874	2,475,350	(2,782,086)	(908,204)	521,857	(256,597.75)	(929,877.93)



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Finance Committee

Proposed Budget Amendment No. 1 Fiscal Year 2020-2021

August 13, 2020

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
FY 2020-2021 Budget Amendment #1

Revenue

	FY 19-20 Actual	FY 20-21 Original	FY 20-21 BA-1	Notes
<u>Licensing Fees</u>				
PST License Application Fee	169,500.00	170,000.00	170,000.00	1
PST License Reciprocity Application Fee	42,450.00	49,000.00	45,000.00	2
PST License Renewal Fee	885,450.00	872,000.00	890,000.00	3
PNT Registration Application Fee	3,360.00	3,500.00	3,500.00	4
PTC Registration Application Fee	25,525.00	28,000.00	28,000.00	5
CPT Certificate Application Fee	41,100.00	55,000.00	50,000.00	6
CPT Certificate Renewal Fee	305,075.00	340,000.00	340,000.00	7
PHY Permit Application & Renewal Fee	275,425.00	281,000.00	75,000.00	8
AMS Registration Application & Renewal Fee	25,350.00	22,000.00	0.00	9
DME Permit Application & Renewal Fee	85,975.00	85,000.00	37,500.00	10
EDK Permit Application & Renewal Fee	10,625.00	12,000.00	0.00	11
CDS License Application & Renewal Fee	542,345.00	532,000.00	500,000.00	12
Credential Reinstatement Fee	28,450.00	25,000.00	28,000.00	13
Delinquent Renewal Fee for PST & CPT	13,637.50	14,000.00	14,000.00	14
Delinquent Renewal Fee for PHY & CDS	12,745.00	12,000.00	12,500.00	15
<u>Sales of Goods & Services</u>				
Product Charge for Duplicate Credentials	3,445.00	4,500.00	3,500.00	16
Product Charge for PST Original Certificate	5,550.00	6,000.00	5,750.00	17
Product Charge for PST Silver Certificate	600.00	500.00	500.00	18
Product Charge for Law Book & Supplement	510.00	500.00	500.00	19
Product Charge for Official List of Licensees	25,050.00	26,000.00	25,000.00	20
Product Charge for Document Copies	27.50	500.00	0.00	21
Service Charge for Document Certification	3,540.00	4,000.00	3,500.00	22
Service Charge for Inspection Services	0.00	3,000.00	0.00	23
Service Charge for PNT Practical Experience	340.00	250.00	250.00	24
Disposal of Assets	0.00	0.00	0.00	
<u>Administrative Fees</u>				
Administrative Fee for NSF Items	300.00	250.00	250.00	25
Administrative Fee for Handling & Mailing	160.00	500.00	250.00	26
<u>Enforcement Activities</u>				
Enforcement: Administrative Hearing Fee	18,750.00	22,000.00	10,000.00	27
Enforcement: Fines	271,000.00	250,000.00	150,000.00	28
Enforcement: Cost Recoveries	24,652.82	25,000.00	10,000.00	29
<u>Prescription Monitoring Program (PMP)</u>				
Assessments	607,875.00	591,000.00	608,000.00	30
<u>Grants</u>				
Private Grants	0.00	42,000.00	42,000.00	31
Government Grants	796,100.64	0.00	647,000.00	32
<u>Miscellaneous</u>				
	<u>23.01</u>	<u>500.00</u>	<u>0.00</u>	33
TOTAL REVENUE	4,224,936.47	3,477,000.00	3,700,000.00	34

Louisiana Board of Pharmacy
FY 2020-2021 Budget Amendment #1

Expenses

	FY 19-20 Actual	FY 20-21 Original	FY 20-21 BA-1	Notes
<u>Operations</u>				
Equipment Rentals	14,651.45	15,000.00	15,000.00	35
Equipment Maintenance	2,239.92	2,200.00	2,300.00	36
Telephone	17,946.06	20,000.00	20,000.00	37
Printing	36,871.37	18,000.00	37,000.00	38
Postage	56,075.33	60,000.00	60,000.00	39
Dues & Subscriptions	13,246.87	11,000.00	14,000.00	40
Financial Service Charges	61,038.45	53,000.00	65,000.00	41
Office Meeting Expenses	2,896.19	5,000.00	5,000.00	42
Office Supply Expenses	20,663.33	22,000.00	22,000.00	43
Utilities	9,302.46	11,000.00	10,000.00	44
Civil Service Assessment (DSCS)	8,321.00	8,300.00	8,400.00	45
Office Insurance (ORM)	21,269.00	22,000.00	22,000.00	46
Depreciation of Fixed Assets	58,351.04	56,000.00	58,300.00	47
Acquisitions	10,546.34	20,000.00	20,000.00	48
Miscellaneous	38.86	0.00	0.00	
<u>Personal Services</u>				
Salaries for employees	1,772,765.00	1,856,000.00	1,825,000.00	49
Wages for temporary labor	9,416.35	20,000.00	20,000.00	50
Payroll Taxes (FICA + FUTA)	28,752.14	32,000.00	28,000.00	51
Health Insurance Premiums (SEGBP)	142,267.16	175,000.00	182,000.00	52
Pension Plan Premiums (LASERS)	1,312,323.15	660,000.00	732,000.00	53
Other Post Employment Benefits (OPEB)	19,288.00	15,000.00	20,000.00	54
Board Member Per Diem	17,475.00	30,000.00	30,000.00	55
<u>Professional Services</u>				
Accounting & Expense Reimbursement	32,528.00	30,000.00	32,000.00	56
Legal & Expense Reimbursement	1,260.00	30,000.00	5,000.00	57
Information Systems	130,404.35	160,000.00	160,000.00	58
Prescription Monitoring Program	258,894.11	215,000.00	175,000.00	59
Drug Price Transparency Website	60,167.72	42,000.00	42,000.00	60
Statewide Integration PMP Gateway	779,192.92	0.00	647,000.00	61
Property Management	22,132.08	30,000.00	25,000.00	62
<u>Staff Expenses</u>				
Executive Director	2,719.90	5,000.00	0.00	63
Assistant Executive Director	2,184.96	5,000.00	0.00	64
General Counsel	5,997.02	10,000.00	500.00	65
Compliance Officer - Travel	3,005.21	7,000.00	3,000.00	66
Compliance Officer - Rental Cars	3,733.92	9,000.00	4,000.00	67
Compliance Officer - Fuel for Rental Cars	1,931.20	4,000.00	2,000.00	68
Compliance Officer - Conference Travel	13,782.28	14,000.00	0.00	69
House Staff Education & Travel	386.80	500.00	0.00	70
Mileage - entire staff	36,525.06	30,000.00	35,000.00	71
<u>Board Expenses</u>				
Board Meeting Expenses	11,653.61	18,000.00	3,000.00	72
Committee Expenses	4,019.11	10,000.00	7,000.00	73
Conference Travel Expenses	3,139.40	20,000.00	0.00	74
President's Expenses	4,263.65	8,000.00	0.00	75
Mileage - Members & President	13,117.83	20,000.00	15,000.00	76
TOTAL EXPENSES	5,026,783.60	3,779,000.00	4,351,500.00	77

Louisiana Board of Pharmacy
 FY 2020-2021 Budget Amendment #1

Summary of Fund Balance

	FY 19-20 Q4 06/30/2020	FY 20-21 Original	FY 20-21 BA-1
Total Revenue	4,224,936.47	3,478,000.00	3,700,000.00
Total Expenses	5,026,783.60	3,779,000.00	4,351,500.00
Net Ordinary Income	(801,847.13)	(302,000.00)	(651,500.00)
Other Income & Expenses			
Investments	131,182.04	0.00	0.00
Disposal of Assets	(3,311.52)	0.00	0.00
Net Income	(673,976.61)	(302,000.00)	(651,500.00)

	FY 19-20 Q4 06/30/2020	FY 20-21 Original	FY 20-21 BA-1
Beginning Fund Balance	1,061,509.08	661,509.64	387,532.47
Total Income	4,356,118.51	3,477,000.00	3,700,000.00
Total Expenses	5,030,095.12	3,779,000.00	4,351,500.00
State-Imposed Adjustments	0.00	0.00	0.00
Ending Fund Balance	387,532.47	359,509.64	(263,967.53)
Reservations of Fund Balance	1,750,000.00	(350,000.00)	(250,000.00)
Unreserved Fund Balance	(1,362,467.53)	9,509.64	(513,967.53)

Notes on Reservation of Fund Balance

Unfunded Pension Liability	1,000,000.00	100,000.00	0.00
Unfunded OPEB Liability	600,000.00	100,000.00	0.00
Compensated Absences	<u>150,000.00</u>	<u>150,000.00</u>	<u>250,000.00</u>
<i>Total</i>	<i>1,750,000.00</i>	<i>350,000.00</i>	<i>250,000.00</i>

Louisiana Board of Pharmacy
FY 2020-2021 Budget Amendment #1

Notes

Revenue

- 1 Using historical data, estimate 567 applicants @ \$300 each
- 2 Using historical data, estimate 300 applicants @ \$150 each
- 3 Using historical data, estimate 8,900 applicants @ \$100 each
- 4 Using historical data, estimate 350 intern applicants @ \$10 each
- 5 Using historical data, estimate 1,120 candidate applicants @ \$25 each
- 6 Using historical data, estimate 500 applicants @ \$100 each
- 7 Using historical data, estimate 6,800 applicants @ \$50 each
- 8 No domestic renewal fees; estimate 600 PHY-NR @ \$125 each
- 9 No domestic renewal fees
- 10 No domestic renewal fees; estimate 300 DME-NR @ \$125 each
- 11 No domestic renewal fees
- 12 No business permit renewals; estimate 24,000 practitioners @ \$20 each
- 13 Using historical data for reinstatement fees for all credential types
- 14 Using historical data for delinquent renewal fees for PST and CPT
- 15 Using historical data for delinquent renewal fees for CDS for practitioners
- 16 Using historical data for duplicate credential charges
- 17 Using historical data, estimate 77 purchases @ \$75 each
- 18 Using historical data, estimate 5 purchases @ \$100 each
- 19 Using historical data, estimate 33 purchases @ \$15 each
- 20 Using historical data, estimate 166 purchases @ \$150 each
- 21 Reduced demand due to increased use of electronic documents
- 22 Using historical data, estimate 175 requests @ \$20 each
- 23 U.S. Consumer Product Safety Commission has paused state contracts
- 24 With some reduced demand, estimate 25 requests @ \$10 each
- 25 With increased online renewals, estimate less checks and NSF charges
- 26 With some reduced demand during pandemic, estimate slight increase on full re-opening
- 27 With some reduced demand during pandemic, estimate 60 cases @ \$250 each
- 28 With reduced number of cases, estimate lower amount of fines assessed
- 29 With reduced number of cases, estimate lower amount of cost recoveries
- 30 Using historical data, estimate 24,320 assessments @ \$25 each
- 31 Private grant from PhRMA for drug price transparency website
- 32 Remaining amount of previous federal grant allocated to FY 21
- 33 Using historical data
- 34 Total revenue is 7.6% increase over original FY 21 budget; 11.4% decrease from FY 20 actual

Louisiana Board of Pharmacy
FY 2020-2021 Budget Amendment #1

Notes (cont.)

Expenses

- 35 Using historical data for equipment rental charges.
- 36 Using historical data for equipment maintenance and repairs
- 37 Using historical data for telephone charges plus greeting recording charges
- 38 Using historical data for printing charges; additional due to rule printing charges
- 39 Using historical data for postage expenses
- 40 Using historical data for dues and subscriptions
- 41 Using historical data plus increased use of online renewals for CDS licenses
- 42 Using historical data for office meeting expenses
- 43 Using historical data for office supply expenses
- 44 Using historical data for utilities, with some reduction due to PHE
- 45 Using historical data for state-assigned assessment
- 46 Using historical data for state-assigned assessment
- 47 Using historical data for depreciation of fixed assets
- 48 Using historical budget allocation for routine replacement of office hardware systems
- 49 Includes performance adjustments
- 50 Using historical budget allocation for part-time student workers
- 51 Calculated value: 1.5% of salaries plus wages
- 52 Using historical data; health insurance premiums average 10% of salaries
- 53 Calculated value: state-assigned pension assessment is 40.1% of salaries
- 54 Using historical data for state-assigned OPEB assessments
- 55 Using historical data for board member per diem expenses
- 56 Using historical data for accounting expenses
- 57 Using historical data for legal expenses with allocation for additional need
- 58 Using historical data for information system requirements
- 59 Using historical data; reduction reflects prior implementation of RxCheck
- 60 Using historical data; reduction reflects adjustment of contract timeline to fiscal year
- 61 Remaining amount of federal grant expenditure allocated to FY 21
- 62 Using historical data for property management expenses
- 63 Staff travel frozen
- 64 Staff travel frozen
- 65 Staff travel frozen
- 66 Using historical data for compliance officer field travel
- 67 Using historical data for compliance officer field travel
- 68 Using historical data for compliance officer field travel
- 69 Staff travel frozen
- 70 Staff travel frozen
- 71 Mileage payments restricted to compliance officer field travel
- 72 Member travel frozen
- 73 Member travel frozen
- 74 Member travel frozen
- 75 Member travel frozen
- 76 Mileage payments restricted to member travel to board and committee meetings
- 77 Total expenses are 14.8% over original FY 21 budget; 13.6% decrease from FY 20 actual.

Louisiana Board of Pharmacy
FY 2020-2021 Budget Amendment #1

Board Action Summary

Date	Action
11/12/2019	Original Budget - Finance Committee Approval
11/13/2019	Original Budget - Board Approval
8/12/2020	Budget Amendment #1 - Finance Committee Approval
	Budget Amendment #1 - Board Approval
	Budget Amendment #2 - Finance Committee Approval
	Budget Amendment #2 - Board Approval
	Acceptance of Final Report

Louisiana Board of Pharmacy
FY 2020-2021 Budget Amendment #1

Schedule A - Personnel Salary Schedule

<u>Class.</u>	<u>Name</u>	<u>Hire Date</u>	<u>FY 19-20 6/30/2020</u>	<u>FY 20-21 Original</u>	<u>FY 20-21 BA-1</u>
Credentials Division					
AS-609	Alise, Tanner E.	5/20/2019	22,630.40	23,536.00	23,545.60
AS-609	Moses, Ashley L.	9/24/2018	28,038.40	29,160.00	29,161.60
AS-609	Taranto, Lee M.	10/2/2017	28,038.40	29,160.00	29,161.60
AS-612	Shelton, Arielle	6/12/2017	29,452.80	30,631.00	33,862.40
AS-612	Schultz, Lindsey M.	1/12/2015	34,694.40	36,082.00	36,088.00
AS-613	Chatman, Amicha R.	1/5/2009	43,097.60	44,822.00	44,387.20
AS-613	Cushenberry, Jonesha C.	10/2/2017	35,963.20	37,402.00	37,398.40
AS-618	Stevens, Sarah B.	10/29/2007	56,035.20	58,277.00	58,011.20
AS-605	[Administrative Coordinator 1]		3 additional positions authorized by DSCS		
AS-609	[Administrative Coordinator 3]		3 additional positions authorized by DSCS		
AS-611	[Licensing Analyst 1]		1 additional position authorized by DSCS		
Compliance Division					
MS-525	Aaron, Cary D.	4/8/2013	118,206.40	122,935.00	120,577.60
MS-525	Dennis, Daniel M.	3/1/2016	113,609.60	118,154.00	117,020.80
MS-525	Gross, Nicole L.	3/6/2017	113,609.60	118,154.00	117,020.80
MS-525	Harris, Alicia P.	2/4/2019	107,000.00	111,280.00	110,198.40
MS-525	Parker, Becky C.	2/4/2019	107,000.00	111,280.00	110,198.40
MS-525	Savoie, Huey J.	8/1/2002	119,308.80	124,081.00	121,700.80
MS-527	Whaley, Benjamin S.	9/17/2007	128,939.20	134,097.00	132,808.00
MS-525	[PST Compliance Officer]		1 additional position authorized by DSCS		
PMP Division					
AS-609	Hartzog, M. Danielle	9/21/2015	32,115.20	33,400.00	33,072.00
AS-609	Montgomery, Nerissa	10/5/2015	32,385.60	33,681.00	33,363.20
AS-609	Ravindranath, Reshmi	8/19/2019	30,000.00	31,200.00	29,203.20
AS-609	[Administrative Coordinator 3]		1 additional position authorized by DSCS		
Administrative Division					
AS-609	Lewis, Robbi L.	8/19/2019	30,000.00	31,200.00	29,203.20
AS-609	[Vacancy: Admin. Coord. 3]		30,000.00	31,200.00	30,000.00
U	Villeneuve, Kelley L.	1/23/2002	62,885.00	65,400.00	65,400.00
MS-528	Fontenot, M. Joseph	12/2/2002	140,608.00	146,233.00	144,830.40
U	Finalet, Carlos M., III	7/24/2000	142,317.00	148,010.00	148,010.00
U	Broussard, Malcolm J.	6/16/1999	182,905.00	182,905.00	190,221.00
AS-605	[Administrative Coordinator 1]		1 position authorized by DSCS		
TS-305	[IT Office Specialist 3]		1 position authorized by DSCS		
TS-310	[IT Tech Support Specialist 1]		1 position authorized by DSCS		
20 + 3 + 1	TOTAL	23	1,768,839.80	1,832,280.00	1,824,443.80

Notes

Entries are annualized hourly rates and not necessarily actual earnings.



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Application Review Committee



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Reciprocity Committee

***New Pharmacist Credentials Issued by Reciprocity
Issued Since 05/15/2020***

	<u>Applicant</u>	<u>Interviewer</u>	<u>Result</u>		
1	Erhard Vitel Dzouankeu Kamdoum (TX)	Waived	PST.023413	issued	05/21/20
2	Ifeoma Gloria Anugwom (TX)	Waived	PST.023416	issued	05/26/20
3	Kirsten Marie Ferraro (MI)	Waived	PST.023417	issued	05/26/20
4	Laura Elena Barron (TX)	Waived	PST.023418	issued	06/02/20
5	You Suck Jung (NJ)	Waived	PST.023420	issued	06/03/20
6	Katheryne Photijak Stack (IA)	Waived	PST.023421	issued	06/03/20
7	Mackenzie Lewis Creamer (TX)	Waived	PST.023422	issued	06/03/20
8	Samantha Michelle Boudreau (NH)	Waived	PST.023423	issued	06/03/20
9	Theresa Ellen Lichtenwalner (PA)	Waived	PST.023424	issued	06/03/20
10	Matthew John Buschjost (MO)	Waived	PST.023425	issued	06/04/20
11	Tiffani Lashai Reed (FL)	Waived	PST.023426	issued	06/04/20
12	Sophia Shaheen Altaf (NY)	Waived	PST.023427	issued	06/04/20
13	Lisa Brown Martin (KY)	Waived	PST.023428	issued	06/11/20
14	Nicole Dao Nguyen (CA)	Waived	PST.023430	issued	06/18/20
15	Bethany Shea LaVergne (NC)	Waived	PST.023435	issued	06/18/20
16	Oscar Santos Ereso Jr (NV)	Waived	PST.023436	issued	06/18/20
17	Andrew Chiwei Wed (DE)	Waived	PST.023438	issued	06/22/20
18	Pamela Nneka Obah (AZ)	Waived	PST.023440	issued	06/22/20
19	Imi Anesu Mvere (AR)	Waived	PST.023441	issued	06/23/20
20	Amber Michelle Kyle (MO)	Waived	PST.023442	issued	06/24/20
21	Howard Samuel Kreisler (CO)	Waived	PST.023443	issued	06/24/20
22	Christine Hayden Davis (MS)	Waived	PST.023444	issued	06/24/20
23	Meyyappan Ramanathan (FL)	Waived	PST.023447	issued	06/29/20
24	Lata Milind Narawane (TX)	Waived	PST.023448	issued	06/29/20
25	Kim-Chau Buu Trinh (MS)	Waived	PST.023454	issued	06/30/20
26	Katherine Marie Melcher (KS)	Waived	PST.023455	issued	06/30/20
27	George Stephan Decelle (NH)	Waived	PST.023457	issued	07/09/20
28	Lauren Elizabeth Levi (OH)	Waived	PST.023463	issued	07/10/20
29	Stephen Gregory Freeman (AL)	Waived	PST.023468	issued	07/13/20
30	Kwadwo Anane-Agyei Baah (TX)	Waived	PST.023469	issued	07/13/20
31	Bethany Christine Lane (OH)	Waived	PST.023470	issued	07/13/20
32	Patrick Lincoln Ryan (MA)	Waived	PST.023471	issued	07/14/20
33	Taylor Rose White (NY)	Waived	PST.023474	issued	07/22/20
34	Catherine Huong-Duyen Vu (PA)	Waived	PST.023475	issued	07/22/20
35	Arwa Ghali Hamza Aboud (TX)	Waived	PST.023485	issued	07/22/20
36	Bradley Daniel Bright (TN)	Waived	PST.023486	issued	07/22/20
37	Karley Mackenzie Bergquist (CO)	Waived	PST.023493	issued	07/29/20
38	Chhime Dokha Sherpa (NJ)	Waived	PST.023497	issued	07/29/20
39	David John Hester (IA)	Waived	PST.023499	issued	07/29/20
40	Natalie Lynne Tucker (OR)	Waived	PST.023502	issued	07/29/20
41	Ripal Amratlal Gandhi (TX)	Waived	PST.023503	issued	07/29/20
42	Ngoc Anh Cindy Cao Vu (MS)	Waived	PST.023508	issued	07/29/20

Total: 42



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Violations Committee

1 **Louisiana Board of Pharmacy**

Policies & Procedures

2
3 *Title:* Violations Committee – Publication of
4 Final Adverse Actions

Policy No. I.C.7.a

5
6 Approved: 04-06-2000

Revised: 08-15-2018

7
8
9 1. The regulatory authority for the Board to publish final adverse actions is found at
10 LAC 46:LIII.355.

11
12 2. The Board shall publish all final adverse actions. ~~(name, license or permit number,~~
13 ~~charge, and sanction) in the official newsletter, except for reprimands, warnings, and~~
14 ~~all cases related to impairment.~~

DRAFT

50
51
52
53
54
55
56
57

Revision History

08-12-2020	<u>Revised Item 2 to remove exclusions and publish all sanctions.</u>
08-15-2018	Re-numbered policy.
05-05-2004	Updated the regulatory citation in Article 1.

DRAFT



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Impairment Committee



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Reinstatement Committee



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Tripartite Committee



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Regulation Revision Committee



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



August 13, 2020

Agenda Item 9-H. Report of Regulation Revision Committee

(1) Consideration of Renewal of Pilot Projects

A. Remote Dispensing System by Highgate Ventures, LLC

The Board initially approved this pilot project for the use of a remote dispensing system at an unlicensed medical clinic in August 2018. The system was operated and controlled by a community pharmacy in Covington. The Board's Regulation Revision Committee relied on observations and data from the pilot project in its development of proposed rule changes now included in *Regulatory Project 2020-2 ~ Automated Medication Systems*. During their August 2019 meeting, the Board took note of the pending rule change and authorized the continuation of the pilot project for one additional year. Due to the closure of the community pharmacy in Covington secondary to the COVID-19 pandemic, Board President Aron authorized the transfer of the remote dispensing system to another community pharmacy in Winnfield. The authority for this pilot project is scheduled to expire on August 31, 2020.

Recommendation: Extend the authority for the pilot project until the *earliest* of the following dates: promulgation of the final rule in *Regulatory Project 2020-2 ~ Automated Medication Systems*, or August 31, 2021.

B. Automated Medication System by Institutional Pharmacies of Louisiana, LLC

The Board initially approved this pilot project for the use of an automated medication system in a correctional center setting in August 2019. The system is operated and controlled by a pharmacy in Scott which specializes in providing medication services for patients in institutional settings. The Board's Regulation Revision Committee relied on observations and data from the pilot project in its development of two sets of rule changes – *Regulatory Project 2019-5 ~ Correctional Center Pharmacy*, which was completed in April 2020, as well as *Regulatory Project 2020-2 ~ Automated Medication Systems*, which is still pending. The authority for this pilot project is scheduled to expire on August 31, 2020.

Recommendation: Extend the authority for the pilot project until the *earliest* of the following dates: promulgation of the final rule in *Regulatory Project 2020-2 ~ Automated Medication Systems*, or August 31, 2021.

NOTICE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTICE: In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; info@pharmacy.la.gov. (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; h&ga@legis.la.gov. (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; s&g@legis.la.gov.

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 5. Pharmacists

§521. ~~Prescription Orders to Administer~~ Administration of Medications

A. ~~Purpose. The rules of this section describe the minimum requirements for the administration of medications to patients by Louisiana licensed pharmacists. Subsection A repealed~~

A. Pharmacists, pharmacy interns, and pharmacy technicians who intend to administer medications to their patients shall obtain a Medication Administration Registration from the board prior to engaging in such activity. Pharmacy interns and pharmacy technicians in possession of the Medication Administration Registration may only administer medications while under the supervision of a pharmacist in possession of a Medication Administration Registration.

~~B. A licensed pharmacist may administer medication directly to a patient upon the prescription or order of a practitioner. Such a prescription or order shall be known as an “Authority to Administer.”~~

~~1. An Authority to Administer is valid only for the pharmacist meeting the requirements herein and is not transferable.~~

~~2. An Authority to Administer, once granted, is valid for a period of time not to exceed six months, unless revoked sooner by the practitioner granting the order. Subsection B repealed~~

B. Medication Administration Registration

1. Eligibility

a. The applicant shall possess a pharmacist license, intern registration, or pharmacy technician certificate issued by the board; and further, such credential shall be active and valid for practice.

b. The applicant shall demonstrate current life safety certification by the American Heart Association through its Basic Life Support (BLS) for Healthcare Providers course, or its successor, or by a board-approved equivalent.

c. The applicant shall demonstrate successful completion of a certificate program for medication administration which has been approved by the board. The board may approve any program which is an evidence-based didactic course that meets current Centers for Disease Control and Prevention (CDC) training guidelines, or other guidelines as designated by the board, and provides a minimum of 20 hours of instruction and experiential training in the following content areas:

i. standards for medication administration practices;

- 38 ii. basic immunology;
39 iii. recommended medication administration schedules;
40 iv. vaccine storage and management;
41 v. informed consent;
42 vi. physiology and techniques for medication administration;
43 vii. pre- and post-administration assessment and counseling;
44 viii. medication administration record management; and
45 ix. management of adverse events, including identification and appropriate response, as well
46 as documentation and reporting.
- 47 2. Application for Initial Issuance
- 48 a. The applicant shall complete the application form supplied by the board and furnish the
49 information requested.
- 50 b. The applicant shall retain evidence of their education, training, and continuing competency;
51 and further, shall furnish copies of such documentation upon request by the board.
- 52 c. The board shall issue the registration with an expiration date matching the expiration date of
53 the life safety certification card supplied with the application.
- 54 3. Renewal
- 55 a. In the event the pharmacist license, intern registration, or technician certificate expires before
56 the expiration date of the Medication Administration Registration, then the authority to
57 administer medications shall terminate. The authority to administer medications requires the
58 primary credential as well as the Medication Administration Registration to be active at the
59 same time.
- 60 b. The renewal of an expired Medication Administration Registration requires demonstration of a
61 current life safety certification as described above.
- 62 c. To maintain continuing competency for medication administration, the pharmacist or the
63 pharmacy technician shall acquire at least one hour of continuing education per year related to
64 this topic. Continuing education activities obtained for this purpose shall be acquired from a
65 provider accredited by the Accreditation Council for Pharmacy Education (ACPE); and
66 further, the credit earned for such programs may be included within the total number of credits
67 required to renew the pharmacist license or technician certificate.
- 68 C. A properly executed Authority to Administer shall:
- 69 1. identify the licensed practitioner's name, office address, and telephone number;
70 2. bear the patient's name, address, gender, and date of birth;
71 3. identify the medication, dose, and route of administration;
72 4. identify the pharmacist authorized to administer the medication; and

- 73 5. ~~bear the date of the original order and the date of any authorized subsequent dose~~
74 ~~administrations. Subsection C repealed~~
- 75 D. ~~Requirements. Unless otherwise specifically authorized by the board, a pharmacist shall meet the~~
76 ~~following minimum standards to qualify for an Authority to Administer:~~
- 77 1. ~~obtain and maintain a license to practice pharmacy from the board;~~
78 2. ~~successfully complete a board approved course of study from a board approved provider that:~~
- 79 a. ~~requires documentation by the pharmacist of current certification in the American~~
80 ~~Heart Association's Basic Cardiac Life Support for Healthcare Providers, its~~
81 ~~successor, or board approved equivalent;~~
82 b. ~~is an evidence based didactic course that meets current Centers for Disease~~
83 ~~Control and Prevention (CDC) training guidelines, or other guidelines as~~
84 ~~designated by the board, and provides a minimum of twenty hours of instruction~~
85 ~~and experiential training in the following content areas:~~
- 86 i. ~~standards for medication administration practices;~~
87 ii. ~~basic immunology;~~
88 iii. ~~recommended medication administration schedules;~~
89 iv. ~~vaccine storage and management;~~
90 v. ~~informed consent;~~
91 vi. ~~physiology and techniques for medication administration;~~
92 vii. ~~pre and post administration assessment and counseling;~~
93 viii. ~~medication administration record management; and~~
94 ix. ~~management of adverse events, including identification and appropriate~~
95 ~~response, as well as documentation and reporting; and~~
- 96 e. ~~provides documentation of the successful completion of the course to the~~
97 ~~participant.~~
- 98 i. ~~The pharmacist shall display the certificate of completion in the~~
99 ~~primary practice site.~~
- 100 ii. ~~The pharmacist shall submit a copy of said certificate to the board~~
101 ~~office for placement in the pharmacist's permanent file. Subsection D~~
102 ~~repealed~~
- 103 E. ~~The pharmacist shall maintain continuing competency to accept an Authority to Administer, as~~
104 ~~evidenced by:~~
- 105 1. ~~a current certification by the American Heart Association's Basic Cardiac Life Support for~~
106 ~~Healthcare Providers, its successor, or board approved equivalent; and~~
- 107 2. ~~successful completion of at least one hour of continuing education per year related to this area~~
108 ~~of practice. Subsection E repealed~~

109 ~~F~~ C. Vaccines110 1. The pharmacist shall maintain and furnish the following information to the practitioner within
111 ~~twenty-four~~ 24 hours of the administration:

- 112 a. Name and address of the patient;
-
- 113 b. Age of the patient, if under 14 years of age;
-
- 114 c. Name of the patient's primary care physician as provided by the patient or patient's agent;
-
- 115 d. Name, manufacturer, and lot number of the vaccine administered;
-
- 116 e. Amount administered;
-
- 117 f. Date of vaccine administration;
-
- 118 g. Site of vaccine administration;
-
- 119 h. Route of administration; and
-
- 120 i. Name, address, and telephone number of the pharmacist administering the vaccine.

121 2. The immunizing pharmacist or his designee shall report the immunization to the state
122 immunization registry within 72 hours of the administration of the immunization.123 ~~G. A pharmacist certified to administer medications may train a pharmacy intern to administer
124 medication, provided the pharmacy intern meets the same educational requirements and minimum
125 standards identified in Subsections D.2 and E of this Section. The intern shall be under the direct and
126 immediate supervision of the certified pharmacist at all times during such training activities.~~127 ~~Subsection G repealed~~128 ~~H D. Pharmacies hosting immunization medication administration activities, as well as pharmacists
129 administering immunizations medications in a location other than a pharmacy, shall comply with the
130 following minimum standards:~~131 a. ~~There shall be sufficient staffing available for the pharmacist to administer the immunization
132 medication and monitor the patient afterward without distraction from other responsibilities.~~133 b. ~~To facilitate emergency management of anaphylactic reactions, there shall be adequate
134 supplies of medication and equipment, as well as pre-determined procedures for the
135 arrangement of emergency medical services.~~

136

137 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

138 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708
139 (October 1988), effective January 1, 1989, amended LR 29:2085 (October 2003), effective January 1, 2004,
140 amended LR 34:1409 (July 2008), amended by the Department of Health, Board of Pharmacy, LR

141

EMERGENCY RULE

Department of Health

Board of Pharmacy

Administration of Medications (LAC 46:LIII.521)

The Louisiana Board of Pharmacy is exercising the emergency provisions of the Administrative Procedure Act, specifically at R.S. 49:953(B), to promulgate an emergency rule to authorize pharmacy technicians to qualify for and obtain a Medication Administration Registration which will authorize them to administer medications including immunizations.

The Board's current rules permit pharmacists and pharmacy interns to administer medications after obtaining a Medication Administration Registration. The proposed rule change will allow pharmacy technicians to qualify for and obtain a Medication Administration Registration. The proposed rule change will increase the number of pharmacy personnel trained and authorized to administer medications.

As the availability of a vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) draws near, the Board anticipates the demand for pharmacy personnel to administer the vaccine will increase. Further, the Board anticipates that demand will be increased by the concurrent flu season. The Board proposes to amend the rule for medication administration registrations to authorize pharmacy technicians to qualify for and obtain such a registration, which will increase the number of pharmacy personnel authorized to administer medications including immunizations.

Given the time necessary for pharmacy technicians to obtain the required education and training prior to the arrival of the coronavirus vaccine and the flu season, the Board has determined this emergency rule is necessary to prevent imminent peril to the public's health, safety, and welfare. This emergency rule shall become effective August 15, 2020 and shall remain in effect for 120 days unless rescinded or renewed.

Title 46

PROFESSIONAL AND OCCUPATIONAL STANDARDS

Part LIII. Pharmacists

Chapter 5. Pharmacists

§521. Administration of Medications

A. Pharmacists, pharmacy interns, and pharmacy technicians who intend to administer medications to their patients shall obtain a Medication Administration Registration from the board prior to engaging in such activity. Pharmacy interns and pharmacy technicians in possession of the Medication Administration Registration may only administer medications while under the supervision of a pharmacist in possession of a Medication Administration Registration.

B. Medication Administration Registration

1. Eligibility

a. The applicant shall possess a pharmacist license, intern registration, or pharmacy technician certificate issued by the board; and further, such credential shall be active and valid for practice.

b. The applicant shall demonstrate current life safety certification by the American Heart Association through its Basic Life Support (BLS) for Healthcare Providers course, or its successor, or by a board-approved equivalent.

c. The applicant shall demonstrate successful completion of a certificate program for medication administration which has been approved by the board. The board may approve any program which is an evidence-based didactic course that meets current Centers for Disease Control and Prevention (CDC) training guidelines, or other guidelines as designated by the board, and provides a minimum of 20 hours of instruction and experiential training in the following content areas:

- i. standards for medication administration practices;
- ii. basic immunology;

- iii. recommended medication administration schedules;
- iv. vaccine storage and management;
- v. informed consent;
- vi. physiology and techniques for medication administration;
- vii. pre- and post-administration assessment and counseling;
- viii. medication administration record management; and
- ix. management of adverse events, including identification and appropriate response, as well as documentation and reporting.

2. Application for Initial Issuance

- a. The applicant shall complete the application form supplied by the board and furnish the information requested.
- b. The applicant shall retain evidence of their education, training, and continuing competency; and further, shall furnish copies of such documentation upon request by the board.
- c. The board shall issue the registration with an expiration date matching the expiration date of the life safety certification card supplied with the application.

3. Renewal

- a. In the event the pharmacist license, intern registration, or technician certificate expires before the expiration date of the Medication Administration Registration, then the authority to administer medications shall terminate. The authority to administer medications requires the primary credential as well as the Medication Administration Registration to be active at the same time.

- b. The renewal of an expired Medication Administration Registration requires demonstration of a current life safety certification as described above.

- c. To maintain continuing competency for medication administration, the pharmacist or the pharmacy technician shall acquire at least one hour of continuing education per year related to this topic. Continuing education activities obtained for this purpose shall be acquired from a provider accredited by the Accreditation Council for Pharmacy Education (ACPE); and further, the credit earned for such programs may be included within the total number of credits required to renew the pharmacist license or technician certificate.

C. Vaccines

1. The pharmacist shall maintain and furnish the following information to the practitioner within 24 hours of the administration:

- a. Name and address of the patient;
- b. Age of the patient, if under 14 years of age;
- c. Name of the patient's primary care physician as provided by the patient or patient's agent;
- d. Name, manufacturer, and lot number of the vaccine administered;
- e. Amount administered;
- f. Date of vaccine administration;
- g. Site of vaccine administration;
- h. Route of administration; and
- i. Name, address, and telephone number of the pharmacist administering the vaccine.

2. The immunizing pharmacist or his designee shall report the immunization to the state immunization registry within 72 hours of the administration of the immunization.

D. Pharmacies hosting medication administration activities, as well as pharmacists administering medications in a location other than a pharmacy, shall comply with the following minimum standards:

1. There shall be sufficient staffing available for the pharmacist to administer the medication and monitor the patient afterward without distraction from other responsibilities.

2. To facilitate emergency management of anaphylactic reactions, there shall be adequate supplies of medication and equipment, as well as pre-determined procedures for the arrangement of emergency medical services.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2085 (October 2003), effective January 1, 2004, LR 34:1409 (July 2008), amended by the Department of Health, Board of Pharmacy, LR 46

Malcolm J Broussard

Executive Director

DRAFT

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 9. Pharmacy Technicians

§907. Scope of Practice; Pharmacist Supervision

A. Pharmacy technician candidates and pharmacy technicians may assist the pharmacist by performing those duties and functions assigned by the pharmacist while under his direct and immediate supervision.

- ~~1. The ratio of candidates to pharmacists on duty shall not exceed one to one at any given time.~~
 - ~~2. The ratio of technicians to pharmacists on duty shall not exceed two to one at any given time.~~
- However, the ratio of technicians to pharmacists on duty may be increased to three to one if no technician candidates are on duty at the same time.

- 1. To facilitate the education and training of pharmacy technician candidates, a pharmacist on duty shall not supervise more than one pharmacy technician candidate at any given time.
- 2. The determination of the appropriate pharmacist-pharmacy technician supervision shall be made by the pharmacist-in-charge. No other person, whether or not credentialed by the board, shall interfere with the independent professional judgment of the pharmacist-in-charge in that determination. Evidence of such interference will subject the pharmacy permit or other licensee to disciplinary action by the board.

B. – C.3. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1212.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 30:2486 (November 2004), effective January 1, 2005, amended LR 32:1049 (June 2006), amended by the Department of Health, Board of Pharmacy, LR 43:2498 (December 2017), effective January 1, 2018, amended LR

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 24. Limited Service Providers

§2425. Telepharmacy Dispensing Site

A. – C.2. ...

D. Closure of Permit

1. When the owner of the permit intends to close the telepharmacy dispensing site permanently, the owner's managing officer and the pharmacist-in-charge shall be accountable to the board for the proper closure of the pharmacy in compliance with Section 1133 of ~~the board's rules~~ this Part.

2. ...

E. Standards of Practice

1. Environmental Standards

a. The prescription department shall consist of ~~an area at least 300 square feet in size~~ sufficient space commensurate with the nature and scope of the pharmacy's practice; this space shall be restricted to authorized personnel only and not accessible to the general public.

E.1.b. – E.1.g. ...

2. Minimum Staffing Requirements

a. The pharmacist-in-charge of the supervising central pharmacy shall be the pharmacist-in-charge of the telepharmacy dispensing site, and this requirement shall operate as an exception to the provisions of ~~Section Paragraph 1105.A.2 and Section Subsection 1105.K of the board's rules~~ this Part. However, the pharmacist-in-charge shall comply with the remaining provisions of Section 1105 of ~~the board's rules~~ this Part.

b. – c. ...

d. A pharmacy intern or pharmacy technician candidate may not practice at a telepharmacy dispensing site.

e. ...

3. Operational Standards

a. The telepharmacy dispensing site shall comply with the provisions of Chapters 11, 25, 27, and 29 of ~~the board's rules~~ this Part except when this Subchapter grants exceptions or imposes more stringent requirements.

E.3.b. – E.3.f. ...

g. A pharmacist shall ~~counsel the patient or patient's agent for all new prescriptions and refills~~

38 comply with the rules for drug utilization review and patient counseling in Chapter 5 of this
39 Part, using ~~the~~ HIPAA compliant technology in the telepharmacy system,

40 E.3.h. – E.4.d. ...

41

42 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

43 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 21:2149 (October
44 2015), amended by the Department of Health, Board of Pharmacy, LR

45

DRAFT

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 24. Limited Service Providers

Subchapter E. Marijuana Pharmacy

§2451. Operation of Marijuana Pharmacy

A. – P. ...

Q. ~~No marijuana shall be sold, dispensed or distributed via a delivery service or any other manner outside of a marijuana pharmacy, except that a caregiver may deliver marijuana to the caregiver's patient.~~
Delivery of Dispensed Marijuana Products. A marijuana pharmacy shall dispense a marijuana product to a patient or his caregiver in the marijuana pharmacy. At the patient's request, the caregiver may deliver a dispensed marijuana product to the patient's location. At the patient or caregiver's request, the marijuana pharmacy may deliver or facilitate the delivery of a dispensed marijuana product to the patient's location. The delivery of a dispensed marijuana product is subject to the following requirements:

1. The marijuana pharmacy shall not deliver or facilitate the delivery of a marijuana product to a location outside the state.
2. The marijuana pharmacy shall ensure the physical integrity and security of the marijuana product while in transit.
3. In the event the delivery of the marijuana product is not completed, the marijuana product shall be returned to the marijuana pharmacy from which it was dispensed.
4. In the event the pharmacist-in-charge of the marijuana pharmacy cannot assure the integrity and security of a returned marijuana product, the pharmacy shall dispose of the marijuana product.

R. – U. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1547 (August 2017).
amended LR

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 24. Limited Service Providers

Subchapter E. Marijuana Pharmacy

§2443. Marijuana Products

A. – D.1.e.v. ...

2. Labeling.

- a. Each product shall be labeled by the producer prior to its sale to the marijuana pharmacy.
- b. Each label shall be securely affixed to the package and shall ~~include, at a minimum:~~ comply with labeling standards for marijuana products promulgated by LDAF.
 - i. ~~The batch or lot number assigned by the producer to the marijuana plant(s) from which the marijuana used in the product was harvested;~~
 - ii. ~~A complete list of solvents, chemicals, and pesticides used in the creation of any marijuana concentrate;~~
 - iii. ~~A complete list of all ingredients used to manufacture the product, which may include a list of any potential allergens contained within, or used in the manufacture of, a product;~~
 - iv. ~~The potency of the THC and CBD in the product, expressed in milligrams for each cannabinoid;~~
 - v. ~~The net weight, using a standard of measure compatible with the LMMTS, of the product prior to its placement in the shipping container;~~
 - vi. ~~A product expiration date, upon which the product will no longer be fit for use. Once a label with an expiration date has been affixed to a product, the producer shall not alter that date or affix a new label with a later date; and~~
 - vii. ~~A statement the product has been tested for contaminants, that there were no adverse findings, and the date of such testing.~~
 - viii. ~~A product identification code registered with the board.~~
- b. The labeling text on any marijuana product shall not make any false or misleading statements regarding health or physical benefits to the consumer. Further, each label shall include all of the following statements:
 - i. ~~“Contains Marijuana. For Medical Use Only. KEEP OUT OF THE REACH OF CHILDREN.”~~
 - ii. ~~“Marijuana can impair concentration, coordination, and judgment. Do not operate a vehicle or machinery under the influence of this drug.”~~

- 40 iii. ~~“There may be additional health risks associated with the consumption of this product~~
41 ~~— for women who are pregnant, breastfeeding, or planning to become pregnant.”~~
42 iv. ~~A statement that it is illegal for any person to possess or consume the contents of the~~
43 ~~— package other than the patient for whom it was recommended.~~
44 e. ~~The labeling text required by this Section shall be no smaller than 1/16 of an inch, shall be~~
45 ~~printed in English, and must be unobstructed and conspicuous.~~
46 c. The label for each product shall bear a product identification code registered with the board.
47 d. The producer may utilize a two-dimensional quick response (QR) code or a package insert
48 which is enclosed or attached to the product container to provide the information required in
49 this Section. If the producer elects to use such supplementary labeling, the label affixed to the
50 outer surface of the product container shall contain the following information, at a minimum
51 i. the batch or lot number ~~referenced at Clause D.2.a.i of this Section;~~
52 ii. the potency of ~~the any~~ THC and ~~or~~ CBD ~~referenced at Clause D.2.a.iv of this Section~~
53 contained therein;
54 iii. the net weight ~~referenced at Clause D.2.a.v of this Section;~~
55 iv. the expiration date ~~referenced at Clause D.2.a.vi of this Section;~~ and
56 v. ~~the any~~ caution statements ~~referenced at Clause D.2.b.i of this Section.~~

57 E. – E.4.f. ...

58
59 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.

60 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1540 (August 2017),
61 amended LR 45:1473 (October 2019), amended LR 46:568 (April 2020), amended LR
62

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 5. Pharmacists

Subchapter B. Professional Practice Procedures

§519. State of Emergency

A. When the Governor issues, or renews, a “State of Emergency” pursuant to the Emergency Assistance and Disaster Act of 1993, R.S. 29:721 *et seq.* or a “State of Public Health Emergency” pursuant to the Louisiana Health Emergency Powers Act, R.S. 29:760 *et seq.*:

- 1. A pharmacist may ~~work in the affected parish(es) and may~~ dispense ~~an one-time~~ emergency prescription of up to a ~~30~~ 90-day supply of a prescribed medication if:
 - a. in the pharmacist’s professional opinion the medication is essential to the maintenance of life or to the continuation of therapy; and
 - b. the pharmacist makes a good faith effort to reduce the information to a written prescription marked “Emergency Prescription”, then file and maintain the prescription as required by law.
- 2. A pharmacist not licensed in Louisiana, but currently licensed in another state, may dispense prescription medications in the affected parish(es) ~~or parishes~~ during the time a state of emergency exists when:
 - a. the pharmacist has some type of identification to verify current unrestricted licensure in another state;
 - b. the pharmacist has obtained a special work permit from the board;
 - ~~b~~ c. the pharmacist is engaged in a legitimate relief effort during the emergency period; and
 - e ~~d~~. the pharmacist and pharmacy notify the board of their presence and approximate location in the affected parish or parishes prior to the engagement of professional practice.

B. The authority provided for in this ~~s~~Section shall cease with the termination of the state of emergency.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2085 (October 2003), effective January 1, 2004, amended LR 33:1125 (June 2007), amended LR

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 11. Pharmacies

Subchapter A. General Requirements

§1103. Prescription Department Requirements

A. – J. ...

K. References. The current edition of the *Louisiana Board of Pharmacy Laws and Regulations* shall be maintained and readily available within the prescription department of a pharmacy. The pharmacy shall maintain access to current and appropriate reference materials pertinent to the pharmacy practice, including but not limited to, pharmacology, drug interactions, dosing, toxicity, specialty care such as veterinary prescription dispensing, and patient counseling.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 23:1310 (October 1997), amended LR 29:2087 (October 2003), effective January 1, 2004, amended LR 39:315 (February 2013), amended by the Department of Health, Board of Pharmacy, LR 46:579 (April 2020), LR

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 5. Pharmacists

Subchapter A. Licensure Procedures

**§506. Preferential licensing procedures for military-trained applicants and their spouses
dependents**

- A. ~~Preferential licensing procedures are available for certain persons. Eligibility for such procedures are available to the following:~~
1. ~~A military-trained applicant is a person who:~~
 - a. ~~Has completed a military program of training, been awarded a military occupational specialty, and performed in that specialty at a level that is substantially equivalent to or exceeds the requirements for pharmacist licensure in this state;~~
 - b. ~~Has engaged in the active practice of pharmacy; and~~
 - c. ~~Has not been disciplined in any jurisdiction for an act that would have constituted grounds for refusal, suspension, or revocation of a license to practice pharmacy in this state at the time the act was committed.~~
 2. ~~A military spouse is a person who:~~
 - a. ~~Can demonstrate marriage to a person in active duty military service or with commitment to reserve duty, as evidenced by legible copies of marriage license and military orders;~~
 - b. ~~Holds a current and unrestricted license to practice pharmacy in another jurisdiction within the United States or any of its territories that has not been disciplined by the agency issuing that license; and~~
 - c. ~~Can demonstrate competency to practice pharmacy through various methods determined by the Board, e.g., evidence of continuing education activity, letters of competency from previous practice manager, remediation examination, or personal interview.~~
- B. ~~Upon receipt of an application for pharmacist licensure by a military-trained applicant or military spouse, the Board office shall mark the application for priority processing and preserve that status until the license is issued, or in the alternative, the Board gives notice of its intent to deny the application and refuse to issue the license.~~
- C. ~~In the event the military-trained applicant or military spouse intends to practice pharmacy before the issuance of the license, the Board may issue a Special Work Permit to that person.~~

- 38 1. ~~The Special Work Permit shall expire 120 days after the date of issue, and the permit shall not be~~
39 ~~renewable.~~
- 40 2. ~~The Special Work Permit shall identify the military trained applicant or military spouse, and~~
41 ~~further, shall indicate the authority for that person to practice pharmacy within the State of~~
42 ~~Louisiana as well as the dates of issue and expiration of the credential.~~
- 43 3. ~~No military trained applicant or military spouse may practice pharmacy prior to the receipt of a~~
44 ~~Special Work Permit or pharmacist license, or with an expired Special Work Permit or pharmacist~~
45 ~~license.~~
- 46 4. ~~The Special Work Permit shall not be eligible for reciprocity to any other jurisdiction.~~
- 47 D. ~~The provisions of this Section shall not apply to a military trained applicant who has received, or is in~~
48 ~~the process of receiving, a dishonorable discharge from the military. Further, the provisions of this~~
49 ~~Section shall not apply to a military spouse whose spouse has received, or in the process of receiving, a~~
50 ~~dishonorable discharge from the military.~~

51
52 A. Definitions

53 The following terms shall have the meaning ascribed to them in this Subsection:

54 *Dependent* – a resident spouse or resident unmarried child under the age of 21 years, a child who is a
55 student under the age of 24 years and who is financially dependent upon the parent, or a child of any
56 age who is disabled and dependent upon the parent.

57 *Jurisdiction* – any state or territory of the United States of America.

58 *Military* – the armed forces or reserves of the United States, including the Army, Navy, Marine Corps,
59 Coast Guard, Air Force, and the reserve components thereof, the National Guard of any state, the
60 Military Reserves of any state, or the naval militia of any state.

61 B. Eligibility

62 The following persons are eligible for the preferential licensing procedures provided by this Section:

- 63 1. A member of the military who has been assigned to duty in Louisiana or his dependent.
64 2. A civilian employee of the United States Department of Defense who has been assigned to duty in
65 Louisiana or his dependent.
66 3. A member of the military or civilian employee of the United States Department of Defense or their
67 dependents who have established this state as their state of legal residence in their military record.

68 C. Requirements

69 Eligible persons seeking preferential licensing procedures shall demonstrate compliance with the
70 following requirements:

- 71 1. The applicant holds a current and valid pharmacist license in another jurisdiction.
72 2. The applicant has held the license in the other jurisdiction for at least one year.

- 73 3. The applicant has satisfied all educational and experiential requirements required by the pharmacy
74 regulatory authority in the other jurisdiction.
- 75 4. The applicant is held in good standing by the pharmacy regulatory authority in the other
76 jurisdiction, or in the event such status is not used in that jurisdiction, the applicant holds an
77 unrestricted license in that jurisdiction.
- 78 5. The applicant does not have a disqualifying criminal record as determined by the board.
- 79 6. The applicant has not had an occupational license revoked by a board in another jurisdiction due to
80 negligence or intentional misconduct related to the applicant's work in the occupation.
- 81 7. The applicant has not surrendered an occupational license due to negligence or intentional
82 misconduct related to the applicant's work in the occupation in another jurisdiction.
- 83 8. The applicant does not have a complaint, allegation, or investigation pending before a pharmacy
84 regulatory authority in another jurisdiction which relates to unprofessional conduct or an alleged
85 crime. If the applicant has a complaint, allegation, or investigation pending, the board shall not
86 issue or deny a license until the complaint, allegation, or investigation is resolved, or the applicant
87 otherwise satisfies the criteria for licensure in this state to the satisfaction of the board.
- 88 9. The applicant has paid all applicable fees in this state.
- 89 10. The applicant has applied for permanent licensure in this state. In the event the applicant fails to
90 qualify for a permanent license as determined by the board, the Special Work Permit issued under
91 the authority of Subsection E of this Section shall be automatically terminated.
- 92 D. Upon receipt of an application for pharmacist licensure by an eligible applicant, the board staff shall
93 mark the application for priority processing and preserve that status until the license is issued, or in the
94 alternative, the board gives notice of its intent to deny the application and refuse to issue the license.
95 The board shall notify the applicant of its licensing decision within 30 calendar days after receiving an
96 application.
- 97 E. In the event the applicant intends to practice pharmacy before the issuance of the permanent license,
98 the board may issue a Special Work Permit to the applicant.
- 99 1. The Special Work Permit shall expire 120 days after the date of issue and the permit shall not be
100 renewable.
- 101 2. The Special Work Permit shall identify the applicant, and further, shall indicate the authority for
102 that person to practice pharmacy within the State of Louisiana as well as the dates of issue and
103 expiration of the credential.
- 104 3. No applicant may practice pharmacy prior to the receipt of a Special Work Permit or pharmacist
105 license, or with an expired Special Work Permit or pharmacist license.
- 106 4. The Special Work Permit shall not be eligible for license transfer or reciprocity to any other
107 jurisdiction.

108 5. The provisions of this Section shall not apply to a member of the military who has received, or is
 109 in the process of receiving, a dishonorable discharge from the military. Further, the provisions of
 110 this Section shall not apply to the spouse of a member of the military who has received, or in the
 111 process of receiving, a dishonorable discharge from the military.

112
 113 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:~~3650~~ 3651.

114 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 39:3075
 115 (November 2013), amended by the Department of Health, Board of Pharmacy, LR

116
 117 * * *
 118
 119

120 **Chapter 9. Pharmacy Technicians**

121
 122 **§904. Preferential licensing procedures for military-trained applicants and their spouses**
 123 **dependents**

- 124 A. ~~Preferential licensing procedures are available for certain persons. Eligibility for such procedures are~~
 125 ~~available to the following:~~
- 126 1. ~~A military trained applicant is a person who:~~
 - 127 a. ~~Has completed a military program of training, been awarded a military occupational specialty,~~
 128 ~~and performed in that specialty at a level that is substantially equivalent to or exceeds the~~
 129 ~~requirements for technician certification in this state;~~
 - 130 b. ~~Has engaged in the active practice of pharmacy; and~~
 - 131 c. ~~Has not been disciplined in any jurisdiction for an act that would have constituted grounds for~~
 132 ~~refusal, suspension, or revocation of a technician certificate to practice pharmacy in this state~~
 133 ~~at the time the act was committed.~~
 - 134 2. ~~A military spouse is a person who:~~
 - 135 a. ~~Can demonstrate marriage to a person in active duty military service or with commitment to~~
 136 ~~reserve duty, as evidenced by legible copies of marriage license and military orders;~~
 - 137 b. ~~Holds a current and unrestricted technician certificate to practice pharmacy in another~~
 138 ~~jurisdiction within the United States or any of its territories that has not been disciplined by~~
 139 ~~the agency issuing that certificate; and~~
 - 140 c. ~~Can demonstrate competency to practice pharmacy through various methods determined by~~
 141 ~~the Board, e.g., evidence of continuing education activity, letters of competency from~~
 142 ~~previous practice manager, remediation examination, or personal interview.~~
- 143 B. ~~Upon receipt of an application for pharmacy technician candidate registration by a military trained~~
 144 ~~applicant or military spouse, the Board office shall mark the application for priority processing and~~

145 preserve that status until the registration is issued, or in the alternative, the Board gives notice of its
146 intent to deny the application and refuse to issue the registration.

147 C. ~~In the event the military trained applicant or military spouse intends to practice pharmacy before the~~
148 ~~issuance of the registration, the Board may issue a Special Work Permit to that person.~~

149 1. ~~The Special Work Permit shall expire 120 days after the date of issue, and the permit shall not be~~
150 ~~renewable.~~

151 2. ~~The Special Work Permit shall identify the military trained applicant or military spouse, and~~
152 ~~further, shall indicate the authority for that person to practice pharmacy within the State of~~
153 ~~Louisiana as well as the dates of issue and expiration of the credential.~~

154 3. ~~No military trained applicant or military spouse may practice pharmacy prior to the receipt of a~~
155 ~~Special Work Permit or pharmacy technician candidate registration, or with an expired Special~~
156 ~~Work Permit or pharmacy technician candidate registration.~~

157 4. ~~The Special Work Permit shall not be eligible for reciprocity to any other jurisdiction.~~

158 D. ~~The provisions of this Section shall not apply to a military trained applicant who has received, or is in~~
159 ~~the process of receiving, a dishonorable discharge from the military. Further, the provisions of this~~
160 ~~Section shall not apply to a military spouse whose spouse has received, or in the process of receiving, a~~
161 ~~dishonorable discharge from the military.~~

162
163 A. Definitions

164 The following terms shall have the meaning ascribed to them in this Subsection:

165 *Dependent* – a resident spouse or resident unmarried child under the age of 21 years, a child who is a
166 student under the age of 24 years and who is financially dependent upon the parent, or a child of any
167 age who is disabled and dependent upon the parent.

168 *Jurisdiction* – any state or territory of the United States of America.

169 *Military* – the armed forces or reserves of the United States, including the Army, Navy, Marine Corps,
170 Coast Guard, Air Force, and the reserve components thereof, the National Guard of any state, the
171 Military Reserves of any state, or the naval militia of any state.

172 B. Eligibility

173 The following persons are eligible for the preferential licensing procedures provided by this Section:

174 1. A member of the military who has been assigned to duty in Louisiana or his dependent.

175 2. A civilian employee of the United States Department of Defense who has been assigned to duty in
176 Louisiana or his dependent.

177 3. A member of the military or civilian employee of the United States Department of Defense or their
178 dependents who have established this state as their state of legal residence in their military record.

179 C. Requirements

- 180 Eligible persons seeking preferential licensing procedures shall demonstrate compliance with the
181 following requirements:
- 182 1. The applicant holds a current and valid pharmacy technician credential issued by the pharmacy
183 regulatory authority in another jurisdiction.
 - 184 2. The applicant has held the credential in the other jurisdiction for at least one year.
 - 185 3. The applicant has satisfied all educational and experiential requirements required by the pharmacy
186 regulatory authority in the other jurisdiction.
 - 187 4. The applicant is held in good standing by the pharmacy regulatory authority in the other
188 jurisdiction, or in the event such status is not used in that jurisdiction, the applicant holds an
189 unrestricted license in that jurisdiction.
 - 190 5. The applicant does not have a disqualifying criminal record as determined by the board.
 - 191 6. The applicant has not had an occupational license revoked by a board in another jurisdiction due to
192 negligence or intentional misconduct related to the applicant's work in the occupation.
 - 193 7. The applicant has not surrendered an occupational license due to negligence or intentional
194 misconduct related to the applicant's work in the occupation in another jurisdiction.
 - 195 8. The applicant does not have a complaint, allegation, or investigation pending before a pharmacy
196 regulatory authority in another jurisdiction which relates to unprofessional conduct or an alleged
197 crime. If the applicant has a complaint, allegation, or investigation pending, the board shall not
198 issue or deny a pharmacy technician certificate until the complaint, allegation, or investigation is
199 resolved, or the applicant otherwise satisfies the criteria for a pharmacy technician certificate in
200 this state to the satisfaction of the board.
 - 201 9. The applicant has paid all applicable fees in this state.
 - 202 10. The applicant has applied for a permanent pharmacy technician certificate in this state. In the
203 event the applicant fails to qualify for a permanent pharmacy technician certificate as determined
204 by the board, the Special Work Permit issued under the authority of Subsection E of this Section
205 shall be automatically terminated.
- 206 D. Upon receipt of an application for a pharmacy technician certificate by an eligible applicant, the board
207 staff shall mark the application for priority processing and preserve that status until the pharmacy
208 technician certificate is issued, or in the alternative, the board gives notice of its intent to deny the
209 application and refuse to issue the certificate. The board shall notify the applicant of its licensing
210 decision within 30 calendar days after receiving an application.
- 211 E. In the event the applicant intends to assist in the practice of pharmacy before the issuance of the
212 permanent pharmacy technician certificate, the board may issue a Special Work Permit to the
213 applicant.
- 214 1. The Special Work Permit shall expire 120 days after the date of issue and the permit shall not be
215 renewable.

- 216 2. The Special Work Permit shall identify the applicant, and further, shall indicate the authority for
217 that person to practice pharmacy within the State of Louisiana as well as the dates of issue and
218 expiration of the credential.
- 219 3. No applicant may practice pharmacy prior to the receipt of a Special Work Permit or pharmacist
220 license, or with an expired Special Work Permit or pharmacist license.
- 221 4. The Special Work Permit shall not be eligible for license transfer or reciprocity to any other
222 jurisdiction.
- 223 5. The provisions of this Section shall not apply to a member of the military who has received, or is
224 in the process of receiving, a dishonorable discharge from the military. Further, the provisions of
225 this Section shall not apply to the spouse of a member of the military who has received, or in the
226 process of receiving, a dishonorable discharge from the military.

227

228 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:~~3650~~ 3651.

229 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 39:3075
230 (November 2013), amended by the Department of Health, Board of Pharmacy, LR
231

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 12. Automated Medication Systems

§1201. Definitions

~~*Automated Medication System*—includes, but is not limited to, a mechanical system that performs operations or activities, other than compounding or administration, relative to the storage, packaging, or delivery of medications, and which collects, controls, and maintains all transaction information. An automated medication system may be profile driven, non-profile driven, or a combination of both.~~

Repealed

~~*Final Checks of Work*—the requirement that only a pharmacist supervises and releases the completed product prepared by a pharmacy technician.~~ Repealed

~~*Floor Stock/First Dose Cabinet*—a medication storage device, which shall be used by personnel, authorized by a protocol established by the pharmacist in charge, to gain access to doses as needed and first doses in patient care areas. In addition, a floor stock/first dose cabinet may be used to store medications in such specialty areas including, but not limited to, emergency room, surgery suite, and endoscopy suites.~~

Repealed

Healthcare Setting – a place where healthcare services are rendered on a routine basis by credentialed healthcare professionals.

~~*Non-Profile Driven*—system does not require prior or concomitant pharmacist review of medication order/prescriptions in order to gain access to the system for medication administration. A non-profile driven system may include, but is not limited to, a night drug cabinet, emergency drug kits, or floor stock/first dose cabinet.~~ Repealed

~~*Off-Site Facility*—the location of a building that houses a licensee of the Department of Health and Hospitals, but which does not house a board-permitted pharmacy.~~ Repealed

~~*On-Site Facility*—the location of a building that houses a board-permitted pharmacy.~~ Repealed

~~*Profile Driven*—system requires that medication orders/prescriptions be reviewed by the pharmacist for appropriateness, dosage, and contraindications prior to, or concomitantly with, being entered into the system, and before access is allowed into the system for medication administration.~~ Repealed

Remote Dispensing System – a profile driven automated medication dispensing system employing bidirectional audio-visual technology to facilitate pharmacist communication with a patient or caregiver.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

38 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
39 (June 2000) effective July 1, 2000, amended by the Department of Health, Board of Pharmacy, LR
40

41 **§1203. Automated Medication System(s) Registration**

42 A. ~~The entire system shall be registered with the board and facilities shall meet the following conditions:~~

43 1. ~~Facility shall possess a:~~

44 a. ~~license from the Health Standards Section of the Department of Health and~~
45 ~~Hospitals, or~~

46 b. ~~Controlled Dangerous Substance License from the Health Standards Section of the~~
47 ~~Department of Health and Hospitals, or~~

48 c. ~~permit from the board.~~

49 2. ~~Registration fee for a facility not permitted by the board is as identified in R.S. 37:1184.C.xii.~~

50 3. ~~No registration fee will be assessed a board permitted pharmacy.~~

51 4. ~~Registration expires annually on June 30.~~

52 5. ~~Initial application shall be completed and signed by the registrant of the facility and the~~
53 ~~pharmacist in charge of the system(s). The completed, signed application and required fee~~
54 ~~shall be submitted to the board office no later than 30 days prior to installation of the system.~~

55 6. ~~Annual Renewal. The board shall make available an application for renewal to each registrant~~
56 ~~on or before May 1 each year. Said application shall be completed, signed, and, with annual~~
57 ~~fee, returned to the board office to be received on or before June 1 each year.~~

58 7. ~~Expired Registration. A registration that is not renewed shall be null and void. A renewal~~
59 ~~application for an expired registration shall be requested by the registrant and the completed,~~
60 ~~signed application may be referred to the board's reinstatement committee for disposition in~~
61 ~~accordance with R.S. 37:1230.~~

62 8. ~~Reinstatement. The holder of a registration that has expired may be reinstated only upon~~
63 ~~written application to the board and upon payment of all lapsed fees and a penalty to be fixed~~
64 ~~by the board. Other conditions of reinstatement may be required at the discretion of the~~
65 ~~board.~~

66
67 A. Requirement for Registration

68 1. A pharmacy intending to supply medications for use within an automated medication system, as
69 defined at R.S. 37:1164, shall obtain an AMS registration prior to engaging in such activity.

70 2. The placement of medications within an automated medication system in the absence of an AMS
71 registration shall substantiate a violation of R.S. 37:1241(A)(12) and shall subject the pharmacy
72 to disciplinary action by the board.

- 73 3. A pharmacy intending to supply controlled substances for use within an automated medication
74 system shall obtain a controlled dangerous substance (CDS) license in addition to the AMS
75 registration. The pharmacy shall also obtain a federal registration from the U.S. Drug
76 Enforcement Administration (DEA) prior to placing controlled substances within the AMS.
- 77 4. The placement of controlled substances within an automated medication system in the absence of
78 an AMS registration, CDS license, and DEA registration shall substantiate a violation of R.S.
79 37:1241(A)(12) and R.S. 40:973 and shall subject the pharmacy to disciplinary action by the
80 board.
- 81 5. The operation of a remote dispensing system without an AMS registration shall substantiate a
82 violation of R.S. 37:1241(A)(12) and shall subject the pharmacy to disciplinary action by the
83 board.
- 84 B. Eligibility for Registration; Exemption
- 85 1. A pharmacy intending to supply medications for use within an automated medication system may
86 do so when the AMS is placed at any of the following locations:
- 87 a. within a facility in possession of a controlled dangerous substance license issued by the board.
88 b. within a hospital or other institutional facility in possession of an operating license issued by
89 the state department of health.
- 90 c. within a detention or correctional facility operated by or under contract with the state
91 department of public safety and corrections or other local governmental entity.
- 92 2. A pharmacy may operate a remote dispensing system when the system is placed within a
93 healthcare setting where the pharmacist-in-charge can ensure the security and environmental
94 integrity of the medications and devices placed within the system as well as the security and
95 confidentiality of the protected health information used therein.
- 96 3. A pharmacy intending to supply medications for use within an AMS which is placed within the
97 building housing that pharmacy shall not be required to obtain an AMS registration; however, the
98 pharmacist-in-charge of the pharmacy shall be responsible for compliance with the operational
99 standards in this Chapter.
- 100 C. Application for Initial Issuance of Registration
- 101 1. The board shall develop an application form suitable for the AMS registration. The board may
102 revise that application form on its own initiative in order to collect the information it deems
103 necessary to properly evaluate an applicant.
- 104 2. The application shall be accompanied by payment of the registration fee authorized by R.S.
105 37:1184.
- 106 3. The board shall not process applications received by facsimile, or that are incomplete, or
107 submitted with the incorrect fee.

- 108 4. The submission of a false or fraudulent application shall substantiate a violation of R.S.
109 37:1241(A)(2) and shall subject the applicant to disciplinary action by the board.
- 110 5. When determined appropriate by the board, the applicant may be required to meet with a
111 committee or agent of the board prior to the issuance of the registration.
- 112 D. Maintenance of Registration
- 113 1. A registration shall be valid only for the pharmacy to which it was issued and the physical location
114 of the AMS identified on the application. The registration shall not be subject to sale, assignment
115 or other transfer, voluntary or involuntary, nor shall the registration be valid for any premises
116 other than the physical location for which it was issued.
- 117 2. A duplicate or replacement registration shall be issued upon the written request of the owner of the
118 registration and payment of the fee authorized by R.S. 37:1184. A duplicate or replacement
119 registration shall be marked as such, and it shall not serve or be used as an additional or second
120 registration.
- 121 3. In the event a pharmacy intends to relocate an automated medication system to a different address,
122 the pharmacy shall notify the board of its intent to do so, providing both current and new
123 addresses. A change in business address may require an inspection by the board or its designee.
- 124 E. Application for Renewal of Registration
- 125 1. The pharmacy shall complete an application for the renewal of the registration and submit it to the
126 board prior to the expiration date of the registration. The application shall be accompanied by the
127 fee authorized by R.S. 37:1184.
- 128 2. The board shall not process applications received by facsimile, or that are incomplete, or
129 submitted with the incorrect fee.
- 130 3. An AMS registration not renewed by the expiration date shall be classified as expired. The
131 operation of an automated medication system with an expired registration shall substantiate a
132 violation of R.S. 37:1241(A)(12) and shall subject the pharmacy to disciplinary action by the
133 board.
- 134 F. Relinquishment of Registration
- 135 1. In the event a pharmacy intends to cease supplying medications or devices to an automated
136 medication system, it shall relinquish the registration to the board no later than 10 days following
137 the effective date of such decision.
- 138 2. A pharmacy may not transfer a registration to another pharmacy.
- 139 G. Application for Reinstatement of Suspended or Revoked Registration
- 140 1. An application for the reinstatement of an AMS registration previously suspended or revoked by
141 the board may only be approved in compliance with R.S. 37:1249.
- 142 2. The applicant shall complete an application form for this specific purpose supplied by the board
143 and shall attach any documentation and fees identified in R.S. 37:1184.

144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271 (June 2000) effective July 1, 2000, amended LR 38:1235 (May 2012), amended by the Department of Health, Board of Pharmacy, LR

§1205. Pharmacist-in-Charge Responsibilities

A. The pharmacist-in-charge shall be a Louisiana licensed pharmacist ~~and has~~ with the following responsibilities:

1. assuring that the system is in good working order and accurately provides the correct strength, dosage form, and quantity of the drug prescribed while maintaining appropriate record-keeping and security safeguards.
2. establishment of a quality assurance program prior to implementation of a system and the supervision of an ongoing quality assurance program that monitors appropriate use and performance of a system, which is evidenced by ~~written~~ policies and procedures developed by the pharmacist-in-charge.
3. ~~provide 30 days written notice to the board of removal of the system.~~
4. define access to the system in policy and procedures of the pharmacy, in compliance with state and federal regulations.
5. assign, discontinue, or change access to the system.
6. ensure that access to the medications complies with state and federal regulations as applicable.
7. ensure that the system is stocked/restocked accurately and in accordance with established written pharmacy policies and procedures.
8. maintain or have access to all records of documentation specified in this Section for two years or as otherwise required by law.
9. ~~notify each licensed prescriber that his medication orders/prescriptions are not restricted to the limited number of medications which are stocked within a facility's automated medication system by placing a prominent notice to that effect on the cover of or near the beginning of such patient's medical chart or medical record.~~
10. continuous monitoring and documentation of temperature in the drug storage areas including a mechanism to alert the pharmacist when defined parameters are out of range as well as an action plan to address such excursions. A pharmacy's failure to document the integrity of the drug supply or remediate for excursions as appropriate shall substantiate a violation of R.S. 37:1241(A)(18) and shall subject the pharmacy to disciplinary action by the board.

180 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

181 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
182 (June 2000) effective July 1, 2000, amended by the Department of Health, Board of Pharmacy, LR

183

184 **§1207. Pharmacist Review**

185 A. System shall be used in settings that ensure medication orders are reviewed by a pharmacist prior to
186 administration and in accordance with established policies and procedures and good pharmacy
187 practice. A policy and procedure ~~protocol~~ shall be adopted for non-profile driven systems to
188 retrospectively review medications orders which cannot be reviewed prior to medication
189 administration, ~~as provided in LAC 46:111.1209.2.~~

190

191 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

192 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
193 (June 2000) effective July 1, 2000, amended by the Department of Health, Board of Pharmacy, LR

194

195 **§1209. Policies and Procedures Repealed**

196 ~~A. The development of an automated medication system policy and procedures is the responsibility of the~~
197 ~~pharmacist in charge, who shall submit the complete automated medication system policy and~~
198 ~~procedures to the board for approval, on request. These policies and procedures shall be reviewed by~~
199 ~~the pharmacist in charge, at least annually and modified if needed, and such review documented.~~
200 ~~They shall include, but are not limited to, the following:~~

- 201 ~~1. criteria for selection of medications to be stored in each system, provided that in facilities~~
- 202 ~~licensed by the Department of Health and Hospitals, but not by the board, the selection~~
- 203 ~~criteria shall not include the substitution by the pharmacist of a product that is not an~~
- 204 ~~equivalent drug product to the product originally prescribed by the physician or practitioner~~
- 205 ~~without the explicit consent of the physician or practitioner;~~
- 206 ~~2. criteria for medications qualifying for use with a non-profile driven system and the locations~~
- 207 ~~and situations that this type of system can be used in; and~~
- 208 ~~3. information on the system as outlined below:~~
 - 209 ~~a. access:~~
 - 210 ~~i. system entry.~~
 - 211 ~~ii. access codes.~~
 - 212 ~~iii. system access privileges.~~
 - 213 ~~iv. changing access privileges.~~
 - 214 ~~v. termination of user.~~
 - 215 ~~vi. temporary access codes.~~

- 216 vii. ~~password assignment.~~
- 217 b. ~~controlled substances.~~
- 218 i. ~~chain of custody.~~
- 219 ii. ~~discrepancy resolution.~~
- 220 e. ~~data.~~
- 221 i. ~~archiving.~~
- 222 ii. ~~stored/uploading to database.~~
- 223 iii. ~~backup.~~
- 224 d. ~~definitions.~~
- 225 e. ~~downtime procedures (see malfunction).~~
- 226 f. ~~emergency procedures.~~
- 227 g. ~~information security/confidentiality.~~
- 228 i. ~~patient information.~~
- 229 ii. ~~medication information.~~
- 230 iii. ~~transaction files.~~
- 231 iv. ~~information update plan.~~
- 232 v. ~~patient update plan.~~
- 233 vi. ~~information access.~~
- 234 h. ~~inspection.~~
- 235 i. ~~installation requirements.~~
- 236 j. ~~maintenance, e.g., service and repair protocols.~~
- 237 k. ~~medication administration.~~
- 238 i. ~~medication and patient validation.~~
- 239 ii. ~~administration verification.~~
- 240 l. ~~medication security.~~
- 241 i. ~~acquisition and disposition records.~~
- 242 ii. ~~proof of delivery.~~
- 243 iii. ~~chain of custody of controlled substances (institutions).~~
- 244 iv. ~~security management and control.~~
- 245 v. ~~medication loading and storage.~~
- 246 vi. ~~medication loading records.~~
- 247 vii. ~~medication containers.~~
- 248 viii. ~~cross-contamination.~~
- 249 ix. ~~lot number control.~~
- 250 x. ~~inventory.~~
- 251 xi. ~~utilization review.~~

- 252 xii. ~~research.~~
- 253 m. ~~malfunction.~~
- 254 i. ~~troubleshooting.~~
- 255 ii. ~~power failure.~~
- 256 n. ~~quality assurance/quality improvement~~
- 257 i. ~~documentation and verification of proper loading and refilling of~~
- 258 ~~device.~~
- 259 ii. ~~removal of drugs for administration, return, or waste.~~
- 260 iii. ~~recording, resolving, and reporting of discrepancies.~~
- 261 iv. ~~periodic audits to assure compliance with policies and procedures.~~
- 262 o. ~~reports.~~
- 263 i. ~~system maintenance.~~
- 264 ii. ~~administrative functions.~~
- 265 iii. ~~inventory.~~
- 266 iv. ~~error.~~
- 267 v. ~~discrepancies.~~
- 268 vi. ~~activity.~~
- 269 vii. ~~problem.~~
- 270 p. ~~medication inventory management.~~
- 271 q. ~~staff education and training.~~
- 272 r. ~~system set up.~~

274 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

275 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
276 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR

278 **§1211. Documentation**

279 A. Documentation as to type of equipment, serial number, content, policies and procedures and location
280 shall be maintained ~~on-site~~ in the pharmacy for review by the board. Such documentation shall
281 include, but is not limited to:

- 282 1. name, address, and permit number of the pharmacy ~~or licensed health care facility~~ and the
- 283 location where the system is operational;
- 284 2. manufacturer’s name and model;
- 285 3. quality assurance policies and procedures to determine continued appropriate use and
- 286 performance of the system;

- 287 4. policies and procedures for system operation, safety, security, accuracy, patient
288 confidentiality, access, controlled substances, data retention, definitions, downtime
289 procedures, emergency or first dose procedures, inspection, installation requirements,
290 maintenance security, quality assurance, medication inventory, staff education and training,
291 system set-up, and malfunction procedures; and
- 292 5. security procedures sufficient to prevent unauthorized access or use, prevent the illegal use or
293 disclosure of protected health information, and comply with any applicable federal or state
294 regulations.
- 295 B. A current copy of all pharmacy policies and procedures related to the use of the system shall be
296 maintained at all off-site facility locations where the system is being used, as well as the pharmacy of
297 the pharmacist in charge.

298

299 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

300 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271

301 (June 2000) effective July 1, 2000, amended by the Department of Health, Board of Pharmacy, LR

302

303 **§1213. Records**

- 304 A. Records and/or electronic data kept by the system shall meet the following requirements:
- 305 1. All events involving access to the contents of the system shall be recorded electronically.
- 306 2. In the event controlled substances are stored in the system, the records shall include the
307 positive identification (as defined in Section 1119 of the Board's rules this Part) of the
308 personnel retrieving and administering the controlled substances to the patient.
- 309 3. These internal records shall be maintained for one year by the pharmacist-in-charge and shall
310 be readily available to the board. Such records shall include:
- 311 a. identity of system accessed;
- 312 b. identification of the individual accessing the system;
- 313 c. type of transaction;
- 314 d. name, strength, dosage form, and quantity of the drug accessed;
- 315 e. name or identification number of the patient, ~~or identification numbers~~ for whom
316 the drug was ordered;
- 317 f. identification of the ~~certified pharmacy technician or pharmacist~~ person stocking
318 or restocking the medications in the system; and
- 319 g. such additional information as the pharmacist-in-charge may deem necessary.

320

321 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

322 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
323 (June 2000) effective July 1, 2000, amended LR 40:2256 (November 2014), effective January 1, 2015, amended by
324 the Department of Health, Board of Pharmacy, LR
325

326 **§1215. Security System(s) Repealed**

327 A. ~~System shall have adequate security system and procedures, evidenced by written pharmacy policies~~
328 ~~and procedures, to:~~

- 329 1. ~~prevent unauthorized access or use;~~
 - 330 2. ~~comply with any applicable federal and state regulations; and~~
 - 331 3. ~~maintain patient confidentiality.~~
- 332

333 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

334 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
335 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR
336

337 **§1217. Stocking and Restocking**

338 A. ~~*On Site Facility System(s)*. The stocking and restocking of all medications in the on-site system shall~~
339 ~~be accomplished by Louisiana licensed pharmacists, and/or Louisiana certified pharmacy technicians~~
340 ~~under the supervision of Louisiana licensed pharmacists. A pharmacist must conduct final checks of~~
341 ~~work performed by a pharmacy technician. The pharmacy shall have a mechanism in place to identify~~
342 ~~the certified pharmacy technician stocking or restocking and the pharmacist checking the accuracy of~~
343 ~~the medications to be stocked or restocked in the automated medication systems.~~

344 B. ~~*Off Site Facility System(s)*. The stocking and restocking of all medications in the off-site system shall~~
345 ~~be accomplished by Louisiana licensed pharmacists; however, the certified pharmacy technician may~~
346 ~~stock or restock an off-site facility system provided a pharmacist is physically present at the off-site~~
347 ~~facility and supervises and verifies the stocking and/or restocking prior to use. The pharmacy shall~~
348 ~~have a mechanism in place to identify the certified pharmacy technician stocking or restocking and the~~
349 ~~pharmacist checking the accuracy of the medications to be stocked or restocked in the system.~~

350 A. The stocking and restocking of medications and devices within an automated medication system shall
351 be performed by a pharmacist, or in the alternative, a pharmacy intern, pharmacy technician, or
352 pharmacy technician candidate under the supervision of a pharmacist.

353 B. When the pharmacy employs electronic product verification procedures as described within this
354 Subsection, the stocking and restocking of medications and devices within an automated medication
355 system may be performed by other licensed personnel approved by the pharmacist-in-charge without
356 the necessity of direct pharmacist supervision.

357 C. **Electronic Product Verification**

- 358 1. A bar code verification, electronic verification, or similar verification process which prohibits
- 359 any human intervention following pharmacist verification of the product may be utilized to
- 360 assure the correct selection of drugs to be placed into an automated medication system.
- 361 2. The use of a bar code, electronic, or similar verification process shall require an initial quality
- 362 assurance validation followed by ongoing quality assurance reviews at intervals no greater
- 363 than 90 days since the previous review, all conducted by a pharmacist.
- 364 3. ~~When a bar code verification, electronic verification, or similar verification process is utilized~~
- 365 ~~as specified in the Paragraph, and in the absence of any human intervention in the product~~
- 366 ~~selection process, the stocking and restocking functions in systems located either on site or~~
- 367 ~~off site may be performed by a pharmacy technician without the necessity of direct~~
- 368 ~~pharmacist supervision.~~

369
370 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

371 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
372 (June 2000) effective July 1, 2000, amended LR 41:1488 (August 2015), amended by the Department of Health,
373 Board of Pharmacy, LR

374
375 **§1219. Packaging and Labeling Repealed**

- 376 A. ~~All containers of medications stored in the system shall be packaged and labeled in accordance with~~
- 377 ~~federal and state laws and regulations and contain an established satisfactory beyond use date based on~~
- 378 ~~U.S.P. standards.~~

379
380 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

381 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
382 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR

383
384 **§1221. Proof of Use Repealed**

- 385 A. For medication removed from the system for patient administration, the system shall document, at a
- 386 minimum, the following:
- 387 1. ~~name of the patient or resident;~~
- 388 2. ~~patient's or resident's medical record number or identification number, or room and bed~~
- 389 ~~number;~~
- 390 3. ~~date and time medication was removed from the system;~~
- 391 4. ~~name, initials, or other unique identifier of the person removing the drug; and~~
- 392 5. ~~name, strength, and dosage form of the medication or description of the medical device~~
- 393 ~~removed.~~

394

395 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

396 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271

397 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR

398

399 **§1223. Wasted, Discarded, or Unused Medications Repealed**

400 A. ~~The system shall provide a mechanism for securing and accounting for wasted, discarded, or unused~~
401 ~~medications removed from the system according to policies and procedures, and existing state and~~
402 ~~federal law.~~

403

404 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

405 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271

406 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR

407

408 **§1225. Inspection Repealed**

409 A. ~~System records shall be available and readily retrievable for board inspection and review during~~
410 ~~regular working hours of operation. The system itself is also subject to inspection at that time.~~

411

412 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

413 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271

414 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR

415

416 **§1227. Out of State Pharmacies Repealed**

417 A. ~~Out of state pharmacies must have applied for and been issued an out of state pharmacy permit by the~~
418 ~~board as identified in regulations. Out of state pharmacies must have the proper pharmacy permit~~
419 ~~issued by the state in which they reside in order to utilize a system in Louisiana.~~

420

421 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

422 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271

423 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR

424

425 **§1229. Violations; Penalties Repealed**

426 A. ~~The board may refuse to issue or renew, or may revoke, summarily suspend, suspend, place on~~
427 ~~probation, censure, reprimand, issue a warning against, or issue a cease and desist order against, the~~
428 ~~licenses or the registration of, or assess a fine/civil penalty or costs/administrative costs against any~~

429 ~~person pursuant to the procedures set forth in R.S. 37:1245, for any violation of the provisions of this~~
430 ~~Section.~~

431

432 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

433 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
434 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR

435

436 **§1231. Revised Statutes and Louisiana Administrative Code Repealed**

437 ~~A. These regulations shall be read and interpreted jointly with Chapter 14 of Title 37 of the Revised~~
438 ~~Statutes and Part LIII of Title 46 of the Louisiana Administrative Code.~~

439

440 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.A.

441 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 26:1271
442 (June 2000) effective July 1, 2000, repealed by the Department of Health, Board of Pharmacy, LR



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Executive Committee



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



August 13, 2020

Chris Pinell, CPA, CITP, CFE, MBA
Pinell & Martinez, LLC
308 S. Tyler Street, Ste. 2
Covington, LA 70433

In connection with your audit of our financial statements as of June 30, 2020 and for the period of July 1, 2019 – June 30, 2020 (period of audit) for the purpose of expressing an opinion as to the fair presentation of our financial statements in accordance with accounting principles generally accepted in the United States of America, to assess our system of internal control as a part of your audit, and to review our compliance with applicable laws and regulations, we confirm, to the best of our knowledge and belief, the following representations. These representations are based on the information available to us as of August 13, 2020.

PART I. AGENCY PROFILE

1. Name and address of the organization.

**Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700**

2. List the population of the municipality or parish based upon the last official United States Census or most recent official census (municipalities and police juries only). Include the source of the information.

State of Louisiana – 4,659,978 [<https://data.census.gov> accessed July 21, 2020]

3. List names, addresses, and telephone numbers of entity officials. Include elected/appointed members of the governing board, chief executive and fiscal officer, and legal counsel.

See Appendix A.

4. Period of time covered by this questionnaire.

July 1, 2019 through June 30, 2020.

5. The entity has been organized under the following provisions of the Louisiana Revised Statute(s) (R.S.) and, if applicable, local resolutions/ordinances.

R.S. 36:259(A)(7).

6. Briefly describe the public services provided.

The Board of Pharmacy regulates the practice of pharmacy to the benefit of the public's health, safety, and welfare. It accomplishes that mission through the fulfillment of two objectives: the restriction of the practice to qualified persons as evidenced by its licensure processes, and the monitoring of practitioners for compliance with all relevant laws and rules as evidenced by its compliance processes. Further, the Board is responsible for the issuance of all controlled dangerous substance licenses to practitioners and facilities. The Board issues and renews those credentials, and further, assesses compliance with all relevant laws and rules through inspections of healthcare facilities.

7. Expiration date of current elected/appointed officials' terms.

See Appendix A.

LEGAL COMPLIANCE

PART II. PUBLIC BID LAW

8. The provisions of the public bid law, R.S. Title 38:2211-2296, and, where applicable, the regulations of the Division of Administration, State Purchasing Office have been complied with.

- A) All public works purchases exceeding \$150,000 have been publicly bid.
- B) All material and supply purchases exceeding \$30,000 have been publicly bid.

Yes No

PART III. CODE OF ETHICS LAW FOR PUBLIC OFFICIALS AND PUBLIC EMPLOYEES

9. It is true that no employees or officials have accepted anything of value, whether in the form of a service, loan, or promise, from anyone that would constitute a violation of R.S. 42:1101-1124.

Yes No

10. It is true that no member of the immediate family of any member of the governing authority, or the chief executive of the governmental entity, has been employed by the governmental entity after April 1, 1980, under circumstances that would constitute a violation of R.S. 42:1119.

Yes No

PART IV. LAWS AFFECTING BUDGETING

11. We have complied with the budgeting requirements of the Local Government Budget Act (R.S. 39:1301-15) R.S. 39:33, or R.S. 39:1331-1342, as applicable:

A. Local Budget Act

- 1. We have adopted a budget for the general fund and all special revenue funds (R.S. 39:1305).
- 2. The chief executive officer, or equivalent, has prepared a proposed budget that included a budget message, a proposed budget for the general fund and each special revenue fund, and a budget adoption instrument that specified the chief executive's authority to make budgetary amendments without approval of the governing authority. Furthermore, the proposed expenditures did not exceed estimated funds to be available during the period (R.S. 39:1305).
- 3. The proposed budget was submitted to the governing authority and made available for public inspection at least 15 days prior to the beginning of the budget year (R.S. 39:1306).
- 4. To the extent that proposed expenditures were greater than \$500,000, we have made the budget available for public inspection and have advertised its availability in our official journal. The advertisement included the date, time, and place of the public hearing on the budget. Notice has also been published certifying that all actions required by the Local Government Budget Act have been completed (R.S. 39:1307).
- 5. If required, the proposed budget was made available for public inspection at the location required by R.S. 39:1308.
- 6. All action necessary to adopt and finalize the budget was completed prior to the date required by state law. The adopted budget contained the same information as that required for the proposed budget (R.S. 39:1309).
- 7. After adoption, a certified copy of the budget has been retained by the chief executive officer or equivalent officer (R.S. 39:1309).
- 8. To the extent that proposed expenditures were greater than \$500,000, the chief executive officer or equivalent notified the governing authority in writing during the year when actual receipts plus projected revenue collections for the year failed to meet budgeted revenues by five percent or more, or when actual expenditures plus projected expenditures to year end exceeded budgeted expenditures by five percent or more (R.S. 39:1311).
- 9. The governing authority has amended its budget when notified, as provided by R.S. 39:1311. (Note, general and special revenue fund budgets should be amended, regardless of the amount of expenditures in the fund, when actual receipts plus projected revenue collections for the year fail to meet budgeted revenues by five percent or more; or when actual expenditures plus projected expenditures to year end exceed budgeted expenditures by five percent or more. State law exempts from the amendment requirements special revenue funds with anticipated expenditures of \$500,000 or less, and exempts special revenue funds whose revenues are expenditure-driven - primarily federal funds-from the requirement to amend revenues.)

Yes No N/A

B. State Budget Requirements

1. The state agency has complied with the budgetary requirements of R.S. 39:33.

Yes No N/A

C. Licensing Boards

1. The licensing board has complied with the budgetary requirements of R.S. 39:1331-1342.
Yes No

PART V. ACCOUNTING, AUDITING, AND FINANCIAL REPORTING LAWS

12. We have maintained our accounting records in such a manner as to provide evidence of legal compliance and the preparation of annual financial statements to comply with R.S. 24:513 and 515, and/or 33:463.

Yes No

13. All non-exempt governmental records are available as a public record and have been retained for at least three years, as required by R.S. 44:1, 44:7, 44:31, and 44:36.

Yes No

14. We have filed our annual financial statements in accordance with R.S. 24:514, and 33:463 where applicable.

Yes No

15. We have had our financial statements audited in a timely manner in accordance with R.S. 24:513.

Yes No

16. We did not enter into any contracts that utilized state funds as defined in R.S. 39:72.1(A)(2) and that were subject to the public bid law (R.S. 38:2211, *et seq.*), while the agency was not in compliance with R.S. 24:513 (the audit law).

Yes No

17. We have complied with R.S. 24:513 A.(3) regarding disclosure of compensation, reimbursements, benefits and other payments to the agency head, political subdivision head, or chief executive officer.

Yes No

18. We have remitted all fees, fines, and court costs collected on behalf of other entities, in compliance with applicable Louisiana Revised Statutes or other laws.

Yes No

PART VI. MEETINGS

19. We have complied with the provisions of the Open Meetings Law, provided in R. S. 42:11 through 42:28.

Yes No

PART VII. ASSET MANAGEMENT LAWS

20. We have maintained records of our fixed assets and movable property records, as required by R.S. 24:515 and/or 39:321-332, as applicable.

Yes No

PART VIII. FISCAL AGENCY AND CASH MANAGEMENT LAWS

21. We have complied with the fiscal agency and cash management requirements of R.S. 39:1211-45 and 49:301-327, as applicable.

Yes No

PART IX. DEBT RESTRICTION LAWS

22. It is true we have not incurred any long-term indebtedness without the approval of the State Bond Commission, as provided by Article VII, Section 8 of the 1974 Louisiana Constitution, Article VI, Section 33 of the 1974 Louisiana Constitution, and R.S. 39:1410.60-1410.65.

Yes No

23. We have complied with the debt limitation requirements of state law (R.S. 39:562).

Yes No

24. We have complied with the reporting requirements relating to the Fiscal Review Committee of the State Bond Commission (R.S. 39:1410.62).

Yes No

PART X. REVENUE AND EXPENDITURE RESTRICTION LAWS

25. We have restricted the collections and expenditures of revenues to those amounts authorized by Louisiana statutes, tax propositions, and budget ordinances.

Yes No

26. It is true we have not advanced wages or salaries to employees or paid bonuses in violation of Article VII, Section 14 of the 1974 Louisiana Constitution, R.S. 14:138, and AG opinion 79-729.

Yes No

27. It is true that no property or things of value have been loaned, pledged, or granted to anyone in violation of Article VII, Section 14 of the 1974 Louisiana Constitution.

Yes No

PART XI. ISSUERS OF MUNICIPAL SECURITIES

28. It is true that we have complied with the requirements of R.S. 39:1438.C.

Yes No N/A

PART XI. QUESTIONS FOR SPECIFIC GOVERNMENTAL UNITS

Parish Governments

29. We have adopted a system of road administration that provides as follows:

- A. Approval of the governing authority of all expenditures, R.S. 48:755(A).
- B. Development of a capital improvement program on a selective basis, R.S. 48:755.
- C. Centralized purchasing of equipment and supplies, R.S. 48:755.
- D. Centralized accounting, R.S. 48:755.
- E. A construction program based on engineering plans and inspections, R.S. 48:755.
- F. Selective maintenance program, R.S. 48:755.
- G. Annual certification of compliance to the auditor, R.S. 48:758.

Yes No N/A

School Boards

30. We have complied with the general statutory, constitutional, and regulatory provisions of the Louisiana Department of Education, R.S. 17:51-400.

Yes No N/A

31. We have complied with the regulatory circulars issued by the Louisiana Department of Education that govern the Minimum Foundation Program.

Yes No N/A

32. We have, to the best of our knowledge, accurately compiled the performance measurement data contained in the following schedules and recognize that your agreed-upon procedures will be applied to such schedules and performance measurement data:

Parish school boards are required to report, as part of their annual financial statements, measures of performance. These performance indicators are found in the supplemental schedules:

- Schedule 1, General Fund Instructional and Support Expenditures and Certain Local Revenue Sources
- Schedule 2, Class Size Characteristics

We have also, to the best of our knowledge, accurately compiled the performance measurement data contained in the following schedules, and recognize that although the schedules will not be included in the agreed-upon procedures report, the content of the schedules will be tested and reported upon by school board auditors in the school board performance measures agreed-upon procedures report.

- Education Levels of Public School Staff
- Experience of Public Principals, Assistant Principals, and Full-time Classroom Teachers
- Public School Staff Data: Average Salaries

We understand that the content of the first two schedules will be tested and reported upon together.

Yes No N/A

Tax Collectors

33. We have complied with the general statutory requirements of R.S. 47.

Yes No N/A

Sheriffs

34. We have complied with the state supplemental pay regulations of R.S. 40:1667.7.

Yes No N/A

35. We have complied with R.S. 13:5535 relating to the feeding and keeping of prisoners.

Yes No N/A

District Attorneys

36. We have complied with the regulations of the DCFS that relate to the Title IV-D Program.

Yes No N/A

Assessors

37. We have complied with the regulatory requirements found in R.S. Title 47.

Yes No N/A

38. We have complied with the regulations of the Louisiana Tax Commission relating to the reassessment of property.

Yes [] No [] N/A [X]

Clerks of Court

39. We have complied with R.S. 13:751-917 and applicable sections of R.S. 11:1501-1562.

Yes [] No [] N/A [X]

Libraries

40. We have complied with the regulations of the Louisiana State Library.

Yes [] No [] N/A [X]

Municipalities

41. Minutes are taken at all meetings of the governing authority (R.S. 42:20).

Yes [] No [] N/A [X]

42. Minutes, ordinances, resolutions, budgets, and other official proceedings of the municipalities are published in the official journal (R.S. 43:141-146 and A.G. 86-528).

Yes [] No [] N/A [X]

43. All official action taken by the municipality is conducted at public meetings (R.S. 42:11 to 42:28).

Yes [] No [] N/A [X]

Airports

44. We have submitted our applications for funding airport construction or development to the Department of Transportation and Development as required by R.S. 2:802.

Yes [] No [] N/A [X]

45. We have adopted a system of administration that provides for approval by the department for any expenditures of funds appropriated from the Transportation Trust Fund, and no funds have been expended without department approval (R.S. 2:810).

Yes [] No [] N/A [X]

46. All project funds have been expended on the project and for no other purpose (R.S. 2:810).

Yes [] No [] N/A [X]

47. We have certified to the auditor, on an annual basis, that we have expended project funds in accordance with the standards established by law (R.S. 2:811).

Yes [] No [] N/A [X]

Ports

48. We have submitted our applications for funding port construction or development to the Department of Transportation and Development as required by R.S. 34:3452.

Yes [] No [] N/A [X]

49. We have adopted a system of administration that provides for approval by the department for any expenditures of funds made out of state and local matching funds, and no funds have been expended without department approval (R.S. 34:3460).

Yes [] No [] N/A [X]

50. All project funds have been expended on the project and for no other purpose (R.S. 34:3460).

Yes [] No [] N/A [X]

51. We have established a system of administration that provides for the development of a capital improvement program on a selective basis, centralized purchasing of equipment and supplies, centralized accounting, and the selective maintenance and construction of port facilities based upon engineering plans and inspections (R.S. 34:3460).

Yes [] No [] N/A [X]

52. We have certified to the auditor, on an annual basis, that we have expended project funds in accordance with the standards established by law (R.S. 34:3461).

Yes [] No [] N/A [X]

Sewerage Districts

53. We have complied with the statutory requirements of R.S. 33:3881-4159.10.

Yes [] No [] N/A [X]

Waterworks Districts

54. We have complied with the statutory requirements of R.S. 33:3811-3837.

Yes [] No [] N/A [X]

Utility Districts

55. We have complied with the statutory requirements of R.S. 33:4161-4546.21.

Yes [] No [] N/A [X]

Drainage and Irrigation Districts

56. We have complied with the statutory requirements of R.S. 38:1601-1707 (Drainage Districts); R.S. 38:1751-

1921 (Gravity Drainage Districts); R.S. 38:1991-2048 (Levee and Drainage Districts); or R.S. 38:2101-2123 (Irrigation Districts), as appropriate.

Yes [] No [] N/A []

Fire Protection Districts

57. We have complied with the statutory requirements of R.S. 40:1491-1509.

Yes [] No [] N/A []

Other Special Districts

58. We have complied with those specific statutory requirements of state law applicable to our district.

Yes [] No [] N/A []

The previous responses have been made to the best of our belief and knowledge. We have disclosed to you all known noncompliance of the foregoing laws and regulations, as well as any contradictions to the foregoing representations. We have made available to you documentation relating to the foregoing laws and regulations.

We have provided you with any communications from regulatory agencies or other sources concerning any possible noncompliance with the foregoing laws and regulations, including any communications received between the end of the period under examination and the issuance of this report. We acknowledge our responsibility to disclose to you and the Legislative Auditor any known noncompliance that may occur subsequent to the issuance of your report.

Secretary _____ Date

President _____ Date

Roster of Board Members & Executive Staff

Carl W. Aron
1209 N. 18th Street
Monroe, LA 71201-5495
318.323.1232
June 30, 2026

Allen W. Cassidy, Jr.
710 N. Main Street
Jennings, LA 70546-5312
337.824.1648
June 30, 2022

J. Robert Cloud
503 McMillan Road
West Monroe, LA 71291-5327
318.329.4641
June 30, 2024

Jacqueline L. Hall
5781 Eastover Drive
New Orleans, LA 70128-2172
504.861.5033
June 30, 2026

Richard M. Indovina, Jr.
1001 Moss Lane
River Ridge, LA 70123-2739
504.473.3180
June 30, 2022

Kevin LaGrange
107 Kentville Circle
Lafayette, LA 70508-6458
337.991.0101
June 30, 2024

Robert C. LeBas
1615 N. Main Street
Opelousas, LA 70570-6618
337.948.9827
June 30, 2024

Richard Mannino
113 W. Charles Street
Hammond, LA 70401-3232
985.542.8466
June 30, 2022

Marty R. McKay
9049 Highway 165 South
Woodworth, LA 71485-8635
318.776.5649
June 30, 2026

Ronald E. Moore
13906 Hootsell Court
Baton Rouge, LA 70816-2719
225.241.2993
June 30, 2020

Blake P. Pitre
301 Roberta Grove Boulevard
Houma, LA 70363-5465
985.693.7496
June 30, 2024

Donald L. Resweber
1379 Burton Plantation Highway
St. Martinville, LA 70582-7438
337.654.3900
Pleasure of the Governor

Douglas E. Robichaux
8860 Quimper Place, Suite 200
Shreveport, LA 71105-5687
318.797.9317
June 30, 2022

Richard A. Soileau
805 Center Street
New Iberia, LA 70560-5505
337.365.6721
June 30, 2020

Raymond J. Strong
5620 Read Boulevard
New Orleans, LA 70127-3106
504.592.6566
June 30, 2022

Rhonny K. Valentine
160 Starlight Point
Natchitoches, LA 71457-2849
318.872.5300
June 30, 2024

Malcolm J. Broussard
Executive Director
3388 Brentwood Drive
Baton Rouge, LA 70809
225.925.6496
Pleasure of the Board

Carlos M. Finalet, III
General Counsel
3388 Brentwood Drive
Baton Rouge, LA 70809
225.925.6496
Pleasure of the Board

M. Joseph Fontenot
Asst. Executive Director
3388 Brentwood Drive
Baton Rouge, LA 70809
225.925.6496
Pleasure of the Board

Kelley L. Villeneuve
Office Manager
3388 Brentwood Drive
Baton Rouge, LA 70809
225.925.6496
Pleasure of the Board

MEMORANDUM OF UNDERSTANDING ADDRESSING CERTAIN
DISTRIBUTIONS OF COMPOUNDED HUMAN DRUG PRODUCTS
BETWEEN THE [insert STATE BOARD OF PHARMACY OR OTHER
APPROPRIATE STATE AGENCY] AND
THE U.S. FOOD AND DRUG ADMINISTRATION

I. PURPOSE

This Memorandum of Understanding (MOU) establishes an agreement between the [insert State Board of Pharmacy or other appropriate State agency] and the U.S. Food and Drug Administration (FDA) regarding the distribution of inordinate amounts of compounded human drug products interstate¹ and the appropriate investigation by the [insert State Board of Pharmacy or other appropriate State agency] of complaints relating to human drug products compounded in [insert State] and distributed outside such State.² This is the MOU provided for by section 503A(b)(3)(B)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 353a), and does not apply to veterinary drug products, biological products subject to licensure under section 351 of the Public Health Service Act (42 U.S.C. 262), and drugs that are compounded by outsourcing facilities under section 503B of the FD&C Act.

II. BACKGROUND

- a. Section 503A of the FD&C Act describes the conditions that must be satisfied for human drug products compounded by a licensed pharmacist or licensed physician to be exempt from three sections of the FD&C Act requiring:
 1. Compliance with current good manufacturing practice (section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B));
 2. Labeling with adequate directions for use (section 502(f)(1) (21 U.S.C. 352(f)(1)); and
 3. FDA approval prior to marketing (section 505 (21 U.S.C. 355)).

¹ For purposes of this MOU, see the definitions of “inordinate amounts” and “distribution of compounded human drug products interstate” (also referred to as “distributed interstate”) in Appendix A.

² As described herein, the State Board of Pharmacy or other appropriate State agency signatory is agreeing to take certain actions as described in Section III below. For example, if a State Board of Pharmacy signs the MOU, the State Board of Pharmacy agrees to take the actions described in Section III below with respect to drugs compounded by pharmacies in that State; in addition, the State Board of Pharmacy agrees that if it receives information about complaints or becomes aware of information about drugs compounded by physicians in the State and distributed interstate, it will forward the information to FDA and the appropriate State regulator of physicians as described in Section III.

- b. To qualify for these exemptions, a compounded human drug product must, among other things,³ meet the conditions in section 503A(b)(3)(B) of the FD&C Act, under which the drug product is compounded in a State that:
 - 1. Has entered into an MOU with FDA that addresses the distribution of inordinate amounts of compounded drug products interstate and provides for appropriate investigation by a State agency of complaints relating to compounded drug products distributed outside such State (section 503A(b)(3)(B)(i)); or
 - 2. Has not entered into an MOU with FDA and the licensed pharmacist, licensed pharmacy, or licensed physician distributes (or causes to be distributed) compounded drug products out of the State in which they are compounded in quantities that do not exceed 5 percent of the total prescription orders dispensed or distributed by such pharmacy or physician (section 503A(b)(3)(B)(ii)).
- c. Section 503A(b)(3) of the FD&C Act directs FDA to develop a standard MOU, in consultation with the National Association of Boards of Pharmacy (NABP), for use by the States in complying with section 503A(b)(3)(B)(i). This MOU is the standard MOU developed by FDA for this purpose.

III. SUBSTANCE OF AGREEMENT

- a. Investigation of Complaints Relating to Compounded Human Drug Products Distributed Outside the State
 - 1. The [insert State Board of Pharmacy or other appropriate State agency] will investigate complaints of adverse drug experiences and product quality issues⁴ relating to human drug products compounded at a pharmacy in [insert State] and distributed outside the State. Any investigations will be performed pursuant to the [insert State Board of Pharmacy or other appropriate State agency]'s established investigatory policies and procedures, including those related to prioritizing complaints, provided they are not in conflict with the terms of this MOU.
 - 2. Any investigations performed by the [insert State Board of Pharmacy or other appropriate State agency] under this MOU will include taking steps to assess (1) whether there is a public health risk associated with the compounded drug product; and (2) whether any public health risk associated with the product is adequately contained.

³ To qualify for the exemptions under section 503A, a compounder must obtain a prescription for an individually identified patient (section 503A(a) of the FD&C Act). This MOU does not alter this condition.

⁴ For purposes of this MOU, see the definitions of “adverse drug experience” and “product quality issue” in Appendix A.

3. After the [insert State Board of Pharmacy or other appropriate State agency]'s investigation, if the complaint is substantiated, the [insert State Board of Pharmacy or other appropriate State agency], in accordance with and as permitted by State law, will take the action that the [insert State Board of Pharmacy or other appropriate State agency] considers to be appropriate and warranted to ensure that the relevant pharmacy investigates the root cause of the problem that is the subject of the complaint and undertakes sufficient corrective action to address any identified public health risk relating to the problem, including the risk that future similar problems may occur.
4. The [insert State Board of Pharmacy or other appropriate State agency] will maintain records of the complaint about adverse drug experiences or product quality issues relating to human drug products compounded at a pharmacy, the investigation of the complaint, and any response to or action taken as a result of the complaint, beginning when the [insert State Board of Pharmacy or other appropriate State agency] receives notice of the complaint. The [insert State Board of Pharmacy or other appropriate State agency] will maintain these records for at least 3 years. The 3-year period begins on the date of final action on a complaint, or the date of a decision that the complaint requires no action.
5. As soon as possible, but no later than 5 business days after receiving a complaint involving a serious adverse drug experience or serious product quality issue relating to a drug product compounded at a pharmacy and distributed outside the State, the [insert State Board of Pharmacy or other appropriate State agency] will, by submission to an Information Sharing Network⁵ or by email to StateMOU@fda.hhs.gov, provide FDA with the information described in the Submission and Disclosure of Information section of this MOU (section III.c.1.a.i-iii).⁶
6. After the [insert State Board of Pharmacy or other appropriate State agency] concludes its investigation of a complaint assessed to involve a serious adverse drug experience or serious product quality issue relating to a drug product compounded at a pharmacy and distributed outside the State, the [insert State Board of Pharmacy or other

⁵ For purposes of this MOU, see the definitions of “serious adverse drug experience,” “serious product quality issue,” and “Information Sharing Network” in Appendix A.

⁶ The information includes the following: (i) Name and contact information of the complainant, if available; (ii) Name and address of the pharmacy that is the subject of the complaint; and (iii) Description of the complaint, including a description of any compounded human drug product that is the subject of the complaint.

appropriate State agency] will share with FDA, as described in the Submission and Disclosure of Information section of this MOU (section III.c.1.a.iv-v),⁷ the results of the investigation as permitted by State law.

7. If the [insert State Board of Pharmacy or other appropriate State agency] receives a complaint involving an adverse drug experience or product quality issue relating to a human drug product compounded by a physician and distributed outside the State, the [insert State Board of Pharmacy or other appropriate State agency] will notify the appropriate regulator of physicians within the State. The [insert State Board of Pharmacy or other appropriate State agency] will also notify FDA by submission to an Information Sharing Network or by sending an email to StateMOU@fda.hhs.gov with the information described in the Submission and Disclosure of Information section of this MOU (section III.c.2.a.-c), if available, as soon as possible, but no later than 5 business days, after receiving the complaint.

b. Distribution of Inordinate Amounts of Compounded Human Drug Products Interstate⁸

1. For purposes of this MOU, a pharmacy has distributed an inordinate amount of compounded human drug products interstate if the number of prescription orders for compounded human drug products that the pharmacy distributed interstate during any calendar year is greater than 50 percent of the sum of:
 - (i) the number of prescription orders for compounded human drug products that the pharmacy sent out of (or caused to be sent out of) the facility in which the drug products were compounded during that same calendar year; plus
 - (ii) the number of prescription orders for compounded human drug products that were dispensed (e.g., picked up by a patient) at the facility in which they were compounded during that same calendar year.

⁷ The information includes: (i) [Insert State Board of Pharmacy or other appropriate State agency]'s assessment of whether the complaint was substantiated, if available; and (ii) Description and date of any actions the [insert State Board of Pharmacy or other appropriate State agency] has taken to address the complaint.

⁸ The distribution of inordinate amounts of compounded human drug products interstate is a threshold for the [insert State Board of Pharmacy or other appropriate State agency] to identify and report certain information to FDA, not a limit on the distribution of compounded human drug products interstate.

Figure 1. Calculating an Inordinate Amount

$$\frac{A}{B} = X, \text{ where:}$$

A = Number of prescription orders for compounded human drug products that the pharmacy distributed interstate during any calendar year

B = The sum of the number of prescription orders for compounded human drug products (i) that the pharmacy sent out of (or caused to be sent out of) the facility in which the drug products were compounded during that same calendar year; plus (ii) the number of prescription orders for compounded human drug products that were dispensed (e.g., picked up by a patient) at the facility in which they were compounded during that same calendar year

If X is greater than 0.5, it is an inordinate amount and is a threshold for certain information identification and reporting under the MOU.

2. On an annual basis, the [insert State Board of Pharmacy or other appropriate State agency] will identify, using surveys, reviews of records during inspections, data submitted to an Information Sharing Network, or other mechanisms available to the [insert State Board of Pharmacy or other appropriate State agency], pharmacies that distribute inordinate amounts of compounded human drug products interstate.
3. For pharmacies that have been identified as distributing inordinate amounts of compounded human drug products interstate during any calendar year, the [insert State Board of Pharmacy or other appropriate State agency] will identify, using data submitted to an Information Sharing Network or other available mechanisms, during that same calendar year:
 - a. the total number of prescription orders for sterile compounded human drugs distributed interstate;
 - b. the names of States in which the pharmacy is licensed;
 - c. the names of States into which the pharmacy distributed compounded human drug products; and
 - d. whether the State inspected for and found during its most recent inspection that the pharmacy distributed compounded human drug products without valid prescription orders for individually identified patients.
4. The [insert State Board of Pharmacy or other appropriate State agency] will, within 30 business days of identifying a pharmacy that has distributed inordinate amounts of compounded human drug products interstate, notify FDA of such pharmacy, through an Information Sharing Network or by email to StateMOU@fda.hhs.gov, and will include the

information described in the Submission and Disclosure of Information section of this MOU (section III.c.1.b).

5. If the [insert State Board of Pharmacy or other appropriate State agency] becomes aware of a physician who is distributing any amount of compounded human drug products interstate, the [insert State Board of Pharmacy or other appropriate State agency] will notify the appropriate regulator of physicians within the State. The [insert State Board of Pharmacy or other appropriate State agency] will, within 30 business days of identifying a physician who is distributing any amount of compounded human drug products interstate, also notify FDA by submission to an Information Sharing Network or by email to StateMOU@fda.hhs.gov.

c. Submission and Disclosure of Information

1. When submitting information using StateMOU@fda.hhs.gov regarding complaints relating to human drug products compounded by a pharmacy and distributed outside the State, or regarding distribution of inordinate amounts of human drug products compounded by a pharmacy interstate, the following minimum information will be included. Note, this information can be submitted to an Information Sharing Network for sharing with FDA.

a. Complaints:

- i. Name and contact information of the complainant, if available;
- ii. Name and address of the pharmacy that is the subject of the complaint;
- iii. Description of the complaint, including a description of any compounded human drug product that is the subject of the complaint;
- iv. [Insert State Board of Pharmacy or other appropriate State agency]'s assessment of whether the complaint was substantiated, if available; and
- v. Description and date of any actions the [insert State Board of Pharmacy or other appropriate State agency] has taken to address the complaint.

b. Inordinate Amounts:

- i. Name and address of the pharmacy that distributed inordinate amounts of compounded human drug products interstate;
 - ii. The number of prescription orders for compounded human drug products that the pharmacy sent out of (or caused to be sent out of) the facility in which the drug products were compounded during that same calendar year;
 - iii. The number of prescription orders for compounded human drug products that were dispensed (e.g., picked up by a patient) at the facility in which they were compounded during that same calendar year;
 - iv. The total number of prescription orders for compounded human drug products distributed interstate during that same calendar year;
 - v. The total number of prescription orders for sterile compounded human drug products distributed interstate during that same calendar year;
 - vi. The names of States in which the pharmacy is licensed and the names of States into which the pharmacy distributed compounded human drug products during that same calendar year; and
 - vii. Whether the [insert State Board of Pharmacy or other appropriate State agency] inspected for and found during its most recent inspection that the pharmacy distributed compounded human drug products without valid prescription orders for individually identified patients during that same calendar year.
2. When submitting information using StateMOU@fda.hhs.gov regarding complaints relating to human drug products compounded by a physician, or regarding distribution of any amount of human drug products compounded by a physician interstate, the following minimum information will be included, if available. Note, this information can be submitted to an Information Sharing Network for sharing with FDA.
 - a. Name and contact information of the complainant or notifier;
 - b. Name and address of the physician that is the subject of the complaint or notification; and

- c. Description of the complaint or notification, including a description of any compounded human drug product that is the subject of the complaint or notification.
3. The parties to this MOU will share information consistent with applicable statutes and regulations. The parties recognize that a separate agreement under 21 CFR 20.88 may be necessary before FDA can share information that is protected from public disclosure. Such an agreement will govern FDA's sharing of the following types of information:
 - Confidential commercial information, such as information that would be protected from public disclosure under Exemption 4 of the Freedom of Information Act (FOIA) (5 U.S.C. 552(b)(4));
 - Personal privacy information, such as information that would be protected from public disclosure under Exemption 6 or 7(C) of the FOIA (5 U.S.C. 552(b)(6) and(7)(C)); or
 - Information that is otherwise protected from public disclosure by Federal statutes and their implementing regulations (e.g., the Trade Secrets Act (18 U.S.C. 1905), the Privacy Act (5 U.S.C. 552a), other FOIA exemptions not mentioned above (5 U.S.C. 552(b)), the Health Insurance Portability and Accountability Act (Public Law 104-191), and FDA's regulations in parts 20 and 21 (21 CFR parts 20 and 21)).

FDA agrees that information provided to FDA by the [insert State Board of Pharmacy or other appropriate State agency] will only be disclosed consistent with applicable Federal law and regulations governing the disclosure of such information, including the FOIA (5 U.S.C. 552(b)), the FD&C Act (21 U.S.C. 301 et seq.), 21 U.S.C. 331(j), 21 U.S.C. 360j(c), the Trade Secrets Act (18 U.S.C. 1905), FDA's regulations in 21 CFR parts 20 and 21, and other pertinent laws and regulations.

IV. ENFORCEMENT AUTHORITIES AND LEGAL STATUS OF AGREEMENT

The parties to this MOU recognize that FDA and the [insert State Board of Pharmacy or other appropriate State agency] retain the statutory and regulatory authorities provided by the FD&C Act, other Federal statutes and attendant regulations, and State statutes and regulations. The parties also recognize that this agreement does not restrict FDA or any other Federal agency from taking

enforcement action, when appropriate, to ensure compliance with Federal statutes, including the FD&C Act and attendant regulations, or prevent the [insert State Board of Pharmacy or other appropriate State agency] from taking enforcement action, as appropriate, to ensure compliance with applicable State statutes and regulations. This MOU does not create or confer any rights for or on any person. By signing this MOU, the [insert State Board of Pharmacy or other appropriate State agency] affirms that it now possesses and will maintain, at the discretion of the State legislature, the legal authority (under State statutes and/or regulations) and the resources necessary to effectively carry out all aspects of this MOU. If State law changes such that the [insert State Board of Pharmacy or other appropriate State agency] no longer has the legal authority or resources necessary to effectively carry out all aspects of this MOU, the [insert State Board of Pharmacy or other appropriate State agency] will notify FDA within 60 calendar days of the change in legal authority.

V. NAME AND ADDRESS OF PARTICIPATING AGENCIES

U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Unapproved Drugs and Labeling Compliance
10903 New Hampshire Avenue
Bldg. 51, Suite 5100
Silver Spring, MD 20993-0002
Telephone: (301) 796-3110
Email: StateMOU@fda.hhs.gov

[Insert State Board of Pharmacy or other appropriate State agency and its contact information]

Upon signing the MOU, each party must designate one or more liaisons to act as points of contact. Each party may designate new liaisons at any time by notifying the other party's liaison(s) in writing. If, at any time, an individual designated as a liaison under this agreement becomes unavailable to fulfill those functions, the parties will name a new liaison within 2 weeks and notify the other party's liaison(s).

VI. PERIOD OF AGREEMENT

- a. When accepted by both parties, this MOU will be effective from the date of the last signature and will continue until terminated by either party. It may be terminated in writing by either party, upon a 60 calendar day notice of termination. Notice of termination will be sent to the address listed in section V of this MOU.

- b. If the [State Board of Pharmacy or other appropriate State agency] does not adhere to the provisions of this MOU, including conducting an investigation of complaints related to compounded human drug products distributed outside the State, the MOU may be terminated upon a 60 calendar day notice of termination.

In case of termination, FDA will post a notice of the termination on its Web site and the [insert State Board of Pharmacy or other appropriate State agency] will notify all pharmacies that compound drug products in the State and notify the State authority that licenses or regulates physicians of the termination and advise them that as of 60 calendar days from the date of the posting of the termination notice, compounded human drug products may be distributed (or caused to be distributed) out of the State only “in quantities that do not exceed 5 percent of the total prescription orders dispensed or distributed” by the licensed pharmacy or physician (section 503A(b)(3)(B)(ii) of the FD&C Act).

VII. APPROVALS

APPROVED AND ACCEPTED FOR THE U.S. FOOD AND DRUG ADMINISTRATION	APPROVED AND ACCEPTED FOR [insert State Board of Pharmacy or other appropriate State agency]
By (Type Name)	By (Type Name)
Title	Title
Date	Date

Appendix A. Definition of Terms for the Purposes of this MOU

- **Adverse Drug Experience:** Any adverse event associated with the use of a drug in humans, whether or not considered drug related, including the following: an adverse event occurring in the course of the use of a drug product in professional practice; an adverse event occurring from drug overdose, whether accidental or intentional; an adverse event occurring from drug abuse; an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action (21 CFR 310.305(b)).
- **Distribution of compounded human drug products interstate:** Means that a pharmacy or physician has sent (or caused to be sent) a compounded drug product out of the State in which the drug was compounded.
- **Information Sharing Network:** An information sharing network designated by FDA for purposes of this MOU to collect, assess, and allow review and sharing of information pursuant to this MOU.
- **Inordinate Amounts:** A pharmacy has distributed an inordinate amount of compounded human drug products interstate if the number of prescription orders for compounded human drug products that the pharmacy distributed interstate during any calendar year is greater than 50 percent of the sum of: (i) the number of prescription orders for compounded human drug products that the pharmacy sent out of (or caused to be sent out of) the facility in which the drug products were compounded during that same calendar year; plus (ii) the number of prescription orders for compounded human drug products that were dispensed (e.g., picked up by a patient) at the facility in which they were compounded during that same calendar year.⁹
- **Product Quality Issue:** Information concerning (1) any incident that causes the drug product or its labeling to be mistaken for, or applied to, another article; or (2) any bacteriological contamination; any significant chemical, physical, or other change or deterioration in the distributed drug product; or any failure of one or more distributed batches of the drug product to meet the applicable specifications (21 CFR 314.81(b)(1)). Contamination in general, including but not limited to mold, fungal, bacterial, or particulate contamination, is a product quality issue.
- **Serious Adverse Drug Experience:** Any adverse drug experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital

⁹ The definition of *inordinate amounts* in this MOU is separate and distinct from and should not be used in relation to the term *inordinate amounts* as it is used in section 503A(b)(1)(D) of the FD&C Act (pertaining to compounding a drug product that is essentially a copy of a commercially available drug product). The interpretation of this term in each instance necessarily is based on the particular context of the distinct provisions within 503A in which the term appears.

anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse (21 CFR 310.305(b)).

- **Serious Product Quality Issue:** Any product quality issue that may have the potential to cause a serious adverse drug experience (e.g., possible contamination, superpotent product).

NOT FOR IMPLEMENTATION

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 27. Controlled Dangerous Substances

Subchapter A. General Provisions

§2701. Definitions

A. Words not defined in this Chapter shall have their common usage and meaning as stated in the *Merriam Webster’s Collegiate Dictionary – Tenth Edition*, as revised, and other similarly accepted reference texts. As used in this Chapter, the following terms shall have the meaning ascribed to them in this Section unless the context clearly indicates otherwise:

* * *

Hemp Facility – a facility licensed by the Louisiana Department of Agriculture and Forestry as a hemp seed producer, hemp grower or hemp processor.

* * *

LDAF – Louisiana Department of Agriculture and Forestry, or its successor.

* * *

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2127 (October 2008), amended by the Department of Health, Board of Pharmacy, LR 46:569 (April 2020), LR 46

* * *

§2705. Licenses and Exemptions

A. – D.3. ...

E. Facilities and Hemp Facilities

1. The issuance of a CDS license to a facility, and the renewal thereof, shall require the possession of a valid and verifiable license or other credential issued by the department, or its successor.

2. The issuance of a CDS license to a hemp facility, and the renewal thereof, shall require the following:

a. a valid and verifiable license as a hemp grower or hemp processor issued by the Louisiana Department of Agriculture and Forestry (LDAF).

b. documentation verifying applicant’s compliance with ISO/IEC 17025 accreditation standards.

F. – J. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

42 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2129
43 (October 2008), amended LR 39:312 (February 2013), amended by the Department of Health, Board of Pharmacy,
44 LR 46:570 (April 2020), LR 46

45

46 **§2707. Licensing Procedures**

47 A. Application for Initial Issuance of CDS License

48 1. – 3. ...

49 4. Applicants not in possession of a valid and verifiable license or other credential from a standing
50 professional board of the State of Louisiana, or from the Department of Health, Bureau of Health Services
51 Financing, Health Standards, or their successors, or from the Louisiana Department of Agriculture and
52 Forestry, shall submit to a criminal history record check upon request by the board. The applicant shall
53 pay for the cost of the criminal history record check. The board shall evaluate the findings of the report
54 of the criminal history record check prior to the issuance of the CDS license.

55 A.5. – D.5.e ...

56

57 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

58 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2131
59 (October 2008), amended by the Department of Health, Board of Pharmacy, LR 43:957 (May 2017), amended by
60 the Department of Health, Board of Pharmacy, LR 46:570 (April 2020), LR 46

From: [Brent Doherty](#)
To: [Malcolm J. Broussard](#)
Cc: [David Eagleson](#); [Shayla Richard](#)
Subject: RE: Board of Pharmacy Update
Date: Tuesday, August 11, 2020 7:15:38 AM
Attachments: [Board of Pharmacy Photo Hosting Overview 8.10.20.docx](#)

Hi Malcolm,

I wanted to follow up with more information on the cost for the photo storage in Metrc and the use of the item approval process. I understand the meeting is this Wednesday, so we did want to provide you with what we believe should be a workable solution from a cost perspective. Attached is the overview of the use of Metrc concerning the Board of Pharmacy's interests. This document was shared with our executive team, and it was determined that we could continue to support the Board of Pharmacy's current level of usage at a reduced price of \$1,200 for the year.

This price is contingent on the fact that we will need to evaluate if any changes would significantly increase the number of photos that would require storage. These reasons would be any additional production/manufacturing facilities or item categories available to be sold to patients. As far as I can tell, we do not anticipate either of these scenarios to occur in the next year.

We want to be understanding partners with you and the Board in helping to regulate the Louisiana Medical Marijuana market as it continues to grow. I hope this reduction in cost will make it amenable for you and the Board to continue to use Metrc for the item approval process and take advantage of all of the other functionality available. Please let me know if you have any questions or comments.

Thanks,

Brent

From: Brent Doherty
Sent: Thursday, July 30, 2020 3:16 PM
To: Malcolm J. Broussard <mbroussard@pharmacy.la.gov>
Cc: David Eagleson <david.eagleson@metrc.com>; Shayla Richard <shayla.richard@metrc.com>
Subject: Board of Pharmacy Update

Hey Malcolm,

I wanted to provide you an update on where we are with the request from the Board of Pharmacy discussed on our call last Thursday. We are sharing an overview of our executive team with the intent to provide a more suitable cost for the Board of Pharmacy based on the value we can provide. Once our executive team provides their feedback, we will follow up with you to provide an additional update. We fully expect to have a clear response and answer for you in anticipation of the Board meeting on August 12th. Please let me know if you have any additional questions.

Thanks,

Brent Doherty
Government Program Manager
(m) 863-606-2260

Brent.Doherty@metrc.com



Overview

The Louisiana Board of Pharmacy has recently engaged in discussions with Metrc to review the Metrc system as the Louisiana Medical Marijuana Tracking System (LMMTS) and its use by the Board of Pharmacy. The Board of Pharmacy would like to explore the use of the system and the associated costs that include the additional hosting for photos. Metrc is also providing a summary of the functionality that is either in use or available to the Board of Pharmacy.

Metrc Functionality Use

- Metrc functionality includes the use of the item approval process which the Board of Pharmacy are active participants to ensure that the final products reaching the pharmacies
- Metrc creates and assigns a product ID code to marijuana products as they are created and approved.
 - This product ID code is designed to match the NDC code that is utilized by the patient management program (PMP) at the pharmacy level
 - The product ID code is used on the labeling of all final products that are transferred to the pharmacies
 - Board of Pharmacy has indicated some potential for changes to their regulations that would not require this Product ID on the labeling
- Metrc automatically sends a file to the PMP vendor with the list of products and their IDs that are being assigned as they are created
 - This file is maintained by Metrc, Board of Pharmacy has indicated that if necessary, they would maintain it themselves
 - The potential drawback to this is that if there is an expanded list of items, this could become labor-intensive to keep up with an increase in product lines
- Metrc tracks all sales to the pharmacies through the tracking of wholesale transfers
 - This process produces a transfer manifest that is used as certification of the transfer for law enforcement
- Board of Pharmacy does not require the use of Metrc to record sales at the pharmacy level, but could utilize the sales if they wanted to be able to have an easily accessible real-time inventory tracking of all pharmacies
 - Board of Pharmacy has indicated that they will use data exports from Metrc transfers and reconcile with their PMP to determine inventory levels if they decide to cease Metrc use
 - This process would be cumbersome and would not give the Board of Pharmacy the opportunity to utilize an already developed for regulators to track inventory in favor of a manual process.

Considerations

- The Board of Pharmacy paid \$18,000 for the first year of the photo storage in Metrc
 - The Board collects \$1,350 in licensing fees from pharmacies, so this becomes a \$16,650 cost that must be budgeted
- Current functionality allows for up to 3 (product, label, packaging) required photos per item. The LDAF recently configured all 3 required for the following item categories:
 - Tincture

- 30 approved Items with 36 photos total
 - 19 rejected items with 45 photos total
- Topical
 - 2 approved items with 2 photos total
- Infused Non-Edible
 - 2 approved items with 2 photos total
- Edible
 - 0 approved items
 - 1 rejected item with 1 photo total
- Oral Thin Film (OTF)
 - 0 items created
- Discussions with the Department of Agriculture indicated that there are no plans to add any more production/manufacturing facilities or item categories
 - Metrc is hosting 86 total photos currently and unless anything changes we do not expect a significant increase in this number
- Malcolm indicated that the annual fee paid by the Board includes LMMS credentiaing fees for up to 50 marijuana pharmacies, the responsibility for which could be shifted to the pharmacies.
 - We need to review this with BOP to ensure we have an understanding of what this is and how we can address this cost



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Report of Assistant Executive Director




LOUISIANA
BOARD *of*
PHARMACY

PRESCRIPTION MONITORING PROGRAM (PMP)

BOARD MEETING – AUGUST 13, 2020


Number of Eligible Prescription Transactions Reported to the PMP

Reporting through 06/30/2020



PMP Reporting Comparisons


Reporting through 06/30/2020



■ All RXs Reported to PMP	12,350,904	12,289,457	11,967,339	11,303,599	10,824,058	5,072,687
■ Only CDS RXs for LA Residents	11,595,884	11,611,045	11,308,677	10,679,449	10,218,867	4,802,125
■ Opioid RXs for LA Residents	5,519,935	5,450,972	5,171,221	4,636,369	4,275,004	1,915,458

Therapeutic Marijuana (TM) PMP Reporting

Reporting through 06/30/2020




	Aug-19	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20	May-20	Jun-20
RX Count	2,445	1,885	2,008	1,819	1,679	1,814	1,635	1,975	1,670	1,996	2,314
Patient Count	1,860	1,511	1,644	1,500	1,372	1,469	1,335	1,567	1,338	1,631	1,872
Prescriber Count	50	57	62	67	66	72	73	81	77	81	88

Total Prescription Count
• 21,240

Total Patient Count
• 6,787


Total Prescriber Count
• 109

TM Patient Count by Patient Postal Code



Patient Count (Sum) by Postal Code

Top 100 Locations by Patient Count (Sum)



PMP User Stats 2020.Q2 (April 1, 2020 through June 30, 2020 (COVID-19))


Healthcare Provider Role	Number of Providers Eligible for PMP Access (as of 06/30/2020)	Number of Providers with PMP Active Access Privileges (as of 06/30/2020)	Number of PMP Requests by Providers through AWARe® During 2020.Q2	Number of PMP Requests by Providers through Gateway® During 2020.Q2
Physician (MD, DO)	13,425	8,798	403,406	2,368,679
Nurse Practitioner (APRN)	3,880	2,997	137,058	331,578
Dentist (DDS)	2,327	1,551	4,489	388
Physician Assistant (PA)	1,030	766	19,460	32,194
Optometrist (OD)	363	153	5	0
Podiatrist (DPM)	167	109	619	0
Medical Psychologist (MP)	93	86	7,090	3,302
Medical Intern/Resident	1,211	1,145	6,163	1,415
Prescriber's Delegate	NA	2,851	185,906	0
Pharmacist (PST)	9,147	4,448	690,478	1,513,016
Pharmacist's Delegate	NA	1,171	60,637	0
Totals	31,643	24,075	1,515,311	4,250,572

PMP User Stats 2020.Q1 (January 1, 2020 through March 31, 2020 (Covid-19))

Healthcare Provider Role	Number of Providers Eligible for PMP Access (as of 04/30/2020)	Number of Providers with PMP Active Access Privileges (as of 04/30/2020)	Number of PMP Requests by Providers through AWARe® During 2020.Q1	Number of PMP Requests by Providers through Gateway® During 2020.Q1
Physician (MD, DO)	13,256	8,787	432,010	2,909,780
Nurse Practitioner (APRN)	3,816	2,962	125,520	411,263
Dentist (DDS)	2,272	1,552	5,694	634
Physician Assistant (PA)	1,014	765	22,884	50,595
Optometrist (OD)	359	154	10	0
Podiatrist (DPM)	164	110	481	0
Medical Psychologist (MP)	93	86	6,613	0
Medical Intern/Resident	1,206	1,128	6,122	0
Prescriber's Delegate	NA	2,790	207,340	0
Pharmacist (PST)	9,098	4,411	529,249	1,685,883
Pharmacist's Delegate	NA	1,116	52,975	0
Totals	31,278	23,861	1,388,898	5,058,155


Louisiana Prescriber & Pharmacist Searches through AWAxRxE and Gateway

(Ending 06/30/2020)



PMP Statewide Integration Project

As of July 1, 2020, the Louisiana PMP is interoperable with **176 licensees** (EHRs and pharmacy management systems) across the state. The **176 licensees** represent more than **1,600 facilities** in Louisiana and are responsible for **1,810,207 PMP requests** in the month of **June**.



GATEWAY REQUESTS BREAKDOWN

Monitor Gateway requests from Licensees, Facilities, Requesters, and Patients Searched.

A Gateway request includes all incoming transactions generated by an end user through an integrated system. Specifically, it includes all 1st/Single calls as well as any 2nd calls for APIs that allow them. It doesn't include outgoing requests to PMP InterConnect.

Total Requests: 1,810,207

Request Successful: (All) | Request Type: (Multiple values) | Licensee: (All) | Year: 2020 | Month: 6

Requests by Licensee (Show Top X Licensees: 300)

Rank	Licensee	Licensee Address	State Code	Zip	Requests (#)
Grand Total					1,810,207
1	Ochsner Health System	1514 Jefferson Hwy	LA	70121	335,272
2	Athena Health	311 Arsenal Street	MA	02472	278,589
3	Walgreen's Pharmacy	200 Wilmot	IL	60015	276,088
4	Franciscan Missionaries of o.	5959 S. Sherwood Forest Blvd	LA	70816	252,288
5	Louisiana Children's Medical	200 Henry Clay Ave.	LA	70118	145,275
6	CVS Health - NariCare Report	1 CVS Drive	Ri	02895	122,256
7	Walmart Pharmacy	702 SW 8th Street	AR	72716	86,613
8	Lafayette General Hospital	920 W. Pinhook Rd	LA	70503	58,111
9	CHRISTUS Health(TX)Statew...	919 Hidden Ridge	TX	75038	55,466
10	North Oaks Health Systems	15790 Paul Vega MD Drive	LA	70403	52,456

NABP PMP InterConnect®

PMP Interstate Data Sharing

As of June 30, 2020, the Louisiana PMP is sharing with 31 states and the U.S. Military Health System (MHS) – Department of Defense (DOD)

Alabama	Kansas	North Dakota
Alaska	Maine	Oklahoma
Arizona	Massachusetts	Pennsylvania
Arkansas	Michigan	Puerto Rico
Connecticut	Minnesota	South Carolina
Delaware	Mississippi	South Dakota
D.C.	Montana	Tennessee
Florida	Nevada	Texas
Georgia	New Mexico	Virginia
Idaho	North Carolina	West Virginia
Iowa		

Law Enforcement Requests

Requests through 06/30/2020



Requests for Full Exemption from PMP Reporting

August 13, 2020

In accordance with LA.R.S:40.4.X-A.1006.C., the Board may issue an exemption from the reporting requirement to a pharmacy whose practice activities are inconsistent with the intent of the program. The Board may rescind any previously issued exemption without the need for an informal or formal hearing.

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
8124	HOS	Acadian Medical Center Pharmacy	Hospital Pharmacy	Yes	Eunice	LA
8076	HOS	Alexandria Emergency Hospital	Emergency room and in-patient hospital	Yes	Alexandria	LA
8104	NR	AxivaRx of Kansas, LLC	Closed door, specialty, home infusion pharmacy	Yes	Lenexa	KS
8095	NR	Biologics by McKesson	Specialty pharmacy for cancer and complex conditions	Yes	Cary	NC
8096	NR	Biologics by McKesson	Non-dispensing pharmacy	No	Cary	NC
4451	NR	BioScrip Pharmacy Services	Home infusion, specialty, mail-order pharmacy	Yes	Dublin	OH
8082	NR	Buy-Rite Drugs, Inc.	Veterinary compounding pharmacy	Yes	Hartselle	AL
8058	NR	Cottrill's Pharmacy	Specialty, independent community, home infusion pharmacy	Yes	Arcade	NY
3542	RC	DCS-N.O. Pharmacy	Community chain (community health center pharmacy)	Yes	Metairie	LA
6269	RC	DCSNO Pharmacy Carrollton	Community chain (community health center pharmacy)	Yes	New Orleans	LA
7403	RC	DCSNO Pharmacy Gentilly	Community chain (community health center pharmacy)	Yes	New Orleans	LA
6270	RC	DCSNO Pharmacy St. Cecilia	Retail chain	Yes	New Orleans	LA

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
6841	RC	DCSNO Pharmacy-NOE	Community chain (community health center pharmacy)	Yes	New Orleans	LA
8092	NR	DeliverIt Pharmacy Infusion Center LLC	Specialty and home infusion pharmacy	Yes	Sugar Land	TX
5274	IR	Diabetes Management & Supplies Pharmacy	Specialty pharmacy for diabetes management	Yes	New Orleans	LA
8044	NR	Empower Pharmacy	Non-dispensing, order processing pharmacy	No	Houston	TX
7530	NR	HCP Pharmacy	Community retail	Yes	Arlington	TX
8087	NR	Healix Infusion Therapy, LLC	Specialty compounding pharmacy	Yes	Sugar Land	TX
8049	NR	Holistic Pharmacy Service	Class G pharmacy	No	Irving	TX
5985	NR	Home Med Pharmacy	Provides maintenance medications via US Postal Service	Yes	Indianapolis	In
8075	NR	Humana Pharmacy, Inc.	Mail order	No	Springdale	OH
8086	NR	Humana Pharmacy, Inc.	Mail order	No	Glendale	AZ
8112	NR	Kroger Specialty Infusion AL	Immunoglobulin therapy	Yes	Dothan	AL
8097	NR	MedWiseRx	Medication therapy management	No	Phoenix	AZ
8038	SAT	Ochsner LSU Health Shreveport-FWCC	Hospital satellite pharmacy (order validation & sterile compounding)	Yes	Shreveport	LA
8045	NR	PipelineRx	Remote medication order entry and review	No	Mount Pleasant	SC
8070	NR	Premier Specialty Infusion, LLC	Specialty medication provider	Yes	Hoffman Estates	IL
8106	NR	Simple Rx Pharmacy	Independent retail pharmacy	Yes	Arlington	TX
8098	NR	Sortpak Pharmacy	Specialty pharmacy (individual packaging)	Yes	Glendale	CA

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
8103	NR	Tulip Pharmacy	Dispenses mainly diabetic supplies	Yes	Rosenberg	TX
8105	NR	Watson Rx Solutions, Inc.	Community, independent, retail pharmacy	Yes	Florence	AL

Staff Recommendation

Approve the proposed waivers conditioned upon execution of the standard Consent Agreement:

**EXEMPTION TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTS
CONSENT AGREEMENT**

WHEREAS, in order to facilitate the pharmacy's request for an exemption to the reporting requirements to the Louisiana Board of Pharmacy's Prescription Monitoring Program (PMP) as required by law, the Pharmacy indicated below agrees to the following terms:

- (1) The Pharmacy shall not be authorized to dispense any controlled dangerous substances (CDS) or *drugs of concern*, with the exception of a hospital pharmacy permit's inpatient dispensing, as identified by the Louisiana Board of Pharmacy (Board) by regulation.
- (2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to the following sanction:
The Pharmacy agrees to pay a fine of \$5,000.00 and reimburse the Board \$250.00 in administrative hearing costs, with total payment due the Board of \$5,250.00, due by certified check or money order within 30 days of notice of this prohibited activity.
- (3) Upon the second instance of receipt of evidence indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to pay the above sanction, the termination of this exemption and the resumption of its reporting to the PMP.
- (4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Report of General Counsel



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Report of Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



August 13, 2020

Agenda Item 10-L: Report of Executive Director

1. Meeting Activity
2. Reports
3. Examinations
4. Operations
5. State Activities
6. Regional & National Activities
7. International Activities

1. **Meeting Activity**

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

August 10 ULM College of Pharmacy ~ P-1 Orientation

2. **Reports**

A. Internal Reports (posted in the Library)

1. Credentials Division
 - a. Census Report
 - b. Licensure Activity Report
 - c. Pending Applications Report
 - d. Exceptions Report
2. Compliance Division
 - a. Census Report – Practitioner Recovery Program & Disciplinary Status
 - b. Complaint Investigation Policy Monitor
 - c. Annual Statistical Report

B. External Reports

Since the last Board meeting, we have filed the following reports on your behalf:

1. La. Office of the Governor – Boards & Commissions
 - a. Annual Report **[Action Item]**
2. La. Office of the Governor – Drug Policy Board / HOPE Advisory Council
 - a. Naloxone Dispensing Report
3. La. Div. of Administration – Office of the Commissioner
 - a. Quarterly Report of Legal Judgments [Act 2018-627]
 - b. Annual Report for Sexual Harassment Complaints [Act 2018-270]
4. La. Div. of Administration – Boards & Commissions
 - a. Annual LaTrac Report of Board Activity [Act 2009-12]
 - b. Quarterly Report of Member Expense Reimbursements
 - c. Ad hoc reports of personnel salaries, meeting notices, and budgets
5. La. Div. of Administration – Facility Planning & Control
 - a. Semiannual Report of Leased Office Space [Act 2016-66]
6. La. Div. of Administration – Property Assistance Agency
 - a. Annual Inventory of Property & Equipment
 - b. Annual Asset Certification Report
 - c. Monthly Agency Fleet Mileage Report

7. La. Div. of Administration – Office of Group Benefits
 - a. Annual Designations of Master User & Agency Coordinator
 - b. Ad hoc reports of non-discrimination testing
8. La. Div. of Administration – Office of Risk Management
 - a. Annual Agency Driver Authorization Report
 - b. Annual Loss Prevention Compliance Audit
 - c. Semiannual Property Exposure Report
 - d. Quarterly Risk Exposure Report
 - e. Quarterly Property Safety & Maintenance Inspections
 - f. Monthly Loss Claims Report
 - g. Monthly Report re Transitional Return to Work
9. La. Div. of Administration – Office of State Procurement
 - a. Monthly Report on Status of Professional Contracts [Act 2015-87]
 - b. Ad hoc reports on contractor performance review
10. La. Div. of Administration – Office of State Register
 - a. Ad hoc notices for rulemaking projects
11. La. Div. of Administration – Office of Statewide Reporting & Accounting Policy
 - a. Comprehensive Annual Financial Report
 - b. Annual Report of Taxable Compensation
 - c. Quarterly Report of Accounts Receivable [Act 1995-745]
12. La. Dept. of Children & Family Services
 - a. Ad hoc rosters for credential renewals for pharmacists and technicians
13. La. Dept. of Culture, Recreation, & Tourism – State Library of Louisiana
 - a. Annual Publications Report Form
 - b. Semiannual Roster & Agency Inventory of Agency Publications
 - c. Ad hoc document publication reports
14. La. Dept. of Economic Development
 - a. Ad hoc rulemaking notices
15. La. Dept. of Health – Bureau of Health Services Financing
 - a. Monthly Report of Pharmacy Openings & Closures
16. La. Dept. of Health – Office of Public Health
 - a. Semi-annual Report of Active MA Registrations
17. La. Dept. of Insurance
 - a. Annual Report of Investigation Referrals [Act 2009-251]
18. La. Dept. of Justice – Office of the Attorney General
 - a. Quarterly Report of Private Legal Fees Paid [Act 2006-611]
 - b. Quarterly Report of Legal Judgments [Act 2018-627]
 - c. Ad hoc notices for emergency rules
19. La. Dept. of Revenue
 - a. Quarterly Employer's Return of State Withholding Tax
 - b. Ad hoc rosters for credential renewals for pharmacists and technicians
20. La. Dept. of State – Division of Archives
 - a. Annual Report of Records Officer Designation
21. La. Dept. of State – State Library
 - b. Annual Report / Roster & Inventory of Agency Publications
22. La. Dept. of State Civil Service
 - a. Annual Confirmation of Agency EEO Policy
 - b. Annual Report of Performance Evaluations
 - c. Ad hoc Payroll Comparison Report
23. La. Dept. of Treasury – Cash Management Review Board
 - a. Quarterly Report of Agency Bank Accounts [Act 2016-587]
24. La. Board of Regents – ULM College of Pharmacy
 - a. Annual Report of Pharmacy Education Support Fees Collected
25. La. State Employees Retirement System
 - a. Monthly Report of Employer & Employee Contributions
26. La. Workforce Commission
 - a. Quarterly Report of Employer's Unemployment Tax

27. La. House of Representatives – Office of the Speaker
 - a. Annual Report of Rulemaking Activity
 - b. Ad hoc notices for rulemaking projects
28. La. House of Representatives – Poynter Legislative Research Library
 - a. Annual Filing of Legislative Reports
29. La. House of Representatives – Committee on Appropriations
 - a. Quarterly Report of Legal Judgments [Act 2018-627]
30. La. House of Representatives – Committee on Commerce
 - a. Annual Report of Licensed Ex-Offenders [Act 2017-262]
31. La. House of Representatives – Committee on House & Governmental Affairs
 - a. Quarterly Report of Board Complaints [Act 2018-655]
32. La. House of Representatives – Committee on Health & Welfare
 - a. Annual LaTrac Report on Board Activity [Act 2009-12]
 - b. Annual Report on Rulemaking Activity
 - c. Annual Notice of Budget Adoption
 - d. Comprehensive Annual Financial Report
 - e. Ad hoc notices for rulemaking projects
33. La. Senate – Office of the President
 - a. Annual Report on Rulemaking Activity
 - b. Ad hoc notices for rulemaking projects
34. La. Senate – Committee on Finance
 - a. Quarterly Report on Legal Judgments [Act 2018-627]
35. La. Senate – Committee on Health & Welfare
 - a. Annual LaTrac Report on Board Activity [Act 2009-12]
 - b. Annual Report on Rulemaking Activity
 - c. Annual Notice of Budget Adoption
 - d. Comprehensive Annual Financial Report
 - e. Ad hoc notices for rulemaking projects
36. La. Senate – Committee on Senate & Governmental Affairs
 - a. Annual Report on Boards & Commissions
 - b. Quarterly Report of Board Complaints [Act 2018-655]
37. La. Legislature – Legislative Auditor
 - a. Comprehensive Annual Financial Statement
 - b. Annual Inventory of Property & Equipment
 - c. Annual Asset Certification Report
 - d. Annual Notice of Budget Adoption
38. La. Legislature – Legislative Fiscal Office
 - a. Annual Notice of Budget Adoption
 - b. Annual LaTrac Report of Board Activity [Act 2009-12]
 - c. Ad hoc impact statements for rulemaking projects
39. La. Legislature – Joint Legislative Committee on the Budget
 - a. Annual Notice of Budget Adoption
 - b. Annual LaTrac Report of Board Activity [Act 2009-12]
40. U.S. Dept. of Commerce – Census Bureau
 - a. Annual Survey of Public Employment & Payroll
41. U.S. Dept. of Health & Human Services – Office of Public Health
 - a. Quarterly Report to ESAR-VHP
42. U.S. Dept. of Labor – Bureau of Labor Statistics
 - a. Monthly Survey of Current Employment Statistics
43. U. S. Dept. of Treasury – Internal Revenue Service
 - a. Annual Filings (Forms 1094, 1095-C, 1096, 1099, W-2, & W-3)
 - b. Quarterly Report of Form 941 – Employer’s Federal Tax Return

3. Examinations

A. Pharmacists

1. MPJE – the results for the first trimester of 2020 are presented in this report.

2. NAPLEX – the results for the first trimester of 2020 are presented in this report.

B. Technicians

1. NHA – the results for the second quarter of 2020 are presented in this report.

2. PTCB – the results for the first half of 2020 are presented in this report.

4. **Operations**

A. Credentials Division

As of May 21, 2020, we had 74,591 active credentials under management by the Board. That number reflects a 6.6% increase from the beginning of this fiscal year on July 1, 2019. About 65% of the credentials (48,611) reside in the Pharmacy Program with the balance in the CDS Program.

We opened the renewal cycle for pharmacy technicians, EDK permits, and AMS registrations on May 1. The renewal cycle closed on July 31 for pharmacy technician certificates and on June 30 for EDK permits and AMS registrations. We opened the renewal cycle for DME permits on July 1; it will close on August 31. We started offering the online renewal option for CDS-APN and CDS-DDS on June 1.

- CPT: We placed 7,195 certificates into renewal. Of that number, 6,503 (90%) renewed timely, and of that number, 96% did so online.
- EDK: We placed 523 permits into renewal. Of that number, 412 (79%) renewed timely.
- AMS: We placed 424 registrations into renewal. Of that number, 356 (84%) renewed timely.
- DME: We placed 523 permits into renewal. Of that number, 442 (85%) have renewed by August 4, with 91% doing so online.
- CDS-APN & CDS-DDS: We placed 1,227 credentials into renewal. By August 4, 395 had renewed, and of that number, 89% did so online.

We are planning to expand the use of virtual credentials. These credentials are identified by the (V) appearing at the end of the credential title. No paper forms for these credentials are created or retained. Beginning January 1, 2021, we plan to issue the PTC and PNT registrations, as well as some (but not all) categories of CDS licenses in virtual format.

B. Compliance Division

Our 7 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflect 1,431 pharmacies within the state, as well as 341 DME permits, and an additional 560 various types of facilities and persons for CDS visits, including hospitals, researchers, animal euthanasia technicians, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began FY 19-20 with 179 cases pending from the prior fiscal years. We opened 403 new cases and closed 400, leaving 182 cases still open for this fiscal year. Of the 400 cases closed, 67% were disposed of through staff activities and the balance through committee and Board action.

You may recall one of the recommendations from the Legislative Auditor in their audit of the prescription monitoring program was for more audits of pharmacies. The PMP office staff routinely audits pharmacies to ensure they are reporting every day they are open. The compliance officers now include PMP audits during their inspections to ensure pharmacies are reporting all of their eligible transactions.

C. Administrative Division

With respect to our record retention project, we are waiting for the state archives to respond to the policy approved by the board. On their approval, we will then implement the record removal process as authorized by the policy.

As noted elsewhere in our credentialing activity reports, we have begun transitioning some of the CDS license renewals to the online option. Initial results have

not revealed any configuration issues, so we plan to expand the number of classifications of CDS licenses eligible for online renewal. We are also working on online applications for certain credentials. We continue to plan for conversion of credentials to virtual status, with some delays due to working through our existing paper stock for those credentials.

D. Marijuana Pharmacies

As you may recall, the enabling legislation adopted in 2015 limits the number of marijuana pharmacy permits in the state to a maximum of ten active permits. The Board's rules for marijuana pharmacies adopted in August 2017 identified the nine regions of the state used by the state health department, allocated one marijuana pharmacy permit to each of those nine regions, and included a provision that the 10th permit may be awarded by the Board when it is convinced of the need for it. Following the conclusion of the competitive application process identified in its rules, the Board awarded the first nine marijuana pharmacy permits in April 2018.

To facilitate the Board's determination of need for a 10th permit, we initiated a data collection process to document patient need as indicated by the ZIP code of the patients with medical cannabis transactions reported by the marijuana pharmacies to the PMP database. The quarterly PMP report now includes data relative to the number of dispensing transactions, the number of patients, and the geographical distribution of those patients.

With the change in the marijuana law opening up the number of physicians and the number of medical conditions eligible for treatment with marijuana, we recommend an additional period of monitoring not to exceed one year. On that timeline, the Board should prepare to initiate the process to award the 10th permit in the spring or summer of 2021.

5. ***Regional & National Activities***

A. National Association of Boards of Pharmacy (NABP)

The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

For your planning purposes, NABP plans to revert back to a physical meeting next year; they have secured a venue in Phoenix, AZ for May 13-15, 2021. Registration details will be provided when they are available.

B. NABP-AACP District 6

The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

For your planning purposes, Districts 6, 7, and 8 are scheduled to meet via videoconference on October 13, 2020. The 2021 conference is planned for the Civana Spa, Resort & Sanctuary in Carefree, AZ on Aug. 29 – Sept. 1. The 2022 conference is planned for Oklahoma; they have not yet secured a venue or date. Registration details will be provided when they are available.

C. MALTAGON

The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

For your planning purposes, the Alabama Board of Pharmacy is scheduled to host this year's conference The Lodge Hotel in Gulf Shores, AL on Oct. 4-6, 2020. Registration details will be provided when they are available.

As a gentle reminder, the Louisiana Board is scheduled to host the conference in 2021. We should be prepared to provide the date and venue for that meeting during the 2020 conference.

6. **International Activities**

A. International Pharmaceutical Federation (FIP)

FIP announced the postponement of their 80th World Congress until Sep. 12-16, 2021 in Seville, Spain. In the interim, they intend to present a virtual version of the congress spread across several dates from September 4-25, 2020. Registration is available at <https://virtual2020.fip.org>. The Forum of Professional Pharmacy Regulators will hold a business meeting and symposium featuring examples of challenges faced by regulatory agencies during the current pandemic and adaptations made.

B. World Health Professions Alliance (WHPA)

WHPA held its biennial World Health Professions Regulation Conference on May 16 in Geneva, Switzerland. Presentations centered on two key topics: the value of strong regulatory bodies to deliver quality care, and the importance of continuing professional development (CPD).

C. dotPharmacy Verified Websites Program

dotPharmacy is a generic top level domain (gTLD) on the Internet. Although it is owned by NABP, the dotPharmacy domain is governed by a global collaboration including the International Pharmaceutical Federation (FIP) and the National Association of Pharmacy Regulatory Authorities (NAPRA – Canada) and endorsed by multiple global partners, including the World Health Organization (WHO), Interpol, and the Pharmaceutical Group of the European Union (PGEU). dotPharmacy is different from most TLDs in that authority to host a website on dotPharmacy is restricted to applicants whose legitimacy has been verified by NABP or one of its global partners. The vision for dotPharmacy is to create an online pharmacy community where patients can go to safely order prescription drugs, knowing the sites have already been verified as legitimate pharmacies that are licensed by the appropriate pharmacy regulatory authority. In addition to pharmacies, the plan is to create a presence for a number of related organizations, including professional membership organizations, colleges of pharmacy, boards of pharmacy, drug manufacturers, and consumer-oriented drug information organizations. dotPharmacy began accepting applications for website registrations in June 2015.

In June 2020, there were 610 registered domains held by pharmacy organizations representing approximately 60% of the physical pharmacy locations in the U.S. That number represents a 5% increase from June 2019. Three-fourths of those domains are held by pharmacies; other types of entities within the registry include manufacturers, distributors, consultants, medical professionals, associations, and regulators. Although most of the domains are based in the U.S., 62 domains are based in other countries around the world, including Canada, the Netherlands, Germany, Malta, Israel, and the United Kingdom. Discussions and negotiations are underway with pharmacy regulatory authorities in Australia, Brazil, China, India, New Zealand, Scotland, South Africa, and Turkey. More information, including a list of registered domains, is available at www.safe.pharmacy.

NABP verification of websites through the dotPharmacy program enables pharmacy websites to comply with e-business requirements established by Google, Bing, Yahoo, Twitter, Snap, Visa, and MasterCard.

The Louisiana Board has two website addresses in the dotPharmacy domain: www.laboard.pharmacy and www.la.pharmacy. The domain name fees for these websites have been waived by NABP. For now, visitors to these sites are automatically re-directed to the Board's website at www.pharmacy.la.gov.

Respectfully submitted,
Malcolm J Broussard
Executive Director

Louisiana Board of Pharmacy
Pharmacy Program - Census Report

		<u>6/30/2019</u>	<u>6/30/2020</u>
PST.VI	LA	9	12
	NR	17	15
	<i>Total</i>	26	27
PST-GVI	LA	20	17
	NR	6	9
	<i>Total</i>	26	26
PST-M	LA	0	0
	NR	8	8
	<i>Total</i>	8	8
PST-MS	LA	3	5
	NR	2	5
	<i>Total</i>	5	10
PST-G	LA	186	192
	NR	31	32
	<i>Total</i>	217	224
PST	LA	5,795	5,661
	NR	3,230	3,244
	<i>Total</i>	9,025	8,905
	Active PST	9,255	9,200
<hr style="border: 1px solid green;"/>			
PNT	LA	892	962
	NR	200	247
	<i>Total</i>	1,092	1,209
PNT-FPG	Total	2	4
	PNT	1,094	1,213
<hr style="border: 1px solid green;"/>			
CPT	LA	6,452	7,037
	NR	147	176
	<i>Total</i>	6,599	7,213
CPT-M	Total	1	2
CPT-MS	Total	1	4
	Active CPT	6,601	7,219
<hr style="border: 1px solid green;"/>			
PTC	LA	1,544	1,864
	NR	51	53
	PTC	1,595	1,917
<hr style="border: 1px solid green;"/>			

Louisiana Board of Pharmacy
Pharmacy Program - Census Report

		<u>6/30/2019</u>	<u>6/30/2020</u>
PHY	CH	9	9
	HOS	161	165
	HOX	5	5
	IN	11	10
	INX	11	11
	IR	597	615
	IRX	8	9
	NR	561	587
	NRN	10	10
	NRP	1	1
	NU	13	12
	PE	0	0
	PEN	0	0
	PEX	4	4
	RC	596	572
	RPP	2	1
	SAT	6	9
	SPL	0	0
	TDS	0	0
	TM	8	9
	PHY	2,003	2,029

AMS	AMS	116	146
	AMS-X	345	310
	AMS	461	456

EDK	EDK	374	401
	EDK-X	6	8
	EDK	380	409

DME	LA	339	341
	NR	301	309
	DME	640	650

CDTM		78	85
------	--	----	----

MAR		3,161	3,325
-----	--	-------	-------

PMP		19,686	21,882
-----	--	--------	--------

SWP		41	75
-----	--	----	----

TMD		127	151
-----	--	-----	-----

TOTAL		45,174	48,611
--------------	--	---------------	---------------

Louisiana Board of Pharmacy
CDS Program - Census Report

<i>Classification</i>	<u>6/30/2018</u>	<u>6/30/2019</u>	<u>6/30/2020</u>
ACS Animal Control Shelter	0	0	0
AMS Automated Medication System	35	40	46
AMX Automated Medication System - Exempt	2	2	2
APN Advanced Practice Registered Nurse	2,975	3,434	3,879
ASC Ambulatory Surgical Center	0	0	0
CRX Correctional Center	0	0	0
DDS Dentist	2,174	2,224	2,327
DET Drug Detection Canine - Private Agency	0	6	7
DEX Drug Detection Canine - Law Enforcement	8	0	0
DIS Distributor	290	285	279
DPM Podiatrist	158	163	167
DVM Veterinarian	1,188	1,216	1,308
DYS Dialysis Center	0	0	0
EMC Emergency Center	0	0	0
EMS Emergency Medical Service	0	0	0
ETC Animal Euthanasia Tech - Cert	3	3	1
ETL Animal Euthanasia Tech - Lead	26	25	28
HOS Hospital	301	297	310
HOX Hospital - Exempt	5	5	5
INT Intern or Resident	318	1,047	1,211
LAB Analytical Laboratory	8	8	8
LAX Analytical Laboratory - Exempt	4	4	5
MD Physician	12,824	13,138	13,409
MDT Physician via Telemedicine	2	11	16
MED Medical Clinic	0	0	0
MFR Manufacturer	45	47	43
MP Medical Psychologist	91	91	93
OD Optometrist	349	360	363
PA Physician's Assistant	783	928	1,030
PHX Pharmacy - Exempt	22	24	25
PHY Pharmacy	1,313	1,279	1,268
REP Sales Representative	0	0	0
RES Researcher	104	106	127
RHC Rural Health Clinic	0	0	0
RNT APRN via Telehealth	5	1	1
ROF Registered Outsourcing Facility	19	19	16
SAC Substance Abuse Clinic	6	6	6
SAX Substance Abuse Clinic - Exempt	0	0	0
MIS Other	<u>0</u>	<u>0</u>	<u>0</u>
<i>TOTAL</i>	<i>23,058</i>	<i>24,769</i>	<i>25,980</i>

Highlighted credentials subject to inspection

Total Credentials Under Board Management

Pharmacy Program	41,770	45,174	48,611
CDS Program	<u>23,058</u>	<u>24,769</u>	<u>25,980</u>
TOTAL	64,828	69,943	74,591

Louisiana Board of Pharmacy
Pharmacy Program - Census Report

		<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>6/30/2015</u>	<u>6/30/2016</u>	<u>6/30/2017</u>	<u>6/30/2018</u>
PST.VI	LA	12	10	9	9	13	16	18	14
	NR	9	10	15	14	15	16	24	20
	<i>Total</i>	21	20	24	23	28	32	42	34
PST-GVI	LA		6	13	13	12	15	26	24
	NR		0	3	5	5	5	10	8
	<i>Total</i>		6	16	18	17	20	36	32
PST-M	LA	3	5	3	1	2	1	0	0
	NR	11	11	11	13	10	10	9	8
	<i>Total</i>	14	16	14	14	12	11	9	8
PST-MS	LA								
	NR								
	<i>Total</i>								
PST-G	LA	158	157	164	166	186	204	216	194
	NR	30	35	32	31	31	35	30	27
	<i>Total</i>	188	192	196	197	217	239	246	221
PST	LA	4,654	4,933	4,981	5,140	5,408	5,304	5,372	5,690
	NR	2,079	2,212	2,527	2,479	2,471	2,835	2,950	3,090
	<i>Total</i>	6,733	7,145	7,508	7,619	7,879	8,139	8,322	8,780
	Active PST	6,935	7,353	7,718	7,830	8,108	8,389	8,577	9,009
PNT	LA	907	938	942	948	952	957	946	910
	NR	137	128	128	127	143	127	145	158
	<i>Total</i>	1,044	1,066	1,070	1,075	1,095	1,084	1,091	1,068
PNT-FPG	Total	5	0	3	6	2	4	3	2
	PNT	1,049	1,066	1,073	1,081	1,097	1,088	1,094	1,070
CPT	LA	5,720	5,509	5,751	6,463	6,584	6,815	6,418	6,433
	NR	145	120	112	138	141	152	141	152
	<i>Total</i>	5,865	5,629	5,863	6,601	6,725	6,967	6,559	6,585
CPT-M	Total	1	0	1	2	1	2	2	1
	CPT	5,866	5,629	5,864	6,603	6,726	6,969	6,561	6,586
PTC	LA	1,574	1,665	1,658	1,870	1,929	1,813	1,971	1,931
	NR	35	39	37	37	52	48	54	69
	PTC	1,609	1,704	1,695	1,907	1,981	1,861	2,025	2,000

Louisiana Board of Pharmacy
Pharmacy Program - Census Report

		<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>6/30/2015</u>	<u>6/30/2016</u>	<u>6/30/2017</u>	<u>6/30/2018</u>
PHY	CH	12	12	12	12	12	12	11	10
	HOS	151	154	158	164	163	160	163	163
	HOX	19	18	14	11	8	7	6	6
	IN	14	10	12	12	11	11	12	11
	INX	11	14	13	11	10	10	11	11
	IR	570	568	558	583	588	576	577	584
	IRX	21	19	17	10	10	7	6	6
	NR	318	361	387	422	473	513	515	534
	NRN	0	0	0	9	9	8	7	8
	NRP	0	0	0	1	2	2	2	2
	NU	15	15	15	15	14	15	14	13
	PE	0	0	0	0	0	0	0	0
	PEN	0	0	0	0	0	0	0	0
	PEX			1	2	2	2	2	3
	RC	576	587	597	619	649	671	651	630
	RPP					0	0	0	1
	SAT				1	3	6	6	6
	SPL					0	0	0	0
	TDS					0	0	0	0
	TM								
	PHY	1,707	1,758	1,784	1,871	1,951	2,000	1,983	1,988
<hr/>									
AMS	AMS	55	64	349	92	456	113	104	498
	AMS-X	301	302	289	359	356	367	335	372
	AMS	356	366	638	451	812	480	439	870
<hr/>									
EDK	EDK	417	435	421	464	474	454	402	435
	EDK-X	13	13	10	10	10	10	9	11
	EDK	430	448	431	474	484	464	411	446
<hr/>									
DME	LA		223	160	209	336	345	346	205
	NR			218	281	267	287	291	437
	DME			378	490	603	622	637	642
<hr/>									
CDTM				41	41	52	59	66	69
MAR				1,617	2,037	2,383	2,603	2,820	3,073
PMP									15,835
SWP		58	78	126	38	54	48	48	45
TMD									71
TOTAL		18,031	18,651	21,405	813	824	817	768	41,770

Louisiana Board of Pharmacy
Pharmacy Program - Census Report

6/30/2003 6/30/2004 6/30/2005 6/30/2006 6/30/2007 6/30/2008 6/30/2009 6/30/2010

PST.VI LA
NR
Total

PST-GVI LA
NR
Total

PST-M LA
NR
Total

PST-MS LA
NR
Total

PST-G LA
NR
Total

PST	LA	4,435	4,486	4,532	4,460	4,522	4,612	4,750	4,860
	NR	1,455	1,484	1,686	1,915	1,975	1,964	2,029	2,098
	<i>Total</i>	5,890	5,970	6,218	6,375	6,497	6,576	6,779	6,958

Active PST

PNT	LA			980	1,079	1,074	1,035	965
	NR			109	117	67	84	153
	<i>Total</i>			1,089	1,196	1,141	1,119	1,118

PNT-FPG	Total								
	<i>PNT</i>	929	995	1,154	1,089	1,196	1,141	1,119	1,118

CPT	LA			4,552	4,587	4,780	4,733	5,363
	NR			163	152	144	109	144
	<i>Total</i>			4,715	4,739	4,924	4,842	5,507

CPT-M	Total							
	<i>CPT</i>			4,715	4,739	4,924	4,842	5,507

PTC	LA			1,081	1,389	1,446	1,510	1,679
	NR			32	32	23	32	35
	<i>PTC</i>			1,113	1,421	1,469	1,542	1,714

Louisiana Board of Pharmacy
Pharmacy Program - Census Report

		<u>6/30/2003</u>	<u>6/30/2004</u>	<u>6/30/2005</u>	<u>6/30/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>
PHY	CH	11	12	12	12	12	11	12	14
	HOS	179	181	181	167	164	167	167	165
	HOX								
	IN	19	27	36	35	36	37	37	27
	INX								
	IR	595	633	729	681	620	588	592	587
	IRX								
	NR	353	339	200	226	240	250	256	286
	NRN								
	NRP								
	NU	13	13	13	17	16	16	16	16
	PE	94	0	0	0	0	0	0	0
	PEN	13	0	0	0	0	0	0	0
	PEX								
	RC	541	555	473	430	491	534	545	562
	RPP								
	SAT								
	SPL								
	TDS								
TM									
	PHY	1,818	1,760	1,644	1,568	1,579	1,603	1,625	1,657
<hr/>									
AMS	AMS AMS-X AMS	136	158	174	173	212	255	306	361
<hr/>									
EDK	EDK EDK-X EDK	474	444	471	428	412	439	388	503
<hr/>									
DME	LA NR DME								
<hr/>									
CDTM									
MAR									
PMP									
SWP									
TMD									
TOTAL		14,088	14,510	15,190	15,461	16,056	16,407	16,601	17,818

Louisiana Board of Pharmacy
Pharmacy Program - Census Report

3/17/1995 6/30/1996 6/30/1997 6/30/1998 6/30/1999 6/30/2000 6/30/2001 6/30/2002

PST.VI LA
NR
Total

PST-GVI LA
NR
Total

PST-M LA
NR
Total

PST-MS LA
NR
Total

PST-G LA
NR
Total

PST	LA	3,642	3,660	4,143	4,247	4,269	4,830	3,887	4,386
	NR	377	446	1,339	1,435	1,421	944	1,901	1,453
	<i>Total</i>	4,019	4,106	5,482	5,682	5,690	5,774	5,788	5,839

Active PST

PNT LA
NR
Total

PNT-FPG	Total PNT							957	976
---------	---------------------	--	--	--	--	--	--	------------	------------

CPT LA
NR
Total

CPT-M	Total CPT							3,216	3,453
-------	---------------------	--	--	--	--	--	--	--------------	--------------

PTC LA
NR
PTC

								2,896	2,372
--	--	--	--	--	--	--	--	--------------	--------------

Louisiana Board of Pharmacy
Pharmacy Program - Census Report

		<u>3/17/1995</u>	<u>6/30/1996</u>	<u>6/30/1997</u>	<u>6/30/1998</u>	<u>6/30/1999</u>	<u>6/30/2000</u>	<u>6/30/2001</u>	<u>6/30/2002</u>
PHY	CH	4	4	4	7	4	4	8	9
	HOS	177	174	171	175	172	171	171	174
	HOX								
	IN	46	45	38	39	19	19	19	18
	INX								
	IR	651	634	636	609	621	602	601	595
	IRX								
	NR	122	152	168	175	216	223	262	313
	NRN								
	NRP								
	NU	9	10	10	9	10	10	12	14
	PE	78	104	102	120	102	102	102	100
	PEN	13	12	12	12	12	12	12	13
	PEX								
	RC	464	473	471	493	505	520	530	535
	RPP								
	SAT								
	SPL								
	TDS								
TM									
	PHY	1,564	1,608	1,612	1,639	1,661	1,663	1,717	1,771
<hr/>									
AMS	AMS AMS-X AMS								109
<hr/>									
EDK	EDK EDK-X EDK							468	461
<hr/>									
DME	LA NR DME								
<hr/>									
CDTM									
MAR									
PMP									
SWP									
TMD									
TOTAL		5,583	5,714	7,094	7,321	7,351	7,437	15,042	14,981

Louisiana Board of Pharmacy
CDS Program - Census Report

<i>Classification</i>	<u>6/30/2014</u>	<u>6/30/2015</u>	<u>6/30/2016</u>	<u>6/30/2017</u>
ACS Animal Control Shelter	1	1	0	0
AMS Automated Medication System	26	29	22	28
AMX Automated Medication System - Exempt	2	1	0	0
APN Advanced Practice Registered Nurse	1,479	1,954	2,296	2,343
ASC Ambulatory Surgical Center	89	87	21	0
CRX Correctional Center	6	4	1	0
DDS Dentist	2,123	2,133	2,134	1,929
DET Drug Detection Canine - Private Agency	0	0	0	0
DEX Drug Detection Canine - Law Enforcement	11	12	9	8
DIS Distributor	324	319	301	284
DPM Podiatrist	133	142	152	136
DVM Veterinarian	1,002	1,045	1,085	1,007
DYS Dialysis Center	4	0	0	0
EMC Emergency Center	22	26	5	0
EMS Emergency Medical Service	50	49	16	0
ETC Animal Euthanasia Tech - Cert	6	5	5	1
ETL Animal Euthanasia Tech - Lead	23	23	22	24
HOS Hospital	272	271	289	278
HOX Hospital - Exempt	6	6	5	5
INT Intern or Resident				
LAB Analytical Laboratory	8	8	8	7
LAX Analytical Laboratory - Exempt	5	5	4	4
MD Physician	11,913	12,124	12,360	11,575
MDT Physician via Telemedicine	2	1	0	0
MED Medical Clinic	89	81	3	0
MFR Manufacturer	42	42	37	38
MP Medical Psychologist	78	82	86	84
OD Optometrist	309	316	326	297
PA Physician's Assistant	449	487	610	667
PHX Pharmacy - Exempt	30	24	21	20
PHY Pharmacy	1,357	1,379	1,367	1,339
REP Sales Representative	0	0	0	0
RES Researcher	113	113	108	100
RHC Rural Health Clinic	12	11	2	0
RNT APRN via Telehealth				
ROF Registered Outsourcing Facility		8	14	13
SAC Substance Abuse Clinic	9	10	7	6
MIS Other	<u>13</u>	<u>11</u>	<u>0</u>	<u>0</u>
TOTAL	20,008	20,809	21,316	20,193

Highlighted credentials subject to inspection

Total Credentials Under Board Management

Pharmacy Program	41,770	44,025	24,583	24,688
CDS Program	<u>20,008</u>	<u>20,809</u>	<u>21,316</u>	<u>20,193</u>
TOTAL	61,778	64,834	45,899	44,881

Louisiana Board of Pharmacy
CDS Program - Census Report

<i>Classification</i>		<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>
ACS	Animal Control Shelter	1	1	1	1
AMS	Automated Medication System				
AMX	Automated Medication System - Exempt				
APN	Advanced Practice Registered Nurse	758	889	1,015	1,103
ASC	Ambulatory Surgical Center	113	90	88	85
CRX	Correctional Center		7	6	5
DDS	Dentist	2,363	2,027	2,048	1,902
DET	Drug Detection Canine - Private Agency	11	0	0	0
DEX	Drug Detection Canine - Law Enforcement	11	14	12	10
DIS	Distributor	400	279	288	273
DPM	Podiatrist	165	139	136	118
DVM	Veterinarian	1,065	922	901	852
DYS	Dialysis Center	63	6	4	3
EMC	Emergency Center	18	14	16	17
EMS	Emergency Medical Service	66	54	50	45
ETC	Animal Euthanasia Tech - Cert	49	16	7	6
ETL	Animal Euthanasia Tech - Lead		12	20	21
HOS	Hospital	438	280	267	263
HOX	Hospital - Exempt		12	14	5
INT	Intern or Resident				
LAB	Analytical Laboratory	15	8	6	7
LAX	Analytical Laboratory - Exempt		4	5	5
MD	Physician	15,269	12,362	11,727	10,698
MDT	Physician via Telemedicine				
MED	Medical Clinic	102	80	86	82
MFR	Manufacturer	58	48	50	45
MP	Medical Psychologist	58	65	67	69
OD	Optometrist	278	275	287	279
PA	Physician's Assistant	272	294	326	344
PHX	Pharmacy - Exempt		50	47	41
PHY	Pharmacy		1,357	1,318	1,329
REP	Sales Representative	88	29	20	7
RES	Researcher	156	109	110	98
RHC	Rural Health Clinic	23	17	12	11
RNT	APRN via Telehealth				
ROF	Registered Outsourcing Facility				
SAC	Substance Abuse Clinic	17	7	9	9
MIS	Other	<u>59</u>	<u>20</u>	<u>14</u>	<u>12</u>
	TOTAL	21,916	19,487	18,957	17,745

Highlighted credentials subject to inspection

Total Credentials Under Board Management

Pharmacy Program	22,823	24,251	24,583	24,688
CDS Program	<u>21,916</u>	<u>19,487</u>	<u>18,957</u>	<u>17,745</u>
TOTAL	44,739	43,738	43,540	42,433

Louisiana Board of Pharmacy
CDS Program - Census Report

<i>Classification</i>	<u>8/1/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>
ACS Animal Control Shelter				
AMS Automated Medication System				
AMX Automated Medication System - Exempt				
APN Advanced Practice Registered Nurse	220	346	479	607
ASC Ambulatory Surgical Center	94	94	101	106
CRX Correctional Center				
DDS Dentist	2,009	2,090	2,177	2,267
DET Drug Detection Canine - Private Agency	11	11	11	11
DEX Drug Detection Canine - Law Enforcement	8	9	9	9
DIS Distributor	236	285	322	363
DPM Podiatrist	146	147	153	161
DVM Veterinarian	817	870	936	1,000
DYS Dialysis Center	58	63	63	63
EMC Emergency Center	17	17	17	17
EMS Emergency Medical Service	56	57	58	63
ETC Animal Euthanasia Tech - Cert	29	31	39	44
ETL Animal Euthanasia Tech - Lead				
HOS Hospital	350	369	387	405
HOX Hospital - Exempt				
INT Intern or Resident				
LAB Analytical Laboratory	13	13	14	14
LAX Analytical Laboratory - Exempt				
MD Physician	12,754	13,195	13,876	14,599
MDT Physician via Telemedicine				
MED Medical Clinic	65	73	78	88
MFR Manufacturer	31	36	43	52
MP Medical Psychologist	30	37	44	50
OD Optometrist	196	230	253	269
PA Physician's Assistant	153	170	194	232
PHX Pharmacy - Exempt				
PHY Pharmacy				
REP Sales Representative	54	57	65	66
RES Researcher	91	100	110	119
RHC Rural Health Clinic	15	19	20	21
RNT APRN via Telehealth				
ROF Registered Outsourcing Facility				
SAC Substance Abuse Clinic	14	14	14	14
MIS Other	<u>80</u>	<u>74</u>	<u>73</u>	<u>58</u>
TOTAL	17,547	18,407	19,536	20,698

Highlighted credentials subject to inspection

Total Credentials Under Board Management

Pharmacy Program	18,031	18,651	21,405
CDS Program	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>
TOTAL	36,438	38,187	42,103

New Credentials Issued
FYE 2019 - 2020
July 1, 2019 - June 30, 2020

Prefix	Subcategory	Credential Type	Total
AMS		Automated Medication System	32
AMS	X	Automated Medication System - Exempt	49
Prefix Totals			81
CDS	AMS	CDS License - Automated Medication System	8
CDS	APN	CDS License - APRN	568
CDS	DDS	CDS License - Dentist	160
CDS	DET	CDS License - Drug Detection / Canine	1
CDS	DIS	CDS License - Distributor	28
CDS	DPM	CDS License - Podiatrist	9
CDS	DVM	CDS License - Veterinarian	84
CDS	ETL	CDS License - Animal Euthanasia Technician, Lead (AET-L)	1
CDS	HOS	CDS License - Hospital	35
CDS	INT	CDS License - Medical Intern or Resident	775
CDS	LAX	CDS License - Laboratory - Exempt	1
CDS	MD	CDS License - Physician	772
CDS	MDT	CDS License - Physician via Telemedicine	6
CDS	MFR	CDS License - Manufacturer	3
CDS	MP	CDS License - Medical Psychologist	3
CDS	OD	CDS License - Optometrist	20
CDS	PA	CDS License - Physician Assistant	148
CDS	PHX	CDS License - Pharmacy - Exempt	1
CDS	PHY	CDS License - Pharmacy	76
CDS	RES	CDS License - Researcher	26
CDS	ROF	CDS License - Registered Outsourcing Facility	4
CDS	TM	CDS License - Therapeutic Marijuana Pharmacy	1
CDS	TPL	CDS License - Third-Party Logistics Provider	7
Prefix Totals			2737
CDTM		Collaborative Drug Therapy Management (V)	9
CPT		Certified Pharmacy Technician	505
DME		Durable Medical Equipment (DME) Provider	27
DME	NR	Durable Medical Equipment (DME) Provider - Nonresident	54
Prefix Totals			81
EDK		Emergency Drug Kit	82
MA		Medication Administration (V)	323
PHY	HOS	Pharmacy - Hospital Inpatient	21
PHY	IR	Pharmacy - Community - Independent	65
PHY	IRX	Pharmacy - Community - Exempt	1
PHY	NR	Pharmacy - Nonresident	98
PHY	RC	Pharmacy - Community - Chain	5
PHY	SAT	Pharmacy - Hospital Off-Site Satellite	3
PHY	TM	Pharmacy - Therapeutic Marijuana	1
Prefix Totals			194
PIC		Pharmacist-in-Charge (V)	155
PMP	CDS	PMP - CDS Credential (V)	1204
PMP	PHY	PMP - PHY Dispenser Account (V)	210
PMP	PST	PMP - Pharmacist (V)	291
Prefix Totals			1705
PNT		Pharmacy Intern	337
PNT	FPG	Pharmacy Intern - Foreign Pharmacy Graduate	2
Prefix Totals			339
PST		Pharmacist	473
PST	MS	Pharmacist - Military Spouse	1
Prefix Totals			474
PTC		Pharmacy Technician Candidate	1013
SWP		Special Work Permit	68
TM	CPT	Therapeutic Marijuana Designation - CPT	1
TM	PNT	Therapeutic Marijuana Designation - PNT	1
TM	PST	Therapeutic Marijuana Designation - PST	17
Prefix Totals			19
Grand Totals			7785

Pending Applications

PHARMACY CREDENTIALS

Prefix	Subcat.	CredentialType	2/6/2019	5/13/2019	8/1/2019	11/1/2019	1/23/2020	5/21/2020	8/3/2020
AMS		Automated Medication System	8	9	7	7	6	1	1
CPT		Certified Pharmacy Technician	33	58	46	32	28	45	57
DME		Durable Medical Equipment	20	12	14	10	6	7	15
EDK		Emergency Drug Kit		7	2	2	3	3	1
PHY	CH	Pharmacy - Charitable	1						
PHY	HOS	Pharmacy - Hospital Inpatient	6	6	9	8	6	1	
PHY	IN	Pharmacy - Institutional	1	1			3	3	3
PHY	IR	Pharmacy - Community ~ Independent	22	18	21	22	15	18	22
PHY	NR	Pharmacy - Nonresident	60	67	61	41	41	32	38
PHY	NRN	Pharmacy - Nonresident Nuclear							
PHY	NU	Pharmacy - Nuclear					1		1
PHY	PEN	Pharmacy - Penal							
PHY	RC	Pharmacy - Community ~ Chain	3	2	1	1	2		1
PHY	RPP	Pharmacy - Remote Processor							
PHY	SAT	Pharmacy - Hospital Off-Site Satellite	1	1	1	2	3	2	2
PHY	SPL	Pharmacy - Special Event		1	1	1			
PHY	TM	Pharmacy - Therapeutic Marijuana	6	2	1				
PIC		Pharmacist-in-Charge			1	0	1	1	1
PNT	FPG	Pharmacy Intern - Foreign Graduate	1				1		
PNT		Pharmacy Intern	74	35	57	139	86	16	37
PST		Pharmacist	272	348	305	234	203	379	421
PTC		Pharmacy Technician Candidate	223	235	245	232	213	198	245
Subtotal			731	802	772	731	618	706	845

CDS CREDENTIALS

Prefix	Subcat.	CredentialType	2/6/2019	5/13/2019	8/1/2019	11/1/2019	1/23/2020	5/21/2020	8/3/2020
CDS	AMS	CDS - Automated Medication System	1	1					
CDS	APN	CDS - APRN	14	11	10	9	11	11	13
CDS	DDS	CDS - Dentist	2	1			3		1
CDS	DET	CDS - Drug Detection / Canine				1	2	1	1
CDS	DIS	CDS - Distributor	15	14	13	2	3	2	1
CDS	DPM	CDS - Podiatrist					1	1	1
CDS	DVM	CDS - Veterinarian		4	1	3	1	1	2
CDS	ETC	CDS - Animal Euthanasia Tech, Certified							
CDS	ETL	CDS - Animal Euthanasia Tech, Lead	3	1					
CDS	HOS	CDS - Hospital	12	13	13	12	11	5	5
CDS	INT	CDS - Medical Intern or Resident	7	7	8	13	10	16	91
CDS	MD	CDS - Physician	24	18	20	8	9	22	42
CDS	MFR	CDS - Manufacturer							
CDS	MP	CDS - Medical Psychologist							
CDS	OD	CDS - Optometrist							
CDS	PA	CDS - Physician Assistant	8	11	14	6	3	5	9
CDS	PHY	CDS - Pharmacy	24	21	20	23	23	20	28
CDS	PHX	CDS - Pharmacy - Exempt	1						
CDS	RES	CDS - Researcher	2	3	5	17	16	15	13
CDS	RNT	CDS - APRN via Telehealth							
CDS	ROF	CDS - Registered Outsourcing Facility	3	2	1				1
CDS	SAC	CDS - Substance Abuse Clinic	5	1	1		3	3	3
CDS	TM	CDS - Therapeutic Marijuana	6	2	1				
Subtotal			127	110	107	94	96	102	211

OTHER CREDENTIALS

Prefix	Subcat.	CredentialType	2/6/2019	5/13/2019	8/1/2019	11/1/2019	1/23/2020	5/21/2020	8/3/2020
CDTM		Collaborative Drug Therapy Management				1			
LB		Law Book							
MA		Medication Administration	10	10	8	8	6	6	7
PMP		PMP - CDS Credential	342	310	310	287	144	82	77
PMP		PMP - MIS Credential							
PMP		PMP - PHY Credential	1						
PMP		PMP - PST Credential	345	2	2	1			
SWP		Special Work Permit	10	10	10	10	10	12	12
TM	CPT	Therapeutic Marijuana Designation - CPT	17	26	26	29	24	23	26
TM	OMO	Therapeutic Marijuana Designation - OMO					1		
TM	PNT	Therapeutic Marijuana Designation - PNT						2	1
TM	PST	Therapeutic Marijuana Designation - PST	7	10	11	16	11	12	13
Subtotal			732	368	367	352	196	137	136

TOTAL	1590	1280	1246	1177	910	945	1192
--------------	-------------	-------------	-------------	-------------	------------	------------	-------------



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



August 13, 2020

Agenda Item 10-L: Report of Executive Director

Section 2 – A – 1 – D ~ Exceptions Report

1. **PIC at Multiple Pharmacies**

Board Policy I.A.4 permits the Executive Director to approve requests from pharmacists wishing to serve as the Pharmacist-in-Charge (PIC) of more than one pharmacy at the same time. The decision to approve such a request requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

[None since last report.]

2. **Special Work Permits for military-trained applicants and their spouses**

LAC Title 46: LIII §904 authorizes the Board to provide preferential licensing procedures for military-trained applicants and their spouses. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On July 16, 2020, Mr. Finalet granted a request of Elizabeth Gardner Ensley. She has been issued SWP.000922 to practice for up to 120 days while her application to become a PTC is in process. The SWP will expire on November 16, 2020.
- On August 3, 2020, Mr. Finalet granted a request of Sarah Ackerman Carter. She has been issued SWP.000931 to practice for up to 120 days while her application to become a PST is in process. The SWP will expire on December 3, 2020.

3. **Special Work Permits**

Board Policy I.A.7 permits the Executive Director to issue Special Work Permits to document the resurrection of expired non-renewable credentials and for other purposes as authorized by the Board. The decision to approve such a request requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On June 1, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Angela Marie Jackson. She had previously obtained PTC.021281 which expired on October 15, 2015. She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
- On June 3, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of India Elizabeth Demouchet. She had previously obtained PTC.023927 which expired on October 26, 2017. She is enrolled in Walgreen's training program and was issued a Special Work Permit for two years to earn the required hours of practical experience.
- On June 17, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of India Makyra Monae Shylynn Hollins. She had previously obtained PTC.024571 which expired on April 12, 2018. She is NHA-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
- On June 22, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Adellah Hani Abdulwahab. She had previously obtained PTC.018015 which expired on April 4, 2013. She is enrolled in CVS' training program and was issued a Special Work Permit for two years to earn the required hours of practical experience.
- On June 22, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Genobea Gabriel Brown. She had previously obtained PTC.020389 which expired on February 23,

2015. She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
- On June 2, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Lakeisha Monique Lewis. She had previously obtained PTC.023399 which expired on May 16, 2017. She is enrolled in Walgreens' training program and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 7, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Mallory Renee Gibson. She had previously obtained PTC.020366 which expired on February 13, 2015 She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 7, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Win Nwe Ni. She had previously obtained PTC.020511 which expired on January 18, 2015 She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 13, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Ebonie Chanyce Strickland. She had previously obtained PTC.024536 which expired on April 4, 2018. She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 17, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Andrionne Danielle Johnson. She had previously obtained PTC.019240 which expired on March 18, 2014. She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 20, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Camilla Renee Lott. She had previously obtained PTC.026006 which expired on March 18, 2019. She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 20, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Pamela Mitchell Roberts. She had previously obtained PTC.026656 which inactivated on January 18, 2020. She is NHA-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 20, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Brittany Renee Courge. She had previously obtained PTC.020500 which inactivated on March 18, 2015. She is NHA-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 22, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Sushama Patel. She had previously obtained PTC.017151 which expired on June 28, 2012. She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On July 31, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Anna Marie Battiste. She had previously obtained PTC.022372 which expired on December 16, 2016. She has graduated from a technician training program and was issued a Special Work Permit for two years to earn the required hours of practical experience.
 - On August 3, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Karla Michelle Nutt. She had previously obtained PTC.05370 which expired on May 16, 2002. She was PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.



Compliance Division Census Report

August 13, 2020

Practitioner Recovery Program

- Probation Completed

None since last report

- Active Probation 34 Pharmacist
 6 Technician
- Active Suspension 40 Pharmacist
 3 Pharmacy intern
 17 Technician
 4 Technician candidate

Disciplinary Restrictions

- Probation Completed

05-29-2020 CPT.010453 Destiny Araine Woolfolk
06-30-2020 PST.019072 Kelly Jean Zaccarelli

- Active Probation 12 Pharmacist
 1 Pharmacy intern
 2 Technician
 0 Technician candidate
 7 Pharmacy permit
 1 CDS-PHY license
- Active Suspension/
 Inactivation 56 Pharmacist
 1 Pharmacy intern
 87 Technician
 21 Technician candidate
 1 Special work permit
 12 Pharmacy permit
 6 CDS-PHY license
 107 CDS license for practitioners

Louisiana Board of Pharmacy
Compliance Division

Complaint Investigation Completion Policy Monitor

	<u>FY 17-18</u> <u>6/30/2018</u>	<u>FY 18-19</u> <u>6/30/2019</u>	<u>FY 19-20</u> <u>6/30/2020</u>	<u>FY 20-21</u> <u>8/4/2020</u>
Pending at Beginning of Fiscal Year	160	180	179	182
New Cases Added	500	433	403	37
Cases Closed	480	434	400	42
Cases Remaining	180	179	182	187
Average No. Days to Close Investigation		52	50	53
No. Investigations Closed > 180 Days		19	13	1
% Investigations Beyond Policy Limit		4.4%	3.3%	2.4%
% Cases Closed by Board Action		27%	33%	48%

Louisiana Board of Pharmacy - Compliance Division
Statistical Summary for Fiscal Year 2019-2020

Individual Performance Data

Investigations

	<u>CDS</u>	<u>Inspections</u> <u>PHY/DME</u>	<u>Total</u>	<u>Cases</u> <u>Assigned</u>	<u>Audits</u> <u>Completed</u>	<u>Reports</u> <u>Submitted</u>
> Compliance Officers						
Aaron, Cary D.						
1st Qtr.	17	56	73	23	0	2
2nd Qtr.	15	59	74	10	0	23
3rd Qtr.	19	42	61	2	0	11
4th Qtr.	6	28	34	9	0	7
<i>Total</i>	<i>57/97</i>	<i>185/302</i>	<i>242/399</i>	<i>44</i>	<i>0</i>	<i>43</i>
Completion Rate:	58.8%	61.3%	60.7%			
Dennis, Daniel M.						
1st Qtr	19	52	71	12	0	7
2nd Qtr	11	55	66	9	0	9
3rd Qtr	16	48	64	8	0	7
4th Qtr	3	22	25	5	0	10
<i>Total</i>	<i>49/72</i>	<i>177/317</i>	<i>226/389</i>	<i>34</i>	<i>0</i>	<i>33</i>
Completion Rate:	68.1%	55.8%	58.1%			
Gross, Nicole L.						
1st Qtr	13	51	64	2	0	10
2nd Qtr	10	53	63	5	0	3
3rd Qtr	17	36	53	7	0	3
4th Qtr	9	14	23	9	0	16
<i>Total</i>	<i>49/89</i>	<i>154/245</i>	<i>203/334</i>	<i>23</i>	<i>0</i>	<i>32</i>
Completion Rate:	55.1%	62.9%	60.8%			
Harris, Alicia P.						
1st Qtr	15	48	63	12	0	5
2nd Qtr	23	25	48	5	0	12
3rd Qtr	24	43	67	6	0	9
4th Qtr	6	28	34	7	0	7
<i>Total</i>	<i>68/104</i>	<i>144/262</i>	<i>212/360</i>	<i>30</i>	<i>0</i>	<i>33</i>
Completion Rate:	65.4%	54.9%	58.9%			
Parker, Becky						
1st Qtr	12	54	66	10	0	0
2nd Qtr	15	46	61	2	0	12
3rd Qtr	7	54	61	5	0	5
4th Qtr	11	24	35	5	0	5
<i>Total</i>	<i>45/64</i>	<i>178/255</i>	<i>223/319</i>	<i>22</i>	<i>0</i>	<i>22</i>
Completion Rate:	70.3%	69.8%	69.9%			
Savoie, Huey J.						
1st Qtr	20	64	84	1	0	7
2nd Qtr	10	54	64	2	0	2
3rd Qtr	7	51	58	3	0	10
4th Qtr	3	39	42	7	0	3
<i>Total</i>	<i>40/60</i>	<i>208/286</i>	<i>248/346</i>	<i>13</i>	<i>0</i>	<i>22</i>
Completion Rate:	66.7%	72.7%	71.7%			

Louisiana Board of Pharmacy - Compliance Division
Statistical Summary for Fiscal Year 2019-2020

	<u>CDS</u>	<u>Inspections</u>		<u>Investigations</u>		
		<u>PHY/DME</u>	<u>Total</u>	<u>Cases Assigned</u>	<u>Audits Completed</u>	<u>Reports Submitted</u>
> Compliance Officers						
Whaley, Benjamin S.						
1st Qtr	4	15	19	0	0	5
2nd Qtr	0	8	8	4	0	3
3rd Qtr	1	9	10	7	0	5
4th Qtr	1	11	12	6	0	6
<i>Total</i>	<i>6/20</i>	<i>43/99</i>	<i>49/121</i>	<i>17</i>	<i>0</i>	<i>19</i>
Completion Rate:	30.0%	43.4%	40.5%			
TOTAL	314	1089	1403	183	0	204
Completion Rate	62.1%	61.7%	61.8%			
> Administrative Officers						
Fontenot, M. Joseph						
1st Qtr	0	0	0	0	0	0
2nd Qtr	0	0	0	4	0	1
3rd Qtr	0	0	0	4	0	0
4th Qtr	0	0	0	2	0	1
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>10</i>	<i>0</i>	<i>2</i>
Finalet, Carlos M.						
1st Qtr	0	0	0	55	0	41
2nd Qtr	0	0	0	37	0	52
3rd Qtr	0	0	0	66	0	52
4th Qtr	0	0	0	35	0	36
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>193</i>	<i>0</i>	<i>181</i>
Broussard, Malcolm J.						
1st Qtr	0	0	0	0	0	0
2nd Qtr	0	0	0	1	0	0
3rd Qtr	0	0	0	1	0	2
4th Qtr	0	0	0	0	0	0
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>2</i>	<i>0</i>	<i>2</i>
Agency Summary						
1st Qtr	100	340	440	115	0	77
2nd Qtr	84	300	384	79	0	117
3rd Qtr	91	283	374	124	0	115
4th Qtr	39	166	205	85	0	91
TOTAL	314	1,089	1,403	403	0	400

Louisiana Board of Pharmacy - Compliance Division
Statistical Summary for Fiscal Year 2019-2020

Summary of Investigations and Adjudications

Number of Cases Pending from Prior Fiscal Year(s)	179
Number of Complaints Received during Current Fiscal Year:	403
Number of Complaints Closed during Current Fiscal Year:	400
Number of Complaints Pending at End of Fiscal Year:	182

Disposition of Closed Complaints:

Withdrawn	10
No violations found	96
Administrative/Field corrections	84
Referred to another agency	11
Administrative sanction	46
Completion of previously-imposed probationary periods	10
Referred to appropriate Board Committee	<u>143</u>
	<i>400 Total</i>

Committee Action on Referrals

11	Case dismissed
127	Voluntary Consent Agreement
11	Reinstatement
21	Modifications of Previous Orders
9	Assessment
2	Letter of Warning
33	Letter of Reprimand
13	Voluntary Surrender
10	Probation
7	Suspension
7	Revocation
14	Other decisions
<u>5</u>	Formal Hearing
3	Suspension
2	Revocation
143	<i>Total</i>

Louisiana Board of Pharmacy - Compliance Division
 Statistical Summary for Fiscal Year 2019-2020

Analysis of Adjudications by Type of Credential

	<u>PST</u>	<u>PNT</u>	<u>CPT</u>	<u>PTC</u>	<u>PHY/DME</u>	<u>CDS</u>	<u>TOTAL</u>
Reinstatement	1	0	10	0	0	0	11
Modification of Previous Orders	19	0	2	0	0	0	21
Assessment	0	0	0	0	9	0	9
Letter of Warning	1	0	0	0	1	0	2
Letter of Reprimand	17	0	8	0	8	0	33
Voluntary Surrender	9	0	2	1	0	1	13
Probation	5	0	1	0	4	0	10
Suspension	6	0	4	0	0	0	10
Revocation	2	0	4	2	1	0	9
Other Decisions	9	0	3	1	1	0	14
TOTAL	69	0	34	4	24	1	132

Louisiana Board of Pharmacy - Compliance Division
Statistical Summary - Cumulative Data

	FY 12-13	FY 13-14	FY 14-15	FY 15-16	FY 16-17	FY 17-18	FY 18-19	FY 19-20
Summary of Complaint Investigations								
Complaints Pending from Prior Year(s)	218	255	252	214	224	160	180	179
Complaints Received During Year	392	479	404	411	391	500	433	403
Complaints Closed During Year	355	482	442	401	468	480	434	400
Complaints Pending at Year End	255	252	214	224	147	180	179	182
Disposition of Closed Complaints								
Withdrawn	25	13	18	18	10	12	5	10
No violations found	32	86	83	48	76	70	88	96
Field/administrative corrections	67	107	113	80	118	63	122	84
Referred to another agency	3	11	7	7	16	79	26	11
Administrative sanction	24	15	21	13	4	37	19	46
Termination of probationary period	24	27	15	23	27	14	11	10
Referred for Board action	<u>180</u>	<u>223</u>	<u>185</u>	<u>212</u>	<u>217</u>	<u>205</u>	<u>163</u>	<u>143</u>
<i>Total</i>	<u>355</u>	<u>482</u>	<u>442</u>	<u>401</u>	<u>468</u>	<u>480</u>	<u>434</u>	<u>400</u>
Committee Action on Referrals								
Cases Dismissed	21	41	31	37	26	55	12	11
Voluntary Consent Agreements	157	155	125	163	159	144	146	127
Assessment only	9	18	28	18	12	12	16	9
Denial / Refusal to Issue	5	5	2	6	4	17	2	0
Letter of Noncompliance	0	0	0	0	9	6	17	6
Letter of Warning	3	13	5	2	5	3	3	2
Letter of Reprimand	19	7	14	35	29	20	29	33
Voluntary Surrender	21	25	15	13	12	18	13	13
Probation	29	31	16	21	17	28	19	10
Suspension	22	6	2	13	4	4	4	7
Revocation	19	5	14	6	10	4	7	7
Other decisions	30	46	29	49	57	32	36	40
Formal Hearings	2	27	29	12	32	6	5	5
Assessment only	0	0	0	0	0	0	0	0
Denial / Refusal to Issue	0	3	2	0	1	0	1	0
Letter of Warning	0	0	0	0	0	0	0	0
Letter of Reprimand	0	0	0	0	0	0	0	0
Probation	0	0	1	1	1	1	0	0
Suspension	1	20	23	1	1	5	2	3
Revocation	1	4	3	10	10	0	2	2
Interlocutory Hearings	0	0	0	0	0	0	0	0
Summary Suspension	0	0	0	0	0	0	0	0

Louisiana Board of Pharmacy - Compliance Division
Statistical Summary - Cumulative Data

	FY 02-03	FY 03-04	FY 04-05	FY 05-06	FY 06-07	FY 07-08	FY 08-09	FY 09-10	FY 10-11	FY 11-12
Summary of Complaint Investigations										
Complaints Pending from Prior Year(s)	46	96	132	124	98	82	112	140	127	197
Complaints Received During Year	355	315	273	250	239	280	519	356	432	349
Complaints Closed During Year	305	279	281	276	255	250	491	369	362	389
Complaints Pending at Year End	96	132	124	98	82	112	140	127	197	157
Disposition of Closed Complaints										
Withdrawn	20	11	7	4	10	3	23	16	26	23
No violations found	36	46	31	36	30	39	49	41	58	51
Field/administrative corrections	25	34	47	70	40	73	65	76	54	83
Referred to another agency	1	1	3	7	11	2	6	7	5	6
Administrative sanction	89	78	73	37	34	38	255	72	42	46
Termination of probationary period										
Referred for Board action	<u>134</u>	<u>109</u>	<u>120</u>	<u>122</u>	<u>130</u>	<u>95</u>	<u>93</u>	<u>157</u>	<u>177</u>	<u>180</u>
<i>Total</i>	<u>305</u>	<u>279</u>	<u>281</u>	<u>276</u>	<u>255</u>	<u>250</u>	<u>491</u>	<u>369</u>	<u>362</u>	<u>389</u>
Committee Action on Referrals										
Cases Dismissed	43	17	16	25	20	19	38	24	39	20
Voluntary Consent Agreements	79	80	91	90	97	67	47	124	132	150
Assessment only	11	11	7	2	4	38	25	18	10	12
Denial / Refusal to Issue								1	9	1
Letter of Noncompliance	0	0	0	0	0	0	0	0	0	0
Letter of Warning	20	14	12	26	18	7	3	5	6	3
Letter of Reprimand	13	5	19	12	18	13	13	30	35	17
Voluntary Surrender	9	10	23	25	17	6	8	34	23	21
Probation	9	17	10	13	16	20	5	17	21	31
Suspension	6	10	4	1	5	10	5	2	2	10
Revocation	11	13	16	11	19	9	4	17	11	28
Other decisions									15	27
Formal Hearings	12	12	13	7	13	9	8	9	6	10
Assessment only	0	0	0	0	1	3	0	0	0	0
Denial / Refusal to Issue	0	0	0	0	0	0	0	0	0	0
Letter of Warning	0	2	0	0	0	0	0	0	0	0
Letter of Reprimand	0	0	1	0	0	0	0	0	0	0
Probation	0	1	0	2	2	0	0	0	1	0
Suspension	4	2	2	0	3	3	0	3	2	2
Revocation	8	7	10	5	7	4	8	6	3	8
Interlocutory Hearings	0	2	3	0	1	0	0	0	0	0
Summary Suspension	0	0	2	0	1	0	0	0	0	0



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Annual Report

Fiscal Year 2019-2020

July 1, 2020

Mission

Created by the Louisiana Legislature in 1888, the mission of the Louisiana Board of Pharmacy remains unchanged over a century later: to regulate the practice of pharmacy in such a manner as to protect the public health, safety, and welfare of the citizens of Louisiana. Toward that goal, the Louisiana Pharmacy Practice Act specifically authorizes the Board to restrict the practice of pharmacy to qualified persons as well as regulate all persons and sites that sell prescription drugs or devices or provide pharmacy care services to consumers in this state.

Licensure

In order to facilitate the restriction of practice to qualified persons, the Board has established educational, experiential, and examination requirements for the credentialing of pharmacists and pharmacy technicians. As authorized by the legislature, the Board has contracted its high-stakes examination procedures with professional testing services.

A. *Examinations for Pharmacists*

The North American Pharmacist Licensure Examination (NAPLEX) and the Multistate Pharmacy Jurisprudence Examination (MPJE) are administered by the National Association of Boards of Pharmacy (NABP). These computer adaptive tests are administered in continuous window opportunities at multiple sites throughout the state. A minimum scaled score of 75 is required to pass each test; the maximum scaled score is 150 for the NAPLEX and 100 for the MPJE. NABP publishes summary data for the examinations on a trimester basis. The results for all Louisiana-based NAPLEX and MPJE candidates in Calendar Year 2019 are summarized here:

NAPLEX

	Jan – Apr	May – Aug	Sept – Dec
No. of Louisiana Candidates	24	186	41
State Mean Scaled Score	76.50	94.04	78.93
Louisiana Pass Rate	70.83%	88.17%	60.98%
No. of National Candidates	1,344	13,199	3,425
National Mean Scaled Score	77.80	95.54	80.17
National Pass Rate	61.24%	89.52%	64.55%

MPJE

	Jan – Apr	May – Aug	Sept – Dec
No. of Louisiana Candidates	157	309	157
State Mean Scaled Score	78.26	78.10	77.53
Louisiana Pass Rate	79.62%	84.41%	75.80%
No. of National Candidates	6,583	18,823	8,714
National Mean Scaled Score	77.38	78.12	76.90
National Pass Rate	76.77%	82.49%	72.66%

B. Examinations for Technicians

The Board has approved two pharmacy technician certification examinations – the Pharmacy Technician Certification Examination (PTCE) administered by the Pharmacy Technician Certification Board and the Examination for Certified Pharmacy Technicians (ExCPT) administered by National Healthcareer Association (NHA). Both examinations are computer adaptive tests which are administered in continuous window opportunities at multiple sites throughout the state. The results for all Louisiana-based PTCE and ExCPT candidates for Calendar Year 2019 are summarized here:

	PTCE		ExCPT	
	<u>Jan. – June</u>	<u>July – Dec.</u>	<u>Jan. – June</u>	<u>July – Dec.</u>
No. of Louisiana Candidates	540	467	121	115
Louisiana Pass Rate	45%	44.1%	67.8%	61.7%
No. of National Candidates	25,636	26,117	6,143	3,295
National Pass Rate	57.7%	56.1%	65.9%	72.2%

C. Census Data

At the close of the fiscal year on June 30, 2020, a review of our credential records yielded the following census information:

	<u>2020</u>	<u>2019</u>	<u>2018</u>
• Pharmacy Program			
1. Pharmacists			
> Number of active licenses	9,200	9,255	9,009
> Number of licensees within state	5,887	5,795	5,690
2. Pharmacy Interns			
> Number of active registrations	1,213	1,094	1,070
3. Pharmacy technicians			
> Number of active certificates	7,219	6,601	6,586
4. Pharmacy technician candidates			
> Number of active registrations	1,917	1,595	2,000
5. Pharmacies			
> Number of active permits	2,029	2,033	1,988
- Community – Independent	624	605	590
- Community – Chain	572	596	630
- Hospital	170	172	175
- Institutional	21	22	22
- Marijuana	9	8	0
- Nuclear	12	13	13
- Charitable	9	9	10
- Correctional	4	4	3
- Remote processor	1	2	1
- Nonresident	598	572	544
6. Equipment Permits			
> Emergency drug kit (EDK)	409	380	446
> Automated medication systems (AMS)	456	461	870
> Durable medical equipment (DME)	650	640	642

	<u>2020</u>	<u>2019</u>	<u>2018</u>
7. Special Activity Credentials			
> CDTM Registration	85	78	69
> Med. Administration Registration	3,325	3,161	3,073
> Special Work Permits	75	41	45
> Marijuana Pharmacy Designations	151	127	71
> PMP Access Registrations	21,882	19,686	15,835
<i>Subtotal of Credentials in Pharmacy Program</i>	<i>48,611</i>	<i>45,174</i>	<i>41,770</i>
• CDS Program			
1. Automated Medication System (AMS)	48	42	37
2. Advanced Practice RN (APRN)	3,880	3,435	2,980
3. Dentist	2,327	2,224	2,174
4. Drug Detection / Canine	7	6	8
5. Distributor	279	285	290
6. Podiatrist	167	163	158
7. Veterinarian	1,308	1,216	1,188
8. Animal Euthanasia Technician	29	28	29
9. Hospital	315	302	306
10. Laboratory	13	12	12
11. Physicians & Interns/Residents	14,636	14,196	13,144
12. Manufacturer	43	47	45
13. Medical Psychologist	93	91	91
14. Optometrist	363	360	349
15. Pharmacies	1,293	1,303	1,335
16. Physician Assistant	1,030	928	783
17. Registered Outsourcing Facility	16	19	19
18. Researcher	127	106	104
19. Substance Abuse Clinic	6	6	6
<i>Subtotal of Credentials in CDS Program</i>	<i>25,980</i>	<i>24,769</i>	<i>23,058</i>
<u>Total Active Credentials under Management</u>	74,591	69,943	64,828

D. *New Credentials*

During the past fiscal year, the Board issued 5,048 new credentials in the Pharmacy Program and 2,737 new credentials in the CDS Program. Of note within the Pharmacy Program, we issued 474 new pharmacist licenses, 505 new pharmacy technician certificates, and 1,013 new pharmacy technician candidate registrations during the past fiscal year. Of note within the CDS Program, we issued new CDS licenses to 1,553 physicians, interns and residents, as well as 568 advanced practice registered nurses, and 160 dentists.

E. *License Transfer (Reciprocity)*

Persons already licensed as a pharmacist by any other state who wish to obtain a license in Louisiana must successfully complete the MPJE as well as the application and criminal background check. Of the 474 new pharmacist licenses issued this past fiscal year, 213 were issued subsequent to completion of the reciprocity process.

Compliance

A. Enforcement

In order to control and regulate the practice of pharmacy in Louisiana, the Board employs seven pharmacist compliance officers to perform routine inspections and special investigations throughout the year in all places under the Board's jurisdiction. In addition to pharmacies, the compliance officers also inspect healthcare facilities to monitor compliance with controlled substance requirements. The compliance officers visited 1,403 pharmacies and other facilities during the year to perform routine inspections, site visits for permit changes and other calls for assistance. The compliance and administrative officers began the fiscal year with 179 cases from the previous fiscal years, received 403 new cases, and closed 400 cases, leaving 182 cases for the next fiscal year. Of the 400 cases closed during the fiscal year: 10 of the original complaints were withdrawn, 10 resulted from completion of previously imposed probationary periods, 96 were determined to be without violation, 11 cases were referred to other agencies, 84 resulted in field/administrative corrections, 46 resulted in administrative sanctions, and 143 cases were referred to the Board's committees. Those committees took no action in 11 of their cases and recommended voluntary consent agreements for 132 cases. Of that number, all but five accepted the proposed Board decision; those five respondents were referred for formal administrative hearings. The decisions from the formal administrative hearings resulted in three suspensions and two revocations.

Compliance officers coordinate other investigative activities with a wide range of agencies, including local police departments, parish sheriff departments, other state regulatory and law enforcement agencies, and federal agencies such as the Drug Enforcement Administration, the Food and Drug Administration, and the Consumer Product Safety Commission. Though the compliance officers utilize the educational approach as the fundamental mechanism to achieve compliance, certain circumstances warrant formal Board action.

B. Adjudications

During the past fiscal year, the Board conducted two formal administrative hearings and levied formal disciplinary action against several credentials. A summary of all the Board's disciplinary decisions is presented here:

<u>Sanction</u>	<u>Pharmacist</u>	<u>Intern</u>	<u>Technician</u>	<u>Candidate</u>	<u>Permit</u>	<u>CDS</u>
Reinstatement	1	0	10	0	0	0
Change Previous Orders	19	0	2	0	0	0
Assessment	0	0	0	0	9	0
Letter of Warning	1	0	0	0	1	0
Letter of Reprimand	17	0	8	0	8	0
Voluntary Surrender	9	0	2	1	0	1
Probation	5	0	1	0	4	0
Suspension	6	0	4	0	0	0
Revocation	2	0	4	2	1	0
Other Decisions	9	0	3	1	1	0

C. *Disciplinary Restrictions*

From time to time, the Board imposes disciplinary restrictions on various credentials, including probation, suspension, and other practice restrictions. Probationary periods are typically imposed for defined periods of time, whereas suspensions may be imposed for defined or indefinite periods of time. As of July 1, 2020 there were several credentials on probation, including 12 pharmacist licenses, one pharmacy intern registration, two pharmacy technician certificates, seven pharmacy permits, and one controlled substance license at a pharmacy. The number of credentials on active suspension include 56 pharmacist licenses, one pharmacy intern registration, 87 pharmacy technician certificates, 21 pharmacy technician candidate registrations, 12 pharmacy permits, six controlled substance licenses for pharmacies, and 107 controlled substance licenses for practitioners.

D. *Practitioner Recovery Program*

The Board established its program in 1988 to assist practitioners obtain treatment for their impairment, maintain their recovery, and assist their re-entry into professional practice. As of July 1, 2020 there were 34 pharmacists and six pharmacy technicians actively engaged in the recovery program. They surrendered their credentials while in treatment; following treatment and upon favorable recommendation by board-certified addiction medicine specialists, they applied for the reinstatement of their credentials. The Board reinstated their credentials on probation, and the licensees practice under various restrictions designed to monitor their re-entry to professional practice. In addition, the credentials for 40 pharmacists, three interns, 17 technicians, and four technician candidates were still on active suspension for impairment reasons.

Board Activity

A. *Legislative*

During the 2020 regular session, the Board sponsored two bills, both of which were successful.

- Act 10 amended the state's list of controlled dangerous substances to harmonize the state list with recent federal scheduling actions.
- Act 202 added new fees for the issuance and renewal of permits for pharmacy benefit managers. The measure also clarified that existing renewal fees for all credentials are annual or per year.

The legislature also adopted HCR 71 which requires the Board to suspend the collection of renewal fees for credentials issued to existing businesses located within the state during the next fiscal year. The fiscal impact of that legislative mandate for the Board is estimated to be approximately \$300,000 in reduced revenue during Fiscal Year 2020-2021.

B. *Regulatory*

The Board's Regulation Revision Committee is tasked with the continuous review of the Board's rules and their recommendation for revision as appropriate. The Board initiated and completed 17 regulatory projects during the fiscal year.

- *Project 2019-1B ~ Licensing of Marijuana Pharmacies* corrected a drafting oversight in the original marijuana pharmacy rule which had omitted the

- requirement for a site inspection prior to the initial issuance of a pharmacy permit to the marijuana pharmacy.
- *Project 2019-2 ~ Pharmacy Immunizations* responded to stakeholder input in two areas. The state health department noted continuing laxity among pharmacist immunizers in reporting immunizations to the state immunization registry. The rule now requires the reporting of immunizations to the state immunization registry within 72 hours of the immunization. Immunizing pharmacists had expressed concern with inadequate staffing in certain pharmacies hosting immunization activities. The rule now contains minimum standards for staffing as well as sufficient equipment and supplies to address patient emergencies.
 - *Project 2019-3 ~ Investigational Drugs* established minimum standards for all pharmacies participating in clinical drug studies and dispensing investigational drugs.
 - *Project 2019-4 ~ Telepharmacy Dispensing Sites* responded to stakeholder input and reduced two restrictions placed in the original rule. The previous requirement that no other pharmacy be located within a 20-mile radius of the telepharmacy dispensing site was modified to a 15-mile radius. The previous requirement that a telepharmacy dispensing site close permanently when a regular community pharmacy opened within a 20-mile radius was modified to require a telepharmacy dispensing site to convert to a regular community pharmacy permit when its dispensing activity achieved an average of 100 prescriptions per day.
 - *Project 2019-5 ~ Correctional Center Pharmacies* implemented the provisions of Act 310 of the 2016 Legislature. That law expanded the authority for state owned and operated correctional facilities to reuse prescription drugs previously dispensed to their offenders, to also include correctional facilities owned and operated by local law enforcement agencies. The rule was modified to include that expansion and other technical changes as well.
 - *Project 2019-7 ~ Veterinary Hospital Pharmacy* amended the rules for hospital pharmacies to recognize veterinary hospital pharmacies owned and operated by a public university within the state and permit the pharmacist-in-charge at such hospitals to allow after-hours access to the pharmacy for emergent purposes.
 - *Project 2019-8 ~ Dispensing Prescription Refills* responded to stakeholder input to address the automatic dispensing of refills not requested or approved by patients. The rule for dispensing prescription refills now requires the approval or request of the patient or caregiver, with an exception for persons residing in long-term care facilities.
 - *Project 2019-9 ~ Delays of Licensure Examinations* responded to stakeholder input. The rule changes remove the required one-year delay after the third failure of a licensure examination for both pharmacists and pharmacy technicians. The rule now permits the applicant to retake such examinations as permitted by the test administrator.
 - *Project 2019-10 ~ License Transfer for Pharmacy Technicians* simplified the process for pharmacy technicians licensed and practicing in other states who wish to transfer to this state.
 - *Project 2019-11 ~ Continuing Education Records* amended the rule for pharmacists which had required them to maintain paper copies of their

continuing education activities at their primary place of pharmacy employment. The rule now requires pharmacists to maintain such records with CPE Monitor[®] and to allow the Board to access their records for audit purposes.

- *Project 2019-12 ~ Partial Fill of Schedule II Prescriptions* implemented Act 32 of the 2018 Legislature which authorized partial fills of Schedule II prescriptions, consistent with recent federal legislation. The rule change amended the state rules for controlled substances to permit such partial fills within the limits noted in federal and state law.
- *Project 2019-13 ~ CDS License for Third Party Logistics Providers* implemented Act 186 of the 2018 Legislature. That law amended the state controlled substance law to require third party logistics providers which distribute controlled substances to obtain a state controlled substance license from the Board. The rule change integrated third party logistics providers, a subset of drug distributors, into the existing rules for credentialing, security controls, and recordkeeping.
- *Project 2019-14 ~ Rulemaking Procedures* implemented a requirement of the state's Administrative Procedure Act which requires state agencies to promulgate rules to inform consumers and stakeholders how to initiate rulemaking requests to the agencies.
- *Project 2019-15 ~ Drug Disposal by Pharmacies* amended several chapters of rules to permit pharmacies to accept returns of previously dispensed prescription drugs and devices for disposal purposes. The rule changes include minimum standards for disposal of controlled substances and hazardous drugs.
- *Project 2019-16 ~ Pharmacy Compounding* amended the current compounding rule to update references to federal laws and rules and to clarify the current limitation on compounding of commercially-available preparations.
- *Project 2019-17 ~ Pharmacy Records* implemented the provisions of Act 602 of the 2018 Legislature. That law introduced a new term in the pharmacy law relative to chart orders; these orders for drugs and devices are used within institutional facilities and are analogous to prescription drug orders. The rule changes integrated chart orders into all existing rules on prescriptions and recordkeeping, and made other technical changes.
- *Project 2019-18 ~ Cannabis Metered Dose Inhaler* implemented Act 284 of the 2019 Legislature. That law amended the state medical marijuana law to authorize the Board to allow the use of cannabis metered dose inhalers as an allowable dosage form. The rule change added metered dose inhalers to the existing list of allowable dosage forms.

As directed by other legislative acts and by its own initiative, the Board started six additional regulatory projects during the fiscal year. Four of those are in various stages of the promulgation process. The proposed rule to license and regulate pharmacy benefit managers is still under review by the Occupational Licensing Review Commission for approval to initiate the formal promulgation process. The Board also adopted an emergency rule to implement the legislative mandate to suspend the collection of renewal fees for credentials issued to existing businesses located within the state during the next fiscal year.

C. Prescription Monitoring Program

The Board continued its operation of Louisiana's Prescription Monitoring Program (PMP). The vendor contract to operate the program is held by Appriss, Inc., based in Louisville, KY. The vendor's operating platform is AwareRx. Further, through its Gateway portal, the Louisiana PMP connects to other federal and state prescription monitoring programs to allow for seamless interstate data inquiries. The number of prescribers and dispensers authorized to access the program's database continues to increase, as has the average number of queries per day. Since the program is required to file an annual report to the legislature, we have appended that report to this one to facilitate its separation.

D. Public Health Emergency

The World Health Organization declared the Novel Coronavirus Disease, COVID-19, a pandemic on March 11, 2020. Louisiana declared a public health emergency due to the COVID-19 disease that same day. The Board office worked with the Board President to begin issuing a series of guidance documents beginning March 13. We reminded our licensees of the provisions of Rule 519 relative to states of emergency and then addressed a number of requests for guidance on different topics. We have issued approximately 30 guidance documents, with some containing temporary waivers of rules and extensions of deadlines.

When the Governor issued the Stay-at-Home order on March 23, we closed the Board office to visitors and sent most of the office staff home. However, the supervisors and administrative officers remained on duty in the office; in addition, the compliance officers remained on duty but suspended their inspections to all but the most critical for new pharmacy permits. Since the Governor declared pharmacies to be essential businesses encouraging them to remain open, and the Board supports those businesses with regulatory services, we have remained open for business. By the end of the first week of the Stay-at-Home order, it became clear we needed all available staff in the office. The floor plan of the Board office building facilitates physical distancing among the staff. We returned the office staff to the office on March 30. Two staff members were required to establish temporary office space in the Board's meeting room, and two particularly vulnerable staff members are still working from home. With the lifting of the Stay-at-Home order and some minor work in the building lobby, we re-opened the office to visitors on May 26.

Like many other organizations, the Board acquired virtual meeting technology in order to continue our essential meeting functions. Although we did not resume formal administrative hearings by the end of the fiscal year, we did transition our board meetings and some committee meetings to a virtual platform. Since committees involve a fewer number of participants, we continued physical meetings for some committees.

We continue to monitor the phased re-opening plan established through various proclamations issued by the Governor. We have developed an exit strategy relative to the temporary waivers, exemptions, and exceptions previously issued during the emergency period. When the Board determines it appropriate to rescind any previous guidance, we will provide advance notice of the effective date of any such changes.

Board Office

The Board currently employs 23 people on a full-time basis in a variety of professional, technical, and clerical roles; the Board also supports the local Cooperative Office Education (COE) program in Baton Rouge area high schools by hiring high school senior students on a temporary basis. The physical and mailing address of the Board office is:

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700

The Board's website address is www.pharmacy.la.gov and general email is received at info@pharmacy.la.gov.

Conclusion

The Board has had an active year on several fronts, and all of these activities have contributed to the overall mission of the board. The officers and members of the Board, as well as the entire office staff, are committed to achieving our goal of protecting the public's health, safety and welfare through appropriate regulation of the practice of pharmacy in this state. We understand that public service is a privilege, and we endeavor to render that service honorably.

Respectfully submitted,
Malcolm J Broussard
Executive Director



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Prescription Monitoring Program Annual Report

Fiscal Year 2019-2020

July 1, 2020

Introduction

The Louisiana Prescription Monitoring Program (PMP) is an electronic database used to collect and monitor prescription data for all Schedule II, III, IV, and V controlled substances, as well as certain drugs of concern, dispensed by a pharmacy in Louisiana or to a Louisiana resident from a pharmacy located in another state. The PMP also provides a venue for monitoring patient prescription history for practitioners.

Act 676 of the 2006 Louisiana Legislature authorized the development, implementation, operation, and evaluation of an electronic system for the monitoring of controlled substances and other drugs of concern that are dispensed within the state or to state residents by pharmacies located in other states. The goal of the program is to improve the state's ability to identify and inhibit the diversion of controlled substances and drugs of concern in an efficient and cost-effective manner and in a manner that shall not impede the appropriate utilization of these drugs for legitimate medical purposes.

The PMP was implemented in August 2008. Pharmacies and dispensing prescribers were instructed how and when to transmit their dispensing transactions to the program vendor for assimilation into the PMP database. Prescribers, dispensers, and other persons authorized to access PMP information were instructed how to secure their access privileges. The web portal to the PMP database was opened to queries on January 1, 2009, and the program remains fully operational.

Advisory Council

The enabling legislation created the PMP Advisory Council to assist the Board in the development and operation of the program. The council consists of the following members, each of whom may appoint a designee:

1. The president of the Louisiana State Board of Medical Examiners;
2. The president of the Louisiana State Board of Dentistry;
3. The president of the Louisiana State Board of Nursing;
4. The president of the Louisiana State Board of Optometry Examiners;
5. The president of the Louisiana Academy of Physician Assistants;
6. The president of the Louisiana Board of Pharmacy;
7. The superintendent of the Louisiana State Police;
8. The administrator of the United States Drug Enforcement Administration;
9. The speaker of the Louisiana House of Representatives;
10. The president of the Louisiana Senate;
11. The chairman of the House Committee on Health and Welfare;
12. The chairman of the Senate Committee on Health and Welfare;
13. The secretary of the Department of Health;
14. The president of the Louisiana State Medical Society;
15. The president of the Louisiana Dental Association;
16. The president of the Louisiana Association of Nurse Practitioners;
17. The president of the Optometry Association of Louisiana;
18. The president of the Louisiana Pharmacists Association;
19. The president of the Louisiana Independent Pharmacies Association;
20. The president of the National Association of Chain Drug Stores;

21. The president of the Louisiana Sheriffs' Association;
22. The president of the Louisiana District Attorneys Association;
23. The president of the Pharmaceutical Research and Manufacturers of America;
24. The president of the Louisiana Academy of Medical Psychologists.

During Fiscal Year 2019-2020, the council convened three of their four regularly-scheduled quarterly meetings; the April 2020 meeting was canceled due to the COVID-19 public health emergency.. Representatives from six of the 24 organizations attended 100% of the meetings; nine entities attended 66%; four attended 33%, and five entities had no representation at any of the meetings. During each of the meetings, program staff presented data concerning the number of prescription transactions reported to the program database as well as the number of queries to the database by prescribers, dispensers, law enforcement, and regulatory agencies. The staff also reported on the addition of new states available through the PMP InterConnect interstate network, as well as the increased utilization by the private sector of the PMP Gateway service, which integrates the PMP access portal into existing practice information systems in a variety of settings, including hospitals, clinics, practitioner offices, and pharmacies. The council reviewed new legislation adopted during the 2019 legislative session, and staff provided updates on the operational implementation of the legislative mandates.

Program Highlights

- *October 8, 2019* – the Board transitioned to an auto-registration process for immediate access to the state prescription monitoring program (PMP) for pharmacist and medical interns.
- *October 29, 2019* – Clinical Alerts enabled. Clinical Alerts provide automatic electronic patient alerts delivered directly to a prescriber user's dashboard and registered email to notify the prescriber that the patient has exceeded a set prescriber/dispenser threshold, exceeded a daily active MME threshold, or has been prescribed an opioid and benzodiazepine concurrently.
- *April 28, 2020* – through participation with the PMP InterConnect™ sponsored by the National Association of Boards of Pharmacy, achieved connection with the United States Military Health System and 31 states/territory/district, including Alabama, Alaska, Arizona, Arkansas, Connecticut, Delaware, D.C., Florida, Georgia, Idaho, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nevada, New Mexico, North Carolina, North Dakota, Oklahoma, Pennsylvania, Puerto Rico, South Carolina, South Dakota, Tennessee, Texas, Virginia and West Virginia.
- *May 21, 2020* – mandatory use monitoring reports relayed to the prescriber's licensing authority.

Louisiana PMP Statewide Integration Project

On January 1, 2019, the Board partnered with the Louisiana Dept. of Health's Office of Public Health, Bureau of Community Preparedness (LDH-OPH-BCP) and Appriss Health to provide a statewide PMP integration option to all healthcare providers in Louisiana utilizing a service called PMP Gateway®. Gateway offers healthcare

providers an option to integrate PMP data within the provider's electronic health record (EHR) or pharmacy information system to provide a streamlined clinical workflow for providers. The integration eliminates the need for providers to log in separately to the PMP web portal; instead, the EHR automatically initiates a patient query and returns the patient's PMP information directly within the provider's EHR or pharmacy information system.

Included as part of the integration, users now have access to an advanced analytics and patient support tool called NarxCare®. In addition to the existing Louisiana PMP functionality, NarxCare aggregates and analyzes prescription information from pharmacies and presents visual interactive information, as well as advanced analytic insights, machine learning risk scores and more to help prescribers and pharmacists provide better patient safety and outcomes for every patient. NarxCare also provides tools and resources that support patients' needs and assists a healthcare provider to connect their patient to treatment when appropriate. This statewide initiative is funded by a Centers for Disease Control and Prevention (CDC) grant awarded to LDH-OPH-BCP and covers the costs of the licensing fees associated with the integration and NarxCare service.

As of June 30, 2020, the Louisiana PMP was interoperable with 176 licensees (EHRs and pharmacy management systems) across the state. The 176 licensees represent more than 1,600 facilities in Louisiana and were responsible for 1,810,207 PMP requests in the month of June 2020. There are an additional 174 licensee applicants pending.

Program Metrics

The data on the following pages provide summary data for the operational aspects of the program for Calendar Year 2019. The first graphic presents information about the use of the information by the authorized users as identified in the governing legislation. Data for the different categories of prescribers are presented, including the number of prescribers authorized to obtain PMP access privileges, the number with active access privileges and the number of queries to the PMP database by those prescribers. Other authorized users include law enforcement and regulatory agencies; information concerning the number of queries originating from those entities is also presented.

The second graphic presents information concerning the numbers of controlled substance prescriptions dispense in the state, including summary data for different types of drugs like opioids and benzodiazepines. Just over 10.8 million prescriptions were dispensed in the state during Calendar Year 2019, with an average of 2.326 prescriptions per Louisiana resident – a 4% reduction from the previous calendar year.

PMP Healthcare Provider Role	Number of Providers Eligible for PMP Access (as of 12/31/2019)	Number of Providers with PMP Access Privileges (as of 12/31/2019)	Number of PMP Requests by Providers through AWA RxE® During 2019	Number of PMP Requests by Providers through Gateway® During 2019
Physician (MD, DO)	13,140	8,760	1,610,093	8,316,025
Nurse Practitioner (APRN)	3,670	2,831	389,426	1,186,248
Dentist (DDS)	2,262	1,533	23,697	2,679
Physician Assistant (PA)	999	727	105,180	141,301
Optometrist (OD)	361	152	46	0
Podiatrist (DPM)	164	110	1,957	0
Medical Psychologist (MP)	91	80	21,654	0
Medical Intern/Resident	1,194	1,065	14,172	288
Prescriber's Delegate	NA	2,633	807,085	NA
Pharmacist (PST)	9,301	4,405	2,024,263	3,000,475
Pharmacist's Delegate	NA	1,021	177,687	NA
Totals	31,182	23,317	5,175,260	12,647,016

Law Enforcement, Prosecutorial Officials, & Specialty Courts	Regulatory Agencies	Other Roles
DEA (patient requests)	Board of Medical Examiners	Medical Examiner/Coroner
Specialty Courts	Board of Dentistry	Louisiana Medicaid
FBI	Board Nursing	Total
Homeland Security	Board of Pharmacy	716
Local Law Enforcement	DEA (licensee requests)	
HHS - OIG	Total	
State Attorney General	9,175	
State Police		
Total		

State Rx per Capita
2.326

Quick Slicers:




- 2012
- 2013
- 2014
- 2015
- 2016
- 2017
- 2018
- 2019
- 2020

Prescriptions
10,829,140

Quantity Dispensed	EACH (TABLETS, KITS, ETC..)	478,444K
	GRAMS (SOLIDS)	3,048K
	MILLILITERS (LIQUIDS)	71,666K
	UNSPECIFIED	1,010K

Days Supply
254,729,528




YoY Prescriptions (#) by Drug Schedule

Schedule 2	2019	4,916,105
Schedule 3	2019	740,493
Schedule 4	2019	4,337,886
Schedule 5	2019	503,530
Unscheduled	2019	319,628
Unspecified	2019	11,498


YoY Prescriptions (#) by Drug Classes

Opioid	2019	4,409,628
Benzo	2019	2,397,980
Anxiolytic, Hypnotics, Se..	2019	951,147
Other	2019	3,070,385


Prescriptions >= 90 MME vs. All




Rx by Patient Demographic Environment



New vs. Refill Prescriptions



Opioids vs. Non Opioids (%)



Conclusion

The program has completed 11 years of operation. Based on feedback from authorized users, it appears to represent an efficient and cost-effective use of resources. Data from the program suggests we have made some progress in the reduction of diversion of controlled substances. Our interstate collaborations have yielded high marks for our program design and operation. We look forward to fully developing the potential of our program to identify and inhibit the diversion of controlled substances in Louisiana.

We value and appreciate the contributions from and collaboration with our partners on the Prescription Monitoring Program Advisory Council. We also acknowledge the contributions from our administrative coordinators, Ms. Danielle Hartzog and Ms. Nerissa Montgomery, and the program manager, Mr. Joseph Fontenot, for their assistance with the development of this report and administrative oversight of the program.

Respectfully submitted,
Malcolm J Broussard
Executive Director



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Roster of Agency Publications

[Minutes of Board Meetings and Administrative Hearings](#)

The board generally meets on a calendar quarter basis. The minutes for a board meeting are approved at the next regular meeting and then posted on the board's website. These documents exist in electronic form only; they are not commercially printed.

[Newsletters](#)

The board publishes a quarterly newsletter in a collaborative effort with the National Association of Boards of Pharmacy (NABP) Foundation. Both parties contribute content for the newsletter, which is published in January, April, July, and October. This newsletter exists in electronic form only and is posted on the websites for both NABP and the board.

[Bulletins](#)

As the need arises, the board may publish a bulletin for all of its licensees or some portion thereof. These electronic documents are distributed by email and are also posted on the board's website.

[Guidance Documents](#)

As the need arises, the board may publish compliance policy guidance documents on certain topics for its licensees. These electronic documents are distributed by email and are also posted on the board's website.

[Louisiana Pharmacy Law Book](#)

The board publishes a compilation of the laws and rules relevant to pharmacy practice in Louisiana. This publication exists in electronic form only and is posted on the board's website.

[Annual Reports](#)

The board publishes an annual report on its activities. The report exists in electronic form only and is posted on the board's website. The board also submits a comprehensive annual financial report to the legislative auditor.

[Commissioned Reports](#)

From time to time, the legislature requests the board's assistance on certain pharmacy-related issues in public health and safety. When requested, the board will prepare commissioned reports for submission to the legislature. These documents exist in electronic form only and are posted on the board's website.

[Prescription Monitoring Program \(PMP\)](#)

The PMP Advisory Council meets quarterly. The minutes for a meeting are approved at the subsequent meeting and then posted on the board's website. The program staff also publishes instruction manuals for dispensers reporting data to the program as well as for all persons making inquiries of the program database. Annual reports are posted on the board's website.

[Pharmacy Benefit Manager \(PBM\) Monitoring Advisory Council](#)

The PBM Monitoring Advisory Council held its organizational meeting in March 2020 is scheduled to meet quarterly. The minutes for a meeting are approved at the subsequent meeting and then posted on the board's website.

Inventory of Agency Publications

(Revised 07-10-2020)

Minutes of Board Meetings & Administrative Hearings

2020 – Feb. 5, Mar. 25, Apr. 2, May 27
2019 – Feb. 19, May 29-30, Aug. 14-15, Nov. 13-14.
2018 – Feb. 21-22, Mar. 27-28, Apr. 17-18, May 23, Aug. 15-16, Nov. 14-15.
2017 – Jan. 25-26, Mar. 14, May 10-11, Aug. 23-24, Nov. 15-16.
2016 – Feb. 23-25, May 4-5, Aug. 10-11, Nov. 16-17.
2015 – Feb. 25-26, May 27, Aug. 12-13, Nov. 18.
2014 – Feb. 12-13, May 7, Aug. 6-7, Nov. 13-14.
2013 – Jan. 29, Mar. 6-7, Aug. 14-15, Nov. 6-7.
2012 – Feb. 1-2, May 2-3, Aug. 22-23, Dec. 12-13.
2011 – Feb. 16-17, May 4-5, Aug. 17, Nov. 16-17.
2010 – Feb. 3, May 5-6, Aug. 11-12, Nov. 9-10.
2009 – Feb. 11-12, May 6-7, Aug. 5-6, Nov. 18-19.
2008 – Feb. 21-22, May 7-8, Aug. 6-7, Nov. 13.
2007 – Mar. 6-7, May 9-10, Aug. 15-16, Nov. 14-15.
2006 – Feb. 15-16, May 17-18, Aug. 15-16, Oct. 5-6, Nov. 9, Dec. 6-7.
2005 – Feb. 17, May 11-12, Aug. 17-18, Nov. 9.
2004 – Feb. 11-12, May 5-6, July 29, Aug. 18-19, Nov. 17-18.
2003 – Feb. 11-12, Feb. 19-20, May 22-23, Aug. 20-21, Nov. 19-20.
2002 – Feb. 20-21, May 8-9, Aug. 21, Nov. 20-21.
2001 – Feb. 8, May 16-17, Aug. 15-16, Nov. 14-15.
2000 – Feb. 10, Apr. 26-27, Aug. 16-17, Nov. 28-29.

For meeting minutes prior to 2000, please contact the board office for assistance.

Newsletters

This document is published in January, April, July, and October. Electronic copies for every year from 1998 forward are posted on the website. Editions from 1997 to 1982 are available in the board office.

Bulletins

<i>Issue No.</i>	<i>Date of Issue</i>	<i>Title</i>
20-02	07-10-2020	New Laws from 2020 Regular Session of La. Legislature
20-01	04-20-2020	New & Revised Rules Effective April 20, 2020
19-03	08-18-2019	Act 426 of 2019 Legislature – Quantity Medically Necessary
19-02	07-26-2019	New Edition of <u>Louisiana Pharmacy Law Book</u>
19-01	07-01-2019	New Laws from 2019 Legislature
18-01	07-01-2018	New Laws from 2018 Legislature
17-02	08-25-2017	Board Policy Statement re Transfer of Unfilled Prescriptions
17-01	07-15-2017	New Laws from 2017 Legislature
16-01	07-15-2016	New Laws from 2016 Legislature
15-02	07-10-2015	New Laws from 2015 Legislature
15-01	03-08-2015	Law Book Update No. 8 (total replacement of all printed pages)
14-05	09-15-2014	Hydrocodone Re-Scheduled by the DEA
14-04	07-15-2014	New State Laws Affecting Pharmacy Practice
14-03	07-15-2014	New State & Federal Requirements for Certain Controlled Substances
14-02	01-15-2014	FDA Actions re Certain Drug Products
14-01	01-01-2014	Law Book Update No. 7 (total replacement of all printed pages)
13-03	08-15-2013	Nonresident Pharmacies
13-02	05-01-2013	Law Book Update No. 6 (total replacement of all printed pages)
13-01	01-07-2013	Notice of Emergency Rule & Delayed Publication of 2013 Law Book
12-01	01-01-2012	Law Book Update No. 5 (total replacement of all printed pages)

New since last inventory report

11-01	01-31-2011	Law Book Update No. 4 (total replacement of all printed pages)
10-01	08-15-2010	New Laws – New Rules – New Website – New Licensure System
09-03	09-15-2009	Immunization Information & Emergency Order
09-02	07-25-2009	New Laws – New Controlled Substances
09-01	04-15-2009	Expedited Partner Therapy
08-03	08-15-2008	PMP, New Laws, & New Rules
08-02	04-07-2008	Technician Renewal Process
08-01	03-10-2008	Board Member Elections and CDTM
07-01	08-15-2007	New Laws & Rules
06-04	11-20-2006	Notice of Regulatory Activity re Project 2006-3
06-03	09-01-2006	Repeal of Certified Pharmacist Preceptor Program
06-02	09-01-2006	Law Book Update No. 3 (total replacement of all printed pages)
06-01	01-30-2006	Notice of Regulatory Activity re §705 and 907 of Board Rules
05-04	08-15-2005	Recent Changes in Pharmacy and Related Laws
05-03	03-04-2005	Electronic Transmission of Prescriptions
05-02	01-31-2005	Prescriptive Authority for Physician Assistants & Medical Psychologists
05-01	01-01-2005	Law Book Update No. 2
04-03	12-15-2004	New Regulation and Other Important Information
04-02	09-15-2004	Law Book Update No. 1
04-01	09-04-2004	Recent Changes in Pharmacy Laws

Guidance Documents

<i>Date of Issue</i>	<i>Title</i>
01-25-2020	Act 220 of 2017 Legislature – Pharmaceutical Cost Transparency
08-06-2014	Medication Therapy Management in the Practice of Pharmacy
08-06-2014	Act 769 of 2014 Legislature & Pharmacist Immunization Recordkeeping
08-01-2010	Prescribers with Authority for Controlled Substances
05-01-2009	Buprenorphine in Treatment of Opiate Addiction
10-15-2008	Medication Guides (MedGuides®)

Louisiana Pharmacy Law Book

The current edition of this electronic reference was published in **August 2019**. The following previous editions are still available: August 2018, January 2018, March 2015, January 2014, April 2013, January 2012, and January 2011.

Annual Reports

Once approved by the board, typically during their summer session, these electronic reports are posted on the board's website. The reports from 2001 forward are posted on the website. The comprehensive annual financial reports audited by the legislative auditor are available from the board office.

Commissioned Reports

The following special reports were commissioned by the Louisiana Legislature, and are posted on the board's website:

<i>Date of Issue</i>	<i>Title</i>
03-31-2017	Report from Louisiana Commission on Preventing Opioid Abuse
01-30-2017	<i>Specialty Drugs</i> , issued in response to SCR 87 of 2016 Legislature
12-23-2015	<i>Marijuana Pharmacy Permits</i> , issued in response to Act 261 of 2015 Legislature
02-01-2012	<i>Administration of Immunizations in Louisiana</i> , issued in response to Senate Resolution 122 of 2011 Legislature
02-01-2012	<i>Legislative Workgroup on Electronic Prescribing</i> , issued in response to House Resolution 108 and Senate Resolution 81 of 2011 Legislature
03-11-2009	<i>Generic Substitution for Epilepsy Medication</i> , issued in response to House Concurrent Resolution 198 of 2008 Legislature

- 07-14-2008 *Prescription Monitoring Program Update*, issued in response to Senate Concurrent Resolution 102 of 2008 Legislature
- 01-24-2006 *Final Report of Prescription Monitoring Program Task Force*, issued in response to House Concurrent Resolution 98 of 2005 Legislature
- 04-20-2005 *Recycling of Unused Previously Dispensed Prescription Drugs*, issued in response to House Concurrent Resolution 292 of 2004 Legislature

[Prescription Monitoring Program \(PMP\)](#)

Minutes from the meetings of the PMP Advisory Council (and its predecessor PMP Task Force) are posted on the board's website:

- 2020 – Jan. 8, [Apr. 8 Cx],
- 2019 – Jan. 9, Apr. 10, Jul. 10, Oct. 16.
- 2018 – Jan. 10, Apr. 11, Jul. 10, Oct. 10.
- 2017 – Jan. 11, Apr. 12, Jul. 12, Oct. 18.
- 2016 – Jan. 20, Apr. 13, Jul. 13, Oct. 26.
- 2015 – Jan. 21, Apr. 8, Jul. 8, Oct. 14.
- 2014 – Jan. 8, Apr. 9, Jul. 9, Oct. 8.
- 2013 – Jan. 9, Apr. 10, Jul. 10, Oct. 9
- 2012 – Jan. 11, Apr. 11, Jul. 11, Oct. 10.
- 2011 – Jan. 12, Apr. 13, Jul. 13, Oct. 12.
- 2010 – Jan. 13, Apr. 14, Jul. 14, Oct. 13.
- 2009 – Jan. 7, Apr. 8, Jul. 8, Oct. 14.
- 2008 – Jan. 16, Apr. 16, Jul. 9, Oct. 29.
- 2007 – Jan. 10, Apr. 11.
- 2006 – Jan. 24.
- 2005 – Jan. 12, Mar. 16, May 18, Aug. 4, Oct. 26, Nov. 30.

Annual reports for the program, from 2009 forward, are published on the board's website:

The following PMP-related guidance documents have been published. For those items with multiple versions, only the most recent is posted on the board's website:

<i>Date of Issue</i>	<i>Title</i>
01-31-2020	AWARxE User Support Manual (v2-3)
10-01-2019	AWARxE User Support Manual (v2-2)
02-01-2019	AWARxE User Support Manual (v2-1)
07-01-2018	AWARxE User Support Manual (v1.1)
11-01-2016	AWARxE User Support Manual (v1.0)
12-01-2017	AWARxE Quick Reference Guide (v1.1)
06-01-2016	AWARxE Quick Reference Guide (v1.0)
06-01-2020	AWARxE Data Submission Dispenser Guidelines (v2.4)
02-01-2020	AWARxE Data Submission Dispenser Guidelines (v2.2)
01-17-2019	AWARxE Data Submission Dispenser Guidelines (v2.1)
07-01-2018	AWARxE Data Submission Dispenser Guidelines (v1.1)
04-01-2016	AWARxE Data Submission Dispenser Guidelines (v1.0)

[Pharmacy Benefit Manager \(PBM\) Monitoring Advisory Council](#)

Minutes from the meetings of the PBM Monitoring Advisory Council are posted on the board's website:

- 2020 – Mar. 10



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Multistate Pharmacy Jurisprudence Examination (MPJE™)

January 1 – April 30, 2020

State & National Summary Data
Frequency Distribution of Scaled Scores

August 13, 2020

Multistate Pharmacy Jurisprudence Examination (MPJE™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in federal and state laws relative to pharmacy practice and is therefore specific for a given state. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the colleges of pharmacy and state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for State of Louisiana	03
Cumulative Report (since January 2018) for State of Louisiana	06



Multistate Pharmacy Jurisprudence Examination[®] (MPJE[®])

State Summary Report

Louisiana

Test Window: January 1, 2020 - April 30, 2020

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
State	60	81.67%	79.68	4.53
National	2903	82.43%	78.18	4.12

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
State	82	79.27%	78.67	4.45
National	4242	75.86%	77.33	4.18

Table 3 Total Scaled Score Min/Max

Table 3 contains information on the range of scaled scores achieved by FT ACPE (First-Time, ACPE-Accredited) candidates as well as the pool of all candidates. It also shows the boundaries of the Scaled Score Range.

	Min	Max
FT ACPE	62	96
All Candidates	62	100
Scale Score Range	0	100

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

The following tables and graphs are scaled score frequency distributions for MPJE candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 4 & Graph 1 State Frequency Distribution of Scaled Scores

Based on Total Tests Administered N = 82

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	0	0%
[35,39]	0	0%
[40,44]	0	0%
[45,49]	0	0%
[50,54]	0	0%
[55,59]	0	0%
[60,64]	0	0%
[65,69]	1	1%
[70,74]	16	21%
[75,79]	29	56%
[80,84]	28	90%
[85,89]	7	99%
[90,94]	1	100%
[95,100]	0	100%





Table 5 & Graph 2 National Frequency Distribution of Scaled Scores

Based on Total Tests Administered N = 4240

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	0	0%
[35,39]	0	0%
[40,44]	0	0%
[45,49]	0	0%
[50,54]	0	0%
[55,59]	0	0%
[60,64]	8	0%
[65,69]	115	3%
[70,74]	899	24%
[75,79]	1996	71%
[80,84]	1017	95%
[85,89]	195	100%
[90,94]	7	100%
[95,100]	3	100%



**Multistate Pharmacy Jurisprudence Examination (MPJE)
for
Louisiana Board of Pharmacy**

	2021			2020			2019			2018		
	<u>Sept - Dec</u>	<u>May - Aug</u>	<u>Jan - Apr</u>	<u>Sept - Dec</u>	<u>May - Aug</u>	<u>Jan - Apr</u>	<u>Sept - Dec</u>	<u>May - Aug</u>	<u>Jan - Apr</u>	<u>Sept - Dec</u>	<u>May - Aug</u>	<u>Jan - Apr</u>
First-Time Candidates, ACPE-Accredited Programs Only												
No. of State Candidates			60			119			272			118
State Pass Rate			81.67%			77.31%			86.40%			86.44%
State Scaled Score Mean			79.68			77.82			78.34			79.25
No. of National Candidates			2,903			5,631			16,509			4,648
National Pass Rate			82.43%			76.36%			84.21%			81.95%
National Scaled Score Mean			78.18			77.41			78.39			78.09
All Candidates												
No. of State Candidates			82			157			309			157
State Pass Rate			79.27%			75.80%			84.41%			79.62%
State Scaled Score Mean			78.67			77.53			78.10			78.26
No. of National Candidates			4,242			8,714			18,823			6,583
National Pass Rate			75.86%			72.66%			82.49%			76.77%
National Scaled Score Mean			77.33			76.90			78.12			77.38



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



North American Pharmacist Licensure Examination (NAPLEX™)

January 1 – April 30, 2020

State & National Summary Data
Frequency Distribution of Scaled Scores

August 13, 2020

North American Pharmacist Licensure Examination (NAPLEX™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in all of the states and territories within the USA as well as all the provinces in Canada. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the colleges of pharmacy and state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for State of Louisiana	03
Cumulative Report (since January 2018) for State of Louisiana	06



North American Pharmacist Licensure Examination[®] (NAPLEX[®])

State Summary Report

Louisiana

Test Window: January 1, 2020 - April 30, 2020

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation
State	5	60.00%	72.40	23.53	11.40	1.52	10.80	1.64
National	302	67.55%	82.63	21.48	11.80	1.29	11.86	1.45

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation
State	13	53.85%	73.46	15.92	11.15	1.07	11.46	1.27
National	969	59.65%	77.84	18.36	11.50	1.10	11.68	1.28

Table 3 Total Scaled Score Min/Max

Table 3 contains information on the range of scaled scores achieved by FT ACPE (First-Time, ACPE-Accredited) candidates as well as the pool of all candidates. It also shows the boundaries of the Scaled Score Range.

	Min	Max
FT ACPE	20	135
All Candidates	8	135
Scale Score Range	0	150

The following tables and graphs are scaled score frequency distributions for NAPLEX candidates.

Table 4 & Graph 1 State Frequency Distribution of Scaled Scores

Based on Total Tests Administered N = 13

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	0	0%
[10,14]	0	0%
[15,19]	0	0%
[20,24]	0	0%
[25,29]	0	0%
[30,34]	0	0%
[35,39]	1	8%
[40,44]	0	8%
[45,49]	0	8%
[50,54]	0	8%
[55,59]	1	15%
[60,64]	2	31%
[65,69]	0	31%
[70,74]	2	46%
[75,79]	3	69%
[80,84]	1	77%
[85,89]	1	85%
[90,94]	1	92%
[95,99]	1	100%
[100,104]	0	100%
[105,109]	0	100%
[110,114]	0	100%
[115,119]	0	100%
[120,124]	0	100%
[125,129]	0	100%
[130,134]	0	100%
[135,139]	0	100%
[140,144]	0	100%
[145,150]	0	100%





Table 5 & Graph 2 National Frequency Distribution of Scaled Scores

Based on Total Tests Administered N = 964

Scaled Score Range	Frequency	Cumulative Percent of the Upper Limit of the Interval
[0,4]	0	0%
[5,9]	1	0%
[10,14]	0	0%
[15,19]	1	0%
[20,24]	4	1%
[25,29]	6	1%
[30,34]	5	2%
[35,39]	9	3%
[40,44]	20	5%
[45,49]	18	7%
[50,54]	26	9%
[55,59]	50	15%
[60,64]	58	21%
[65,69]	89	30%
[70,74]	104	41%
[75,79]	129	54%
[80,84]	115	66%
[85,89]	93	76%
[90,94]	84	84%
[95,99]	56	90%
[100,104]	31	93%
[105,109]	25	96%
[110,114]	24	98%
[115,119]	9	99%
[120,124]	5	100%
[125,129]	0	100%
[130,134]	1	100%
[135,139]	1	100%
[140,144]	0	100%
[145,150]	0	100%



**North American Pharmacist Licensure Examination (NAPLEX)
for
Louisiana Board of Pharmacy**

	2021			2020			2019			2018		
	<u>Sep - Dec</u>	<u>May - Aug</u>	<u>Jan - Apr</u>	<u>Sep - Dec</u>	<u>May - Aug</u>	<u>Jan - Apr</u>	<u>Sep - Dec</u>	<u>May - Aug</u>	<u>Jan - Apr</u>	<u>Sep - Dec</u>	<u>May - Aug</u>	<u>Jan - Apr</u>

First-Time Candidates, ACPE-Accredited Programs Only

No. of State Candidates			5			21			181			3			24			204			1
State Pass Rate			60.00%			61.90%			90.06%			66.67%			45.83%			89.22%			0.00%
State Scaled Score Mean			72.40			81.62			94.68			71.33			76.04			94.10			50.00
No. of National Candidates			302			1,777			12,364			374			2,019			12,271			290
National Pass Rate			67.55%			67.59%			90.59%			67.11%			72.76%			91.64%			64.48%
National Scaled Score Mean			82.63			82.58			96.80			82.00			84.56			97.54			72.20

All Candidates

No. of State Candidates			13			41			186			24			50			215			17
State Pass Rate			53.85%			60.98%			88.17%			70.83%			50.00%			86.98%			35.29%
State Scaled Score Mean			73.46			78.93			94.04			76.50			76.24			93.10			72.88
No. of National Candidates			969			3,425			13,199			1,344			3,582			13,152			1,349
National Pass Rate			59.65%			64.55%			88.52%			61.24%			69.24%			89.57%			56.56%
National Scaled Score Mean			77.84			80.17			95.54			77.80			82.00			96.25			77.61



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Examination for the Certification of Pharmacy Technicians (ExCPT™)

April 1 – June 30, 2020

Cumulative Record (since January 2018)

August 13, 2020

National Healthcareers Association
ExCPT

	Calendar Year 2021				Calendar Year 2020			
	<u>4th Qtr</u>	<u>3rd Qtr</u>	<u>2nd Qtr</u>	<u>1st Qtr</u>	<u>4th Qtr</u>	<u>3rd Qtr</u>	<u>2nd Qtr</u>	<u>1st Qtr</u>
First-Time Candidate Group								
No. of LA Candidates							25	40
No. of LA Candidates who passed							14	27
State Pass Rate							56%	68%
No of National Candidates							1475	1503
No. of National Candidates who passed							943	1101
National Pass Rate							64%	73%
Multiple Attempts Group								
No. of LA Candidates							0	0
No. of LA Candidates who passed								
State Pass Rate								
No. of National Candidates							58	66
No. of National Candidates who passed							26	33
National Pass Rate							45%	50%

National Healthcareers Association
ExCPT

	Calendar Year 2019				Calendar Year 2018			
	<u>4th Qtr</u>	<u>3rd Qtr</u>	<u>2nd Qtr</u>	<u>1st Qtr</u>	<u>4th Qtr</u>	<u>3rd Qtr</u>	<u>2nd Qtr</u>	<u>1st Qtr</u>
First-Time Candidate Group								
No. of LA Candidates	56	58	71	48	32	34	32	7
No. of LA Candidates who passed	36	35	39	41	22	20	16	2
State Pass Rate	64%	60%	56%	85%	69%	59%	50%	29%
No of National Candidates	1602	1536	3942	1835				
No. of National Candidates who passed	1183	1123	2503	1356				
National Pass Rate	74%	73%	63%	74%	70%	70%	61%	66%
Multiple Attempts Group								
No. of LA Candidates	0	1	1	1	5	2	6	2
No. of LA Candidates who passed	0	0	1	1	2	2	3	1
State Pass Rate	0%	0%	100%	100%	40%	100%	50%	50%
No. of National Candidates	85	72	194	172				
No. of National Candidates who passed	36	37	95	94				
National Pass Rate	42%	51%	49%	55%	55%	40%	47%	62%



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Pharmacy Technician Certification Examination (PTCE™)

January – June 2020

Cumulative Record (since January 2000)

August 13, 2020

Pharmacy Technician Certification Examination (PTCE™)

This computer adaptive competency assessment is administered by the Pharmacy Technician Certification Board (PTCB). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in most of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a designated testing center at any time following approval by PTCB and receipt of an Authorization to Test (ATT) document from PTCB. Individual scores are available to applicants immediately after the test; certificates are mailed to the applicant within 30 days following the examination. Summary reports are provided to the state boards on a semi-annual basis.

Table of Contents

PTCE Pass Rates, National v Louisiana, January to June, 2020	03
Cumulative Report (since January 2000)	04



January 1, 2020 - June 30, 2020

PTCE 2.0	First Time Test Takers		Repeaters		Total	
	Exams Graded	Pass Rate	Exams Graded	Pass Rate	Exams Graded	Pass Rate
Louisiana	38	58%	22	32%	60	48%
National	2,996	57%	801	40%	3,797	53%

PTCE 3.0	First Time Test Takers		Repeaters		Total	
	Exams Graded	Pass Rate	Exams Graded	Pass Rate	Exams Graded	Pass Rate
Louisiana	137	63%	1	100%	138	63%
National	9,369	74%	110	56%	9,479	73%

PTCE® performance shown in percentage of questions answered correctly by knowledge domain:

PTCE 2.0	Louisiana	National
Medication Order Entry and Fill Process	67%	67%
Medication Safety	69%	69%
Pharmacology for Technicians	60%	63%
Pharmacy Billing and Reimbursement	69%	67%
Pharmacy Information System Usage and Application	57%	58%
Pharmacy Inventory Management	72%	69%
Pharmacy Law and Regulations	68%	69%
Pharmacy Quality Assurance	72%	75%
Sterile and Non-Sterile Compounding	55%	60%

PTCE 3.0	Louisiana	National
Medications	67%	66%
Federal Requirements	62%	70%
Patient Safety and Quality Assurance	66%	73%
Order Entry and Processing	69%	72%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Data

<u>National Data</u>	<u>2000-2021</u>	<u>Totals</u>	<u>7/1/2021 to 12/31/2021</u>	<u>1/1/2021 to 6/30/2021</u>	<u>2000-2020</u>	<u>Totals</u>	PTCE 3.0 <u>7/1/2020 to 12/31/2020</u>	PTCE 2.0 <u>1/1/2020 to 6/30/2020</u>	<u>2000-2019</u>
<i>First Attempt</i>									
No. of Candidates Attempting							9,369	2,996	
No. of Candidates Passing							6,933	1,708	
Pass Rate							73.9%	57.0%	
<i>Repeaters</i>									
No. of Candidates Attempting							110	801	
No. of Candidates Passing							62	320	
Pass Rate							56.4%	39.9%	
<i>Totals</i>									
No. Candidates Attempting							9,479	3,797	947,066
No. Candidates Passing							6,995	2,028	655,121
Pass Rate							73.8%	53.4%	69.2%
<u>Louisiana Data</u>									
<i>First Attempt</i>									
No. of Candidates Attempting							137	38	
No. of Candidates Passing							86	22	
Pass Rate							62.8%	57.9%	
<i>Repeaters</i>									
No. of Candidates Attempting							1	22	
No. of Candidates Passing							1	7	
Pass Rate							100.0%	31.8%	
<i>Totals</i>									
No. Candidates Attempting							138	60	18,069
No. Candidates Passing							87	29	10,634
Pass Rate							63.0%	48.3%	58.9%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

National Data	2000-2019	Totals	7/1/2019 to 12/31/2019	1/1/2019 to 6/30/2019	2000-2018	Totals	7/1/2018 to 12/31/2018	1/1/2018 to 6/30/2018	2000-2017
<i>First Attempt</i>									
No. of Candidates Attempting		42,153	21,127	21,026		39,794	17,277	22,517	
No. of Candidates Passing		25,503	12,887	12,616		24,049	10,539	13,510	
Pass Rate		60.5%	60.9%	60.0%		60.0%	61.0%	59.9%	
<i>Repeaters</i>									
No. of Candidates Attempting		9,600	4,990	4,610		9,049	4,235	4,814	
No. of Candidates Passing		4,462	2,295	2,167		4,114	1,948	2,166	
Pass Rate		45.5%	45.9%	47.0%		45.0%	45.9%	44.9%	
<i>Totals</i>									
No. Candidates Attempting	947,066	51,753	26,117	25,636	895,313	48,843	21,512	27,331	846,470
No. Candidates Passing	655,121	29,965	15,182	14,783	625,156	28,056	12,477	15,579	597,100
Pass Rate	69.2%	57.9%	58.1%	57.7%	69.8%	57.0%	58.0%	57.0%	70.5%
Louisiana Data									
<i>First Attempt</i>									
No. of Candidates Attempting		733	331	402		852	400	452	
No. of Candidates Passing		345	152	193		383	184	199	
Pass Rate		47.1%	45.9%	48.0%		44.9%	46.0%	44.0%	
<i>Repeaters</i>									
No. of Candidates Attempting		274	136	138		377	172	205	
No. of Candidates Passing		105	54	51		145	71	74	
Pass Rate		38.3%	39.7%	36.9%		38.5%	41.3%	36.1%	
<i>Totals</i>									
No. Candidates Attempting	18,069	1,007	467	540	17,062	1,229	572	657	15,833
No. Candidates Passing	10,634	449	206	243	10,185	521	252	269	9,664
Pass Rate	58.9%	44.6%	44.1%	45.0%	59.7%	42.4%	44.1%	40.9%	61.0%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

	<u>2000-2013</u>	<u>1/1/2014 to 6/30/2014</u>	<u>7/1/2014 to 12/31/2014</u>	<u>2000-2014</u>	<u>1/1/2015 to 06/30/2015</u>	<u>7/1/2015 to 12/31/2015</u>	<u>2000-2015</u>
<u>National Data</u>							
No. of Candidates Attempting	628,957	26,423	27,085	682,465	22,197	36,167	740,829
No. of Candidates Passing	470,680	15,233	15,125	501,038	13,280	21,643	535,961
Pass Rate	74.8%	57.7%	55.8%	73.4%	59.8%	59.8%	72.3%
<u>Louisiana Data</u>							
No. of Candidates Attempting	11,002	630	568	12,200	480	632	13,314
No. of Candidates Passing	7,451	287	265	8,003	255	304	8,562
Pass Rate	67.7%	45.6%	46.7%	65.6%	53.1%	48.1%	64.3%
<u>National Data</u>							
		<u>1/1/2016 to 12/31/2016</u>		<u>2000-2016</u>		<u>1/1/2017 to 12/31/2017</u>	
<i>First Attempt</i>							
No. of Candidates Attempting		43,958			43,180		846,470
No. of Candidates Passing		26,814			25,908		597,232
Pass Rate		61%			60%		71%
<i>Repeaters</i>							
No. of Candidates Attempting		9,372			9,131		
No. of Candidates Passing		4,217			4,200		
Pass Rate		45%			46%		
<i>Totals</i>							
No. Candidates Attempting		53,330		794,159	52,311		846,470
No. Candidates Passing		31,031		566,992	30,108		597,100
Pass Rate		58%		71%	58%		71%
<u>Louisiana Data</u>							
<i>First Attempt</i>							
No. of Candidates Attempting		840			843		
No. of Candidates Passing		412			405		
Pass Rate		49%			48%		
<i>Repeaters</i>							
No. of Candidates Attempting		458			378		
No. of Candidates Passing		156			129		
Pass Rate		34%			34%		
<i>Totals</i>							
No. Candidates Attempting		1,298		14,612	1,221		15,833
No. Candidates Passing		568		9,130	534		9,664
Pass Rate		44%		62%	44%		61%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

	2000-2009 Data	<u>1/1/2010</u> <u>3/31/2010</u>	<u>4/1/2010</u> <u>6/30/2010</u>	<u>7/1/2010</u> <u>9/30/2010</u>	<u>10/1/2010</u> <u>12/31/2010</u>	2000-2010 Data	<u>1/1/2011</u> <u>3/31/2011</u>	<u>4/1/2011</u> <u>6/30/2011</u>	<u>7/1/2011</u> <u>9/30/2011</u>	<u>10/1/2011</u> <u>12/31/2011</u>
<u>National Data</u>										
No. of Candidates Attempting	415,875	11,611	15,033	16,025	12,774	471,318	11,219	14,026	12,356	14,031
No. of Candidates Passing	309,035	8,521	11,216	12,349	9,275	350,396	8,366	10,472	9,565	10,826
Pass Rate	74%	73%	75%	77%	73%	74%	75%	75%	77%	77%
<u>Louisiana Data</u>										
No. of Candidates Attempting	9,843	217	421	320	268	11,069	247	437	268	257
No. of Candidates Passing	6,688	121	287	219	166	7,481	161	306	182	168
Pass Rate	68%	56%	68%	68%	62%	68%	65%	70%	68%	65%
							<i>Changed to semi-annual reports</i>			
	2000-2011 Data	<u>1/1/2012</u> <u>3/31/2012</u>	<u>4/1/2012</u> <u>6/30/2012</u>	<u>7/1/2012</u> <u>9/30/2012</u>	<u>10/1/2012</u> <u>12/31/2012</u>	2000-2012 Data	<u>1/1/2013 to 6/30/2013</u>	<u>7/1/2013 to 12/31/2013</u>		
<u>National Data</u>										
No. of Candidates Attempting	522,950	11,851	14,356	14,375	11,180	574,712	25,448	28,797		
No. of Candidates Passing	389,625	9,232	11,044	10,982	8,471	429,354	19,581	21,745		
Pass Rate	75%	78%	77%	76%	76%	75%	77%	76%		
<u>Louisiana Data</u>										
No. of Candidates Attempting	12,278	246	368	329	239	13,460	622	537		
No. of Candidates Passing	8,298	158	269	226	168	9,119	412	351		
Pass Rate	68%	64%	73%	69%	70%	68%	66%	65%		

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

	2000-2005 Data	<u>3/11/2006</u>	<u>7/22/2006</u>	<u>9/9/2006</u>	<u>11/18/2006</u>	2000-2006 Data	<u>2/5/2007</u> <u>3/9/2007</u>	<u>4/24/2007</u> <u>5/25/2007</u>	<u>8/27/2007</u> <u>9/28/2007</u>	<u>11/26/2007</u> <u>12/31/2007</u>
<u>National Data</u>										
No. of Candidates Attempting	225,206	12,383	18,992	3,029	15,285	274,895	8,768	10,730	14,666	10,881
No. of Candidates Passing	177,102	8,559	12,609	2,006	9,145	209,421	6,034	7,487	10,497	7,472
Pass Rate	79%	69%	66%	66%	60%	76%	69%	70%	72%	69%
<u>Louisiana Data</u>										
No. of Candidates Attempting	5,713	288	420	59	312	6,792	216	306	266	207
No. of Candidates Passing	4,179	181	239	37	137	4,773	133	196	177	121
Pass Rate	73%	63%	57%	63%	44%	70%	62%	64%	67%	58%
	2000-2007 Data	<u>2/4/2008</u> <u>3/14/2008</u>	<u>4/28/2008</u> <u>6/20/2008</u>	<u>8/18/2008</u> <u>10/10/2008</u>	<u>11/10/2008</u> <u>12/19/2008</u>	2000-2008 Data	<u>1/1/2009</u> <u>3/31/2009</u>	<u>4/1/2009</u> <u>6/30/2009</u>	<u>7/1/2009</u> <u>9/30/2009</u>	<u>10/1/2009</u> <u>12/31/2009</u>
<u>National Data</u>										
No. of Candidates Attempting	319,940	7,547	14,291	16,385	11,792	369,955	13,087	8,424	13,735	10,674
No. of Candidates Passing	240,911	5,165	10,155	11,781	7,770	275,782	9,141	6,363	10,067	7,682
Pass Rate	75%	68%	72%	72%	66%	75%	70%	76%	73%	72%
<u>Louisiana Data</u>										
No. of Candidates Attempting	7,787	128	392	304	215	8,826	301	260	238	218
No. of Candidates Passing	5,400	72	233	182	118	6,005	184	196	166	137
Pass Rate	69%	56%	59%	60%	55%	68%	61%	75%	70%	63%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

	1995-1999 Data	<u>3/25/2000</u>	<u>7/22/2000</u>	<u>11/18/2000</u>	<u>3/10/2001</u>	<u>7/14/2001</u>	<u>11/10/2001</u>	<u>3/16/2002</u>	<u>7/27/2002</u>	<u>11/16/2002</u>
<u>National Data</u>										
No. of Candidates Attempting	58,382	8,101	12,317	12,941	8,442	12,057	10,608	8,874	13,399	11,521
No. of Candidates Passing	47,973	6,206	10,006	9,520	6,116	9,799	8,354	7,072	10,681	9,164
Pass Rate	82%	77%	81%	74%	72%	81%	79%	80%	80%	80%
Louisiana Data										
No. of Candidates Attempting	514	141	346	327	187	310	324	269	383	308
No. of Candidates Passing	390	92	271	221	125	227	228	184	269	213
Pass Rate	76%	65%	78%	68%	67%	73%	70%	68%	70%	69%
	2000-2002 Data	<u>3/29/2003</u>	<u>7/26/2003</u>	<u>11/15/2003</u>	<u>3/20/2004</u>	<u>7/17/2004</u>	<u>11/13/2004</u>	<u>3/19/2005</u>	<u>7/23/2005</u>	<u>11/19/2005</u>
<u>National Data</u>										
No. of Candidates Attempting	98,260	12,147	14,162	13,401	11,508	15,942	13,795	13,673	18,250	14,068
No. of Candidates Passing	76,918	9,506	11,720	11,006	9,100	12,196	10,818	11,009	14,246	10,583
Pass Rate	78%	78%	83%	82%	79%	77%	78%	81%	78%	75%
Louisiana Data										
No. of Candidates Attempting	2,595	385	384	351	285	382	290	337	488	216
No. of Candidates Passing	1,830	294	286	271	211	281	214	274	351	167
Pass Rate	71%	76%	74%	77%	74%	74%	74%	81%	72%	77%



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Agenda Item 11

Request for Opinion

Delivery of Dispensed Prescriptions to Lockers for Employees

Mr. Adria A. Kerr
Director of Retail Pharmacy
Franciscan Missionaries of Our Lady Health System



RxONE | Mary Bird Perkins
4950 Essen Lane
Baton Rouge, LA
PH. 225-374-0260

RxONE | Med Plaza
7777 Hennessy Blvd
Baton Rouge, LA
PH. 225-765-8951

RxONE | Livingston
5000 O'Donovan Blvd
Walker, LA
PH. 225-271-6098

RxONE | St. Francis
309 Jackson Street
Monroe, LA
PH. 318-966-6290

RxONE | Tower Drive
2600 Tower Drive
Monroe, LA
PH. 318-966-7242

Date: 03/16/2020

To: Louisiana Board of Pharmacy

From: Adria Kerr, R.Ph.
Director of Retail Pharmacy
Franciscan Missionaries of Our Lady Health System

Subject: Request for Louisiana Board of Pharmacy Approval _ Delivery of filled prescriptions to lockers for employees

EXECUTIVE SUMMARY

The in-house retail pharmacy locations of Franciscan Missionaries of Our Lady Health System (FMOLHS) fill a significant number of employee prescriptions through the self-funded health plan at a discounted copay. This service is available during the pharmacy hours of operation Monday through Friday. FMOLHS is comprised of several hospitals throughout the state and employs staff that work shift work outside of pharmacy business hours as well as some at off site locations. The pharmacies would like to provide these employees the ability to pick up prescriptions 24/7 without extending the pharmacy hours through the use of lockers as a drop off similar to the process other pharmacies follow for mail order.

The solution we propose is to allow fill prescriptions to be dispensed at the pharmacy point of sale and delivered to employee lockers where the employee can access the prescription at their convenience.

PROPOSED WORKFLOW

- The pharmacy fills a prescription for an employee including the offer of counseling and collections of payment. This is completed in the four walls of the permitted pharmacy.
- The employee enrolls in workplace delivery to a designated drop off location (aka locker)
- The pharmacy courier transports the filled prescription to the locker, places the bag in the locker, and locks the locker.
- The employee is responsible for checking the locker and removing the contents.
- The pharmacy does not have access to the locker when it is locked and cannot return prescriptions not picked up back to stock.



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



New Agenda Items Added During Meeting



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



Announcements



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



August 13, 2020

Agenda Item 13: Announcements

- | | |
|----------------|--|
| August 26 | Public Hearing [Zoom] (<i>proposed changes to Regulatory Project 2020-1 ~ Prescription Monitoring Program</i>) |
| August 27 | Occupational Licensing Review Commission [Zoom] |
| August 28 | Deadline for return of board member nomination election ballots |
| September 3 | Counting of returned ballots for board member nomination election |
| September 7 | Labor Day – <i>Board office closed</i> |
| September 9 | HOPE Advisory Council Meeting |
| September 9-11 | MPJE Annual Review Conference [<i>remote</i>] |
| September 15 | Violations Committee Informal Conference |
| September 30 | NABP Executive Officers Forum |
| October 1 | dotPharmacy Executive Board Meeting
Drug Policy Board Meeting |
| October 4-6 | MALTAGON Conference – Gulf Shores, AL |
| October 13 | NABP-AACP District 6-7-8 Annual Meeting [Zoom] |
| October 14 | Louisiana Pharmacy Congress
PBM Monitoring Advisory Council Meeting
PMP Advisory Council Meeting |
| November 3 | National Election Day – <i>Board office closed</i> |
| November 11 | Veterans Day – <i>Board office closed</i> |
| November 17 | Reinstatement, Impairment, Finance, & Executive Committees |
| November 18 | Board Meeting |
| November 19 | Administrative Hearing |
| November 26 | Thanksgiving Day – <i>Board office closed</i> |
| November 27 | Acadian Day – <i>Board office closed</i> |

End of Meeting Binder